var title_f0_35_560="Retrograde pyelogram showing retroperitoneal fibrosis";
var content_f0_35_560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retrograde pyelogram showing retroperitoneal fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retrograde pyelogram of the right kidney from a patient with biopsy-proven retroperitoneal fibrosis. There is marked hydronephrosis with blunted calyces and dilatation of the upper ureter. At the level of the L3 and L4 vertebral bodies, there is medial deviation of the ureter (arrow) and the lower ureter a normal caliber.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan R Diamond, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_560=[""].join("\n");
var outline_f0_35_560=null;
var title_f0_35_561="Long term tubes";
var content_f0_35_561=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Long-term tympanostomy tubes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long-term tympanostomy tubes are intended to remain in the eardrum for 15 months or longer. They include butterfly (B), Paparella (P), and T-tube (T).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Isaacson G, Rosenfeld RM. Care of the child with tympanostomy tubes. A visual guide for the pediatrician. Pediatrics 1994; 93:924. Copyright &copy; 1994 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_561=[""].join("\n");
var outline_f0_35_561=null;
var title_f0_35_562="Chorioamnionitis";
var content_f0_35_562=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chorioamnionitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross photograph of the umbilical cord and fetal surface of the placenta illustrating opaque membranous surfaces characteristic of inflammation from chorioamnionitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_562=[""].join("\n");
var outline_f0_35_562=null;
var title_f0_35_563="Dysplastic kidney pathology";
var content_f0_35_563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal dysplasia: microscopic section",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microscopic section of a dysplastic kidney showing cartilage (arrows). Tubules (T) are poorly formed with cystic changes (C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_563=[""].join("\n");
var outline_f0_35_563=null;
var title_f0_35_564="Cefoxitin: Patient drug information";
var content_f0_35_564=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cefoxitin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     see \"Cefoxitin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/32/29188?source=see_link\">",
"     see \"Cefoxitin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10327785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mefoxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14965749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cefoxitin For Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701743",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cefoxitin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699187",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to store closely.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11319 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_564=[""].join("\n");
var outline_f0_35_564=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10327785\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965749\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015429\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015428\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015433\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015434\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015436\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015431\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015432\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015437\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015438\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=related_link\">",
"      Cefoxitin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/32/29188?source=related_link\">",
"      Cefoxitin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_35_565="Postadolescent acne";
var content_f0_35_565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postadolescent acne",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 280px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEYAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwTVI0tmkLyPCksbEQqmGx/CMdh6k1DpElxBeW8mqtIsZUiJWbaMcH8B71uW2kwpeSSqUvbrAXZuLJuPXc3c/TiibSY5LdxdvuSD7hPVBnnHqOwrnc+iNVDuX4UePSpbiUOtjdAjb0bzOcHHpjt+NdP4bVtEjs5Q5lj2HzlQ5DRnqw+h5/OuVsLm4nie0uslFYS26lf4ScZPv1z6ZrrrW3uYjFJaS7U3HGAGwQMMGHv39fSiLu7ouENNTqNOEls0hSZ2VcbTwQ6kfK35HFbtnL9ojMkZRbpWy8TdQR0z6Vxvh/URbywwFdgky6xsdwTnordME9AeQciupuw7QW95bshuFPzPnmRSeh9RmtYvS6OhFfUYUmsLktGyzwjzlDc44ydmOvOQR6Vgz6ZHLM16N8thGibynDADncvp82APoK6NpI/JLMzKVz5RPODkfIfrnr6VlKkkNnfQRwDLBiYixCFSMgjuAuT17/AFp6N6lwu2WrO7l1C78qP95cxhXSdSSlwcZ5/UH3rV1ib/iVWsMQLrev5Me4/MhPLHj0AYZrK0yO1s7qKKIbLW6G5XlYgxPtyysP4Q+B9CPerf8ArbubK/KIiLdHbG5iPmb23Db+R9aqepbir2Ny2u/Oj82FjIm7ynAXG7HA/IdfrV1t8UuyNiGwWB4O3ngY78Vh6NeXE0tvHCi+Y6jMLMVwT/y0z6cfkBW3HJuLYcq7kld3B6cn/PrSswatoU9RZoUgmAPl+aiuRxiM4AOPbj6c1KCIr4SRhsMCuQPl3DuO3IOPypl6JLhgsKsmCPk6h8/MDjtgjke1OnHmW8MDOSjru+9jDkBgBjoCev0pAmXIow8RLlnbGQDxtPUH60sDAIy+YSyOxYjPHqMD644605P9JgWSQ5Z/3jMylSD0/LimMWkWUwrtEg/eqvBz/PjoKNhc19yRCU3MJAdgBVU/+v1OamkmV4yjMiq3B5ODn/69QxRjZ5Sg9myh456En1qwI1fzJFRV3cfLzwP1GfX8qQna4WiLDagB2aQnLEDIBGMAZ6n34HPtS3LPL8gG58h9rLuDEdc/X/Ad6bI4WEb1O19qE/wj269ecVNKShCuoUOyqFGQCDyAfQZx9cUDSsV9yXiJLHL+6OZELg4weQB6nikRmmkbIWOIbSVLcp83UkEZJ4+gFOs44XhMcsrsGctsUBUB6EA9x1+nbpVsOhIJjQwKp5WMKgyOMc45AHXnjIp2KcraCwJbsVZ5QFXJAjP3Rxn8SalRDIRKp3rzgcqgU9Pcnjt/Wkk3u6yOpEjA7QF6L9OuTx/SpGEpKofMkXIwI5NwX3yBn8fagi5EEc7Whnn8yHkFRtO/0XjLflnPWmTT5jZJJNp4j6HOD6joB0omjARxHucY2cZAz0PsD6nNRwoZPMDqN/G7B27vYHOPxx3o9C13JwqJDE64YZBPzMcVWuppFmCSSGUORvTbt2MPUjrkfjVlVmijfzkYJt+YmQMT6YAPPqPfNQSLG2VtUlADHzSy5XPHzDcMgdPpSY4q71DdJK0u7zY3UDY0igHHpjPH0/Oq77HkkuAREzYDLz8p7nAP8vara3KybvtIhWWNeWYgfLkZ2n8KrTB2dZBExY9ZABxgcEEckY+lIqN7kRkXeCQC55LITkHtkDqOlUb5WdJ2Dqs2wsjtHkA+pH6fjU6uLlQskxyWK8tyWH+PapJF2LGxI44JK5z2OalmtrMw7cTxw5lBDcF8Ljr3HaqdzcAt5iONqdh9yTj9K1ZlOJJFYhAMNkdv6j/Cq1xbJNHEWRYzxkjhfrS8irJ6sw5VVI2dNxMp3/vOCD2yO3171j3doXOzayqqkANztyc4B75ro7uxLmMRLg9XVehA6YP1wcVRu4mixEYzJuHzJu5Q9yPY0mhNdjhby2EwliYsXjyFB6Mp9D6j3rmbm0dSySEdwG5yAPWvTb6yhKLK7A8ZOBzj3rlLuyzv6kgkKc9vUH86zlAiTUked3MRTESkjHzIG7+vNZdzG8Ayc7T0weldpqFqMhyFBBJ5GCD0zXOSQMyMrsrrg/j6URlZ2ZySVirYXjxzp8x2/WvRdHnFwiqzspxngd68xeN0wVGEHT29s12HhbUlVEBJIBxjPNawtccHZnfiyEqAksxx64xXSaFpkEaiXOWxnb/LNR6WsV/BEwXew7jjFdLpNrHxEeAflGPX1NdKSud0EpK5d0yyE5LDOSo4zgV11vYfY7YSXSbIl/jY52k9qoaXGIzHtXpkN/jVvWL+J7KREkZsAsVJ4Jx1IppW1Mqt72Wx5547137FDPNcSrsTLFhwMCvmLxT4ovdeunLyutrn5I8/qfU16b8cNUMempaRvnzpADjsBzXiQGTgVkved2cWLqNPkiSRLLNKscQZ5GOAo6k1o2ulXMl4YJVdWX7yjrn0rpPBmnWkUEOoXP7yVZcLCv3m+p7CvQPC2lWhuTPJIPOmYnDHkEnjnvW86doJJ+8/wMsPQcpXa0RwEXhErCHuI50Mg+QUuoeDX8rfapICBz8xI6V7Vd6Z5l75d7LEsKR5VMjk5rLuyLJ5jaGNpmAEKryrD3qFT5fiZ2zpRa92J518O7bVNF8TRWtznyZMEpu+6fWvc/EDstnGyEB2XA57VjeE/DM11fC+u1PnMckkcLTfH+rJb4SPYGX5etVtBtnFKPI0uxxqxw21uFKK0bHYIEGGmPY+uB1z3qjHpdzqMUi3Fw2YWGEjVVVB9cct79B0FbU1lJ5cixhdzcyspyT6Aue/sKs2R2QRTxriJQ0crjj5SfvH6f1ritrZmnLpc5Q2M8N7aFbuQPA3zBtuUycLzj6n8K6m7s9QS+SGKa3S8EeSnk7FmB6g7TwR34+lZL2tze3U8yQKzTIe/Ve36YrZsNQmu7aBL+Fnu4BtSb+9tGcN9R3oglsLlsStPLNaRx3FmscZIYmBstjHcHHIPcEn1rWtkmgJjijmctglAFJ5+8du7r+FIJTPcKYxi6zuUuQUfI4LdhgZ+b2FLZLcOF8+GRWDFeuTEeoGe4z39xWtikn0Fh1JXnP261ukIYL5v2dgQCDjd1BB4HOOtWPNMcxgihu445IA0fnARtEy5AALfeHzEY5rUF2LtXEkEW1htm3dRnpxjp2z+FQ+Q7y29qGUNbsjRzLxuQ5Az69cH8KepdmiK5sTfwl9kSz44MYPlgDGG5+8c9QeR2p+lW5a1nl84iRHBWJm5iQZD47njoeprTjhEMHmJmGIkxyL/BESTyR/X3pkTGDUWSaNIpZuQp5WQjg49QygH8BTsrplqTsXLC1giEjuwl84llIBGEAwAD2Aq402x0kdTtVC3OMtz0/HFQ20ZURSOELhVjZdwOzBIPtngVNa7WkYyozx7OJDhTzzzn8eapu4O24jMXuvLSTIIdxKBxjbjB9Rgn65ptgrf2XCs6lEACYxySMd/fj86zPE9+dI0h7lgczRPGMHBJIwpx6ZGPzrP8O6+krW9vPuSYPtZ3zh+PvYI4+g9BSVr2ZrHDzlHnWx09u5aa5BTBL/AHW47ZPA6DufrVuMxSPtU45OOOevJP64rPZg0ku3dsKqFy3zck5KkdOv481LAq+aY0kQsqKr7DwQTwM+/PHYCp8jFosCNFl3QqVeRdrDGMA8jPv/AEqQSMimON9kIUhgp6d+T647VHC77gwUM5G3g9Rznntn1NWIszZyhO1lwAO2OD9fT6UgHSRq0WSMq5yB3yeh/M9/6VHu+ZGnBIHz7RncpJxz6n+XNPuJGkxkqjEggkZ3ZPJ+o6fXpSRxeX5fzH5yzfKflJPU+pJAxxTH01JUYSIUaDb8x3LtBMWeflPY8VOOXQLGpTqMgl2J+vTPTI9MVHaeY8L3UscghDlY2ySu4HHOPQjHPp3qxgqr7AS5bG4gbyB1IA6dT+fTNMjqJEEWVhuxOfv+WCxwOx6cdeO2etI8bs8gyAi/J83RT14GOw9O5qZUAnZSMKBgKxB2gcZxwc5PSpCsTsQVZkBOV3bsH0BH09DSC9iopZ4kZXQx5yR1Vueue/40PE0ScMFXoQMgkZ+6cjGPf8s1VchJonRRHEHCgDIyM9Tnpj2OasyKJWJRWJ/gXzMYwe69x14PbmkaNWJGgWGXCOWj8vdjAcLk4JyvA+uKrXKOEYNB94HhxwR6gg+lOYIBvjmKt8xIJ6LjkcjpioiFTblw2BuT+MAE5BB9aGOIrP8ANG5cJHs4CKrYPPJHPGM/p9KcIPJZMBpEyCQCGJHPIPGMZqJSsYfyx527LZDc5znkj+tJOS/IMYic4GWJIPoWNK5YptXWUOERlGSyt8pz0+Yfh6d6jZ/LID5QnI2cgMcdvp1qWLaXAfG4ceYV5x2znr6c1WmGQ4Z/mLEDdkq/t7dvSj0KWu5n35Iu5IOVAOQSM5yO/Y80gQFI8blYYOBjHX9asKiiB45kAH3UZScKf7wz24wRQ8bJJk7CpIz3B/HsaRbdtDPniVGEcW8gHIAXGB7GsPW2uI9KuJLJUmuVG6FH4yc9M9q6eQlbgRGTBJwCei+1Z95abAyodztkqT29Qf8AGi2lhJrqcjbyy3thHNdQLFdHHmITjn2/I1k6jbElyEUoeNvTH4V1zwLJvjb/AFoQEgvwRn0rEu0AYiWPKMc8dB7n/Goa7j80cRqFsoMgKtgEYYHIrnru2Q7mVAoAxx0Nd/qiK252H3WKv9PUVz01oDJKFPGM8Hr7j86iUb7GE43RxT22JGEmWTHKjgH3z7UafE0FzuHDt94DkE1sXNuqSPv3KD0z3qAKgdSnyjcFxjoff2pRfQ5ZNxZ6H8O9biguXtrhRunwFkJwFPevWFCWapNIysqnDKBzz0x6188xAmSN1OHByCDXpWh+PI5bGO01OP8A0iMbRI38Q7fjXfTaa13OmjiNddjsm12ET4EhU8qBzz3yarXWoebG7M4wByR3rl11DzkYom524HsPersam5MOEzsIYjsR71m22z0HyyWh5J8U7C7vZI5IFaRUY8DnrXAaLYm71KO3k3Rg8scYIAr6ok8MpcI7J5UiL8zB+2elYF54NtZhLJJEkDp0kXjNChKOiPPqYaNSfOmc/Z6LGmkr9kQYVR8wHUVr2XhE3M8bliEYZDDgZxV/Q3htQbeRfnjPIbvV+PW1guGjgOIgOO4yapxi9WdMJSpx5UGm+CBA7bnLbsuS5Jx9K6S28NWFkUeZwSOcDt9KwY9amdn3MRngYrP1jX/ItyWclgO7dqqLgtkc1arJbs6jxN4itNLsHjt2VBjkjrXzX4z8VtqV2Y7Vjnd8zA0njfxbNqFw1vA5CD5WOa4lT8w5780OTm7y2PMlLsfTd1CwIJ2DPKr0xVLUlUQC1j+Y3DbGwMYT+I4+n8xWjfBvM34Y9BkDgEGsyWyEj/M/IyB8xHB7ZHbNc7Z1pXIUjktnDRO0qrlTGAS6KR/Qdj/hWlZvG09rcFlWGSPYXQ8JKehz254I/wBqrunQotvEse1dh2qFGM56/hgVFd2nkTxyQMNkhJmjxwDjkj3xwfw9KpKw0kxLGwie38u4IMdu+5GJ+62QRwOxzj6Ct2zkkuIUS4J84Fl+Y7iG54z3BwMHpxWTpt2811K2czXEYIzyruvDHHZsDOO1a1tGFmaR5C0TkhVXj5mI+Ufzpq3QprUnsI25acBWaVoowSCd+PXHIPbsDxUdz5iSgRKga1fKEn5WYHlfXnH5gVNpc1xLclY4yViBUN2XHXHqSOcU5Y83DpwQVZRxy5BGDVX00NJR7k/2hZ0hePa7zIR5Tn7xBPJHpnAz/Sq17bCSwJth+9bEkSOMHKjp7EgEf/qpTHIt8nmP97KHy/4TxkZ7A4z+lXN5h3R+X5kUhLKQck47fj1/Ckw06EGkXXmI8QVXjYeaG+6GVlVgPzJz61oRyxys8rEGOTKEgds9RjqOMe1Y2kQERXPnKX8lh5eWyNuCDjHc/wAq1vNluxI052NtDYU529xz6dOO/Skh6FHW4UvwYpLbzQnBDn5SCMKOOcgnI+lUtN0+7kulvNQZ5XhjKKshLbVAwF55AHTBrftYzMVnTKpjOepY5549ecfgKVcRzMqFDGpKsMEEvjt6k5GO3U09Wae1tHlQ63RApUs5yQWwOOPT2znj/GljQQO+FjKyMWOe+eucd+gx74qaKR3tsyEqCckqBlj9B2xwKhTMSBnRWYAswU9e45/M49OakwLkaxkk7mx90Ltx/knP4VIDH9oVCpxkZPbGMAYH+0cf/rqpJKI1IlmCKSqp8wGMrnGe5PWp1jadk3v5ZDFtiEjtwSfTqQO1MVu5LGS8aAoMpllw2e+P0xgCrUS7JiI8DaSZVwflBH3c9cYwcDqarsYo0ZYkCuADjGMcH5fXJwPpUnzLJGhGwpuY7iCN3bA7D3P07ULQLXHea622NzmRlPAO0KcY3Y9QOfXmmWocRFzE8UbuSuTjPPXJ7cZOOme+RUEi3Js/NgWKYqfLCtIUMg3ckDB4789fbNaCtK0fJVA+GJcDAA9ieoPb/CminoPZ5BGSMkkk4K/ewDjIPT8fqaXylbcC6qVTGA+ADnkEYzSyzBD8rFyo+TuSepIOBk8Drx700J5ihGVlhUBnQcEZ4GP6dPWpZKfURIv9IjVmkSVT0DErj156cDjvUgVZPKlh81kx6EFxjoM/Xoe9PRlW3QyIyFsFlbIQkZwp5wSM9vemNJGRucIW52blwP8AaOO9AXuIoZI4iRLnGVk8oAAg55z7HrxUZMaBx5gQNlWAQgN1Ocj69OelRsrozCCZmmbBVyMbVB4Xng56YPpUiuUVY5YfMYksCfvKemRt/DPNK47dSkFKEMuxXKAF1cE/iOw/rVdLuO4JiysuR1ZSucHuO9aQRI40WVZgj5YfdAb6sM85xx/jVZY03qTF5EcfJi+8/qc9fXv6+1KxtFrqORwvIdPlOWV25APqMcH86juVdygXAjPO/flRn+tWFMzriZ5WZQwBYYBX0OOSRn8qieORCUZYML0cZZWHYc8igE1cqzWxBJAznqCeD/8AW+lMEXmWzKSyrgE5OR9DUxdPNKk9c5O77pzRJ0C5VhtwQ3BB7EHvSG7mHrV0lrbPdyAiKNeo5GegA/zxmq/2r7baQXEDExsoJYPnZx90j1rYlt1kLCVN8e7ONo49M9qz2jhgyYlUEdlA49R/WlrfyGrGRLkSrJIxR2IjGBjIPvVG6tJC8okkDQn7pA+6Md635544pI43UMH5GBgfUVm3Kh3cEbQPmVlOOfQ/1plXsc1PbMsaFfmIBBJ/jHr6ZrGvLaNZhJHuKtwVA6Z4PHpXT3UMyxKI1PynDICAayL6CTDSRldhB528r6//AKqiWhLRx+o2xR2BUtHnCkcgViPC8bEEEhjnGc/Wu2nCeZ9maLHmD5Si5HAyMntXPX8SJMVJ2ZOQTnn8aylpqjGcNNitbyhTjackYz6Vb3iUbScjsagCCM7RzgY4pYwfNIIPI+9W0ZvY4mrFiyvJrcuYpSpxjPqK6XTvGXkfu5oFfJGGj4OK5CZG4I+/69selURNJDON27gcEdPpVKs46M0jOSPaLT4iaagCCB03AA55q4/iDTdTj3I4ZWBymc4968JkmkEu6PGe45qS2u5VYdVZT2PIrT603pY0VdxPSNeXIMkB2EHAbP3h6Vh2uoGK7Ejj5SMYz3rNh1yeS32yHfEv3hnqapahcmONpImOSMlal1NboHiZSVjuzqcZjyDtH1zXnHj/AMTFy0FvKDIxwQP4R61m3XiFoI8qSHIwf8K4+5ne5uJJpOWc5NbxmnG559RylLUizzzSp99frTacn31+tSI+q7+Py5pASME5GRwBms5YFkkALbwMgY6Adq6DUbRZ5281toJwD7elUpUVSroOVJ+VRyQOKxt3PRT0KpknNur2sQeXIfHTLLj8v/r1fgUX1mJI3UyMCwycHcCeo+pI/Gorafy5lGwCPd5uB7cEVYSRoniEKqrGQkggYQkZx9DitEMp6WkKak0hRmWaMNG55OWY4APrww+la1vbNdBgQUjimLLz/FuzkDvzx+NVLG3NrfSTogMMbBcKMsrddw9Bg4NayOuGRcgyH7w9QecCklbcerJraRwreTvJMh4PGUIwR9O/4UKpjDpGRvc4RyMbUJz17YAI/GnWJ23TTqA42vGOevTv/L0xTr52eC0jUfMSYmCKeSOcY92AFNsfUabaOaQHadpRWZRxuXcxXp0xx+dMvoS8c4LlDIv/ACzySoHAPsDk/gKmiIiiRQVWNlAkQc4wDwCe2eM02ASOZHkIMkjBQHyNqquMcdRn86egru9yppBke71DlFt459oByF4VQefQAnjuafNK8175cYDLtGRggZAyenJ4Pb1NO06KNNOcRzgvLmR17Fmbk/l/L3q+saJM7WzsCu9QwP3AR1+vX8x3qbDTLNqGgMSyEBgOFjOBnqCMdOP5UhQiMBd7Ox+83Oe+cdc8UgyB5lyz/PxHGCMEdMH16f0pbhjIWHKv8qnI6cdOPyPtTZEtxksctw6L8sERwSeSQuOnv1psZlVIDlS+wrI2OGPt7DnNSyzBYZhJjceAu3PQZA9s0xUYMWJI3kZULwWwR+VSUndCWiRhEUsSyMMSADk89PbGfwrTt5d0IbPfLZ5Yj2H64rPlTyljJY5VCwIHCLgAfQ/56VaR1iXcSGH8KrggZwCc+vam9C2rlhXVNu4AJgAg8n159B9OtJBIkgaWNDkEndkDzB3wQOn/AOqoi7yzKisgjCgEg5LHnp2OQB7Cp1kiNssbAAheSOcjHKj1/wA+1GoJEqRzbVC7oo1QMzAkZ4znHcD360xExLGqrI0zsz71iDbTjdkk8g989KYskKgBPMDquNhcj5sdCOxOfwFV984yio8jSnaERc57Accnofyp7IrlNgFfK+VQ6Mdu5iSX6ceymovPKTKiRssrkOzsxOM8DPvnpiqkE67ASIg2TujclWHHcY9uB6/Sr9rcGLfbnastwoyZdpZE993C+3PH1pEONkOdJ2kYMrKsZwScB8g5bHtnv1600mR1EroI5T8uwEDA/DoPb/8AXTwsJVx5WxIgCdp3KBjBYk5wfr+FLuU8xoQ5BCFlGcHsPwxwKRNyp9kSPELNCsIYr90gAeqjvj2xTorOacCG3VGdurt8p45yT6+nerWwlUVV81Acbfl+bJ54H8v5VXkB3FUKrKPm2qeuD0H+HXjqKQ7toiRWCbndtxHTOw7s9O2OnT8s09WRjujV2MhJ6fdPqOeegpjyHzeVLKzA+YBweOuM9f0qaZZWUi2KeavAD4P5jjHfrmgq3cib5iMK4k6/c5B/2TjvxSXfylZI3KZPCOuAR1I6/wD16akr+U2cjk5Q+vp3x0FRj7zANlT0JOdvt9PpRYtR1EldN+5TkHng/MD7f4VX80SRFmwSOSAMZ57/AIVbcNNGoR5DjuwypXv+I9ary28KOzRBFyoVtvHP+NJopWK3kRtIynAyowedpHp+FVZ4GLbolVQ3BYcg89MVd3bCD5zkgA4OCM5qKby413O2YpGBJUnGenTtikGqM27tw4AKL1Hfp9KqTQh4ZFV1yD8q46D1H61rXXzIoXlehwcis/a0kagqFcfN9P8AA0x3ZzssDZVWDEE5Vs9P/wBfpTfJCxLKNvzZVgBnkelaFxB87NI6vtyDx1FUpIjgEO0ceDkEADOe5/KoG9THubNSzdCxOCcY4FYupaeFy8ihht+XJ/HFdNcWXILBkZVwQvTPWseaWK4klt9rb0PccHFS2tmRK/Q5kW2xzuJ2jkE8d6jih+fI6AZOa3VtyGfdH+7XqRwB/k1mzRxsm9WcbTxjsf60locjV2VHjbcVypjx19/SqklqSxdWVlA+6BzWliQwhuWDEjBHJ4602EozkOxUYyMeg7fSna5CVjKe1VQCABg9h19RURiij5QsqkgfT8K3p0M3yRx/KV3LJGeVPv6/hUA08rwG8xiMYOM/iP8ACm4ikjECskoCDpzkHg04yMC0crbVJ+mT71JeQeU25N6tjLL2P/16oXUJWVHR3kUg5XPf3pJ2MWcxr8MccitGT6MPQ1kV1uoxC4sGVU39w2OQR29q5YRsXK7Tu9K6aSvaKIk+rIqcn31+tIeKVPvr9aok+v7gSEl0Ybu4zWffRKqxOxLSS84HUHua1ooPJ8xGLsGbHPpnoP1qlqEhhjWVsptGDznA6VCWmp6N9bFZIWkmi3qvmKF3MpyCO/8A9f6Vf8ppbvy5IwIpgwyw7gYGR3A615rF4yaLxRNFEE+yoRFg9I1PGeePxr0oXAkgieCTMcxHz9Sy9wPbgdOuauMlJA04uzLVpEGgmaPKRyM4DL2Gfl/HvUtuY3uFI2sY4+AOSPX8c0seFtx8rgsuEj9CcDn3JzU1rGsCTIgG8MDkgjbjGPrz6UWGnYYqLbbYBgrEchQMkAk5Ppkn+VSxSSP89yu5lAZEjO0bvY+vIqpdxsoVss+5SSW4GemPfrUwcy+WGBVkG5h02gjHPryBSYPUkjiLxkjA3L95cYz2H55qKRjmaNQfNnYICBgIoBzg9hjH4mrnmQWlqkjEqm35RjJBZsBR6noB9ahsAvmu8keBFu3LnOTzhR9M/rSsK9yzAFjWKKJNzom0jIURgeo7H29hQAsSRrOqAKd23B3YGDkj1OMVDHvUlJFCcADDZwe/5ZqRwTN5aNuckltwBwMdSf6dhQx+Q5A4Uuyqigbm9AOuePpx9DU6s8aouPvcADgLxyfy9f8ACq8uBJExAYSOE5OAABwcd8Yq2xdivlg9wGY5OMjv+f50gepA9thHmldlYlBEQOjFuAf+Agn8anUIA4ckndjarDcSTnn/AD3obbiJXJQk5U+vPUHseKIo1SfcobyU4JIySw7e1AIWZDIGbDOCQAwz+7OfTvgdu/SnxsVAZmVYk5BK5II47ZJ+lSBZyysBlyRgk5254GP1plvHMbhVXDxjkc/MzHqxyOnJ4oKvoO+aSUwFhvIzgOGIB6gcAADvUk0ayRyRhWQ42s6Nggdevb6j6U6Hcqs+0bjIRtOOFHA5PQ96jRmETLtWb5jmTPUg5x7gd6LlLfQnkSMQ7MLGCflMYOQT+PT+WabbARLGJAtu3SNekhOOoHbGPx71VlBjgGQ6h9zMVI5Ht1A9B601rie5jAuNvllcFWALKMAYZh14HT0ouaKF0aN1O73Bfa4a4Od5y3PXnHf9OetSzfvYTIHSMY6jAGc9Tk8n0rNtpfNeRJo5I4CoABUruxjqecD8TV8cEhY8gncPnOT6Ngjtj9aVyJLlFgDFIvtBDog4TaVjbHT3zn1P0qQSMjrMsTllBBTpj1yT/T2pOImDszsrj5wCME+vfP0HaiZSwEhjYoFIQjjOeoGfyoIvdj5ZhiUkxrICF2gbmUnAx1xVdHWLCNIYVTAxjcGBzgAjgfT9asqE2F4Bs8tBkbBxnnn3J9SaYxcuFuA56gEpgA+3Yc/XvikJA6gzKY2mw/Pl7doAB4Kgjg9RxwaR4/MkR1hM0vAcLEQc4/i6Z5/nT94BVZB5YwdxJP7wntyfrTAj72DBXROA2cgD69v/AK1A0yldaZIxAhbySpDDI5IP58UQrIkKhSVXIUg/MTV0hvIKSSDdJnY0ZPy5+vBPA5NRq6yqFuIpldRtJJwMdvw6UGqm2rMqSpteNmWUsG+XB4OfT/D2pXXEqSDay4IGMgj69qZsaKR4w4dYwW2jOWHqM9DTSdqZnbLp1HTB/wAKRT8ynIpL8IUAJbHUNjrn3/KmkZjG0qV+8M8cfjVuSMKx3gYZuoPT8qa6nec4Dk/KTzvx2FFjRyTM2Rna32sxAPdeDg9D9aqwwKikJM0pwcktyT71enkEeS+BhuF25HPYVSZgvKJjZy2T25/Kiy3EinMnzb4xngluxH+cVnCOQzzs+WhcDC4yy1umGKRVkUEYyFx0wf51mSxNHKdu7KEgjdnrzn2qWrgVJLZiSHJ2dPm5wPcVj3Nl++3SHarEncDjntiuhUBwHBYMw3YGeT3/AP1VjXbDMiNIwEbbuV5JI5NJx1uZyuYsglzKkQ3FELkAdVJP+frVFlcSxPG4+z+XneBkgn27j1reW2fyynmOCSRjHDAd81RdFhlkGJW+UMAVwOP5VLuczstUULuPPllQuG5VhwCR9PXmohJDG23aBHgkqQCD0/LnvV6AZd96jyCCDG3JHORjtVmW3RvLIGd6kYYYZR/X3qlrqYzaWjMt7OYTRG3RWnRNzRswwQvJGPpz/KljzLAzIilAxxj5guecE10dvpcFxHHK8bOYsjfnop6cD0wefwpYbKOxuVil/eW7LtdVONoPG4E+hGcHsa2USYzVrM881yyuNS0wppzyC6iO4HPbnjNZFp9pjjRb9FWbgMc5DY75rvNctoNNSSYyCNCQi7OdxycggeuMivNfEGuo0wFkcJIMs5/p6H/61T7J30JcebbYg1K5gs5mkORc8jZnhwehNY17f294zSPCUuCoHGAo+gqlPK0khZ2ZvQsecVXP4Cto+49DKcUB+ahPvr9abTk++v1obuSfa11bAn5t29W9e2arTRptCTRR4kU7s/xA+v8AhWneqBclz90DBz61luFKuVTLb+EPOVx046c0onU23oeLfEDwtPp89zcWQkaF1XACksSX3dBwo9j6CvTvC8E8+jWtzNFLG2zaiZz5Y6Yz/XuT6Vp3apd4tsAYIDNhdqLxuJ9CeB+FakKiJ5TwybQFYDjGT+uKFC17Grm2tdxrRruUKmWwgXLcHkn14HeiLeZnhc7mBy/Jwp9D+ZNI8CboTu3HaSWz3x1+nb35qQriNpAcucjbnj8z9D+dPzJuVnzJPDOc4QEQIe2fl3Afj1/wqXZFbITtLSO24bRuLADHT8fwqGzLzbjjbu+YIVJZQCepPTgYA9KttEtvkxq7S4A3LyVzxnmk3zFN20IrJ/tkcEsqCNVx5cQHKcEnPvjqe2eKmt1i4CxFVzv68nqR7d8/jiqyzKfliARAdpfJIC56DPUk/jVx2RFSPaFY9wM8k+/fqPzpWKSJHKRuZEIMuCN3Hyj29OnX8KTZ8mJsBZRubJydo5OfQcf5NCW6+aiq2wABiN3YcgD/AGucn61T1K3ubnZFZh0SSULNsG/bHgjnPp97b7UhwjzOyLaMhuYW/dzyh8LEjccAk5J4FXmDPuZ9zRjGQvC59B3xWPpNk1lbwwyPFPd+Wu6WOMIGY8Z2fw8DOPWtiNVYRx427ugPJX1OT7UNF1IqL0EjjxAS3yg557kemf5e1OgEZ2+XtEYJ3FepP4duR+NOmgLxkBTgDhQD8o9T+lPRhEQvlnaBktjqP6/SkyI6rQXykCRyDC46Ag54H86jjZ1i8zY6ofvO+SD3yOeKsuu9du7YynOR/Cfb3z+fJpkkMe4bY5JAcMq5wBj3+vb9aQLbUjWZChw4kbOSSeRx04HXBxVhiUjiDqqrk8M3zEHBA4+n41G8qx7U/duBkjA757qOfpzTmjDqW2lCTxlFXIzySp+nX3pj2Ggs6gbB5j5+6oOCDjgeh7j0+lMuPIbYQjFmOWIxtJz0VejHNW4zFhhKFwFHdvmH55Ap8pY3DSK5VuAHXBHT16+2eOtLYalqZ9ubnzma7XdGrmNVI+VO+APp39c1byx2qFzG3J2ZAJ64z2OKr2kpSV0DLndw2SR9MDuauMSyLtRFLLnzM5KgEHr0/qKW5c3rqQDByyxyDZn5tu5gO/XjaPXv2qeQO6neNnYEgDeM88kcAZGM8Zz6Ux2IjaQSYQsN25c59D9PSmrIWBeNGZDw3y53jrjGP580iNx8mVj2STMWCjbHkvkH1HGalD/uwH2yRg/NhmGRng5zx37CoSwkuHYN5cjDaxddxA649fyHpQYws7BndX2jcC2c+m0dc/UHrQOxNE4eJoolEqgBWAlUkg9cZPBGP/10yFwxVt3G3A2ggMc56H7uPSq0SSQuxihjAyDlmVQwJwBu759O3erBkD/u5Fww4Cdxg+p4x1pja7CeU7qVRVKMSGI5GeuQBnPNRoDtKoC6cr8rYz6Z9e1TmSOG4AYbRIxx5iZ3cen+e1REBZCbfYr5I54BPfI6d/TFMFcijVsRCVSSPkOMD9R1NOcuuEf5jglioxu/P/PFNuIw2/cVBP3l9APakEiNtJZow3yfMpzk8Dn0pFbkM0QcK5G9CDna3Q4qvIpEqKu51xncv8I9qmdXWZ3YjqcArgYH/wCr9aZLENkMucxj5vvY4/r9KDRFK4jctlt+AMgdQfrVSRQU3M+5VfacjnpV/A3ZcsCzcA9u/wDKqjQMzoxGWDFlVT6UIozHvbG2ffcuIctgBiQSTgZI9OlMliQuRjYpbacc5Hbn8ak1vTbO9aOWWMoyg7gDwarXUX2R7hnZ/KIBCjJy3Tj0qJNmjUbJx3Ek3KJIwMOeAN3HPX6/WqF9Ek0sZdCFHyjPbg9frxUk1xci9LxxwfZY4vkZidyt6Yxxxj86iickxhWABXdtbnI6/nnFI55rQpJ+5ieNl2oz5Urk57fhzUBkMrC3u4j5wUEsOQw7Ej9a1/IhMUaBXCpkNnjnceT+PesLUHjs7mQSsyy+WxjY84Hp+tNnJJkQ8lJDJEwEbDlXHOB049v61JdSwqyyhyoyoY85zg9Pbr+lc5d6wvmSMpGwjGOoJ9f61kT68scSAsqqgHBOScHJx70RnHYwd5PU9Eg1eOO0RZHGZZiAvQbQfmB+uFIrD1vxE1jJIyMkrxR+W4fBAHB6HgHj8+K4m78SXc7iK0KqPMAzwxEjAgDB/wB3Gfxrn9U1GRZJx9odi2DyfvA85J+v/wBaui9tTeFONtS34h8Q3OoCdLiYGR28w7B1JP3SfbAIrkzIyk7OhGDmpSs85LpFIybtoZVJ+bBOPr3psBjjjlkmTeSpWMHpk8Z98fzxQrvUyq1FtErNkufc0FSM5GCDjHegqwUNhgp6HHWhWKnIJBx1przOZu43tQn31+tPcrsRQq5GSSM5Oex/z3pq8OAfWhqwj7ivW8zzM87c8rwQO9Y13JmKNUbO45X5hxz1PcVqTSGNX/eAuqtuOMZ/Ks6O3f7TK7d0PzMMAnjt6YqUzp0TMzTckzNdRsW8sEurBiX3YHHoAM5rUifYhRixQDZlR1x+GPyqI24jQCMoolbcXC5bdntjtg+tXYwiM4hQKg+9lsD/APXxirkaymmtCaKNGU/IO+Cvf65+vAomdhOseCgLDHoPp6dhk9qPMCorkAqeh259en41VVg/nCZnCPwUX+M579z244pXMty0il3RgrJDKT044z/KpZVVySQvl9NoOe/TPr2/Go9qRu0e2TcybVJOO36CjzNluhjIIPZOx9B/n0qSgtfOt7lIVVCzpgEjhcZPJ7d+e/Aqx99mlfiQYWMDnZnuSf4j69MUQRI6CWWIADJ2k9fr/M/WmPIMI4dI3BBCgdyOv1A6U2y0TsRuEY6nGRgZyegx+ZNSRMv2fYzgMe5GTjnvVaEEzmYkkEEOcEdasx28ao8bIpy3zcjuen8vXgUh3SKN9INkEbjDyHeUC5IGcAZ/vY/LPtV2Ab13wKcY4TnLdOpPT+tAUu/CE5J3Ps6KOw/zzUkMxDybQu5xu2hTgY7n1PvSXmaN3RPbxnbmX5ifmAXp+I9O1IkaHAVZGYncgDHr35xSxDzAsIGB0zz2/wA5pzSGMlRIrFWAbd3IHQfSkxIcuCq7BmYjYPlJwPr09qWV1V2QkBMALgHGR7jvnAAqVSdsaAOgC9Vboffv/wDXqQgl2Cw7mUEKpI5qQuVZYpyoV12knGFO447ge2e/406NUjzlFc5AZ8gjIx6jO3271NJBtKCPMjtjeZQdowOvGTj9KcdqRO85chAC24hD/nAHv6dapaC5rjEkk5YGPavzkcAZHZuec8deaSIqjNHLEjt1Kxtty3bJ69+n41Kq+Yhc70G3MbSKQS3XPPPtzUFjPGZ5oooZI/s5MZcggOSPmwT94A9/rxgUmUthYYmjmRnYxZXYCjcHnuBz9T3pXVEmBOMklh8uduDgADj8qtQEEB13SSyArGgY9+OPXPNRyxNsbzI0eU5XCNuXOORyBnAGPX3pA3d6lOeFyd7o3l5PLLgsRnnr06ipUit43VST5rDcUyWYcdepxnr9KkhhWPLSbJDnO8hnb6bR8vr1z1qKKNTGiyRyxRx5+UgDJ69P7vegadxrOslu0gll2jlmd8ce59PYetNW0uADcyJb3cBxtSPh0B6g55yepwTn2qwtv9pcq6um3ksUQg5HAUHrxz0zQ8caxmTydkZCoXckA556d+/TimUmtkRQvGZGWVZwpOQrONvPVSBltw9yR04pUZd4TzisMmArHnacZxnJGfwqOWOzhJVcBpDiMvGkfP155xUPmwzh3P7qQ9Pl+X3/AB9qClG+qJ5ijyLHv2MTlWZRyQPTv+dOVWVWWTAZlDAE8k5oZUa3ilVNsyuxXOBvB6ZA6VJcY2RkMsTcBdpBBJ7njOOvSiwvQqtMonJcqONpXPNKwQxLk8E7lJ9fT+tTi1ZDcgRiSL7xXfgjPTHPToe9U3hCtGYfNEZXDgsCWPqD6daWxWj2K8rNEAGkwJmIjOANo6Y/PNK4jEpcJnC+WwI429eP50+SOSaZIAFKYJdTwc+xpkzRicKzsS2WIXlVHQfypvYshYRhwFypQdB2z3/Kqr3DNJICoj2fdcHPPf8Az71LqcbNp075cPjkhsHGOn9KqgiycbSZFCbRnuQQfwNC1GldXI7whQzqcxkLkYzjvzWZdB3G9WBUkENnA2//AK60tRhE0zAOREV2lOm7plqoXETR2iqgVN5ygU9TnOPbp+VTYpWsctqOqbZQr5QM24tkfL71p2s4lhQqwG7CD5fz+tZWtaSr3pEauU+6M84yeta+nRpHZIq7d6fKhPHJ4B/Goje7FW5FFWKl7fNGQ4ykbj5TnnPp7dK5HVLxmikLM3QkAnOFz19sV0uuWjG3dW5MrEYB5yOa5m4s8pu46Fdxzgg5HX61M29jhm1ynm/iO5ks1YIdoclNh5/H/PrXOw3DSM3mlj8uFVeOemMe9dB40s5Wu4wquzDIA9RXNCKVMNtZSOVPTmtKCjynInK+hZmkZCiuRgDI55HP+P41XuZVdisWRGAAM9T7n8ab5bscsDj1p6pCI1yrl++Rge1b6Gjc56PQkmvg9sYEiCoGzGSfmQHORnvn1PpVMAscL/hVtIo2RjuUEEYU5BOe/TtSpbgS7GwQcFTwQRTu2R7F9yCW6nlt4LeSV2hg3eWhPC7jk4+ppiOVVwDgMMH3qxPCuWMYbYDjnt9e1PNk5AeDLEJ5mCOceuKabvcl0mtikQwwzA88gnvSL98fWp7uWaYp50jOFGFz0AznA/OoE+8PrRKyehnZrc+37tiWMghLsoILBgDnFUy2/coxuVApBUtzjGMDr261bkZmG9dijf1A6e+Dz7/pVF3KOJG3+TgsrEDPPfjr9DUpHVPUrPtkfYwcMXG7PCA4wOPb3p0G1YQyhnZcErI24E9M8fWoZ97PtH7tshiS2Swx2+uRirBmkWNC6AIF+U4DHHsfX8KdhJluCRSyKVbcBg5Yjk8f4HikgGxMrIFJcOcbQD/U/XvVN7xbeEyQ5D4IAZBnOeMkdgMntmnxlWkIkleSJOSxw2zHGAOO/HPfNMFuWpslozGX2SAFiTg9e/5n86e/mRMrJhwRgSSZx+Q/lUIkbycqCo53hUx09yfUimrcYvliDHcVLsNpYhdvHt+FKxpG5oxR/unZd0px8zEdOf5UiozXDY27AB1wSuOv44/KosSKSxL7XICgtwecEkjof04p0CK90UjjZQAf+Ajj5fTpx+FSyloXI5fNzHIqMFG49eB6Uke4Mq7UJQHvkA9857nAoKmKAhSkbleAB9zvz65HrS2aNG8pfaCwXkL64Pf2pbsXoSDc6ussSEn5QCduF9/apUgIIaN1DvGcYHIB/rSO+FZgevy/IMhevB/wqVmwrKqM3Ql+mCcdcdepplaomkwA7RjcEGMbSwBPb9RSwIEwpYNMBtJbk+v86ZvSMM6klSSVI6sB9fccVZ+feqKBtwcFSd30B/KkGoBis6IV3MHJ346Zz1p1syGUqp2sG+ZlJyTg/mRnNJFiaMNgj0kI6EjnI7H86VSNw818AY2RovABHJB7nOOPf2oBjlQLEqxna74iREYE89Sc9x2z05pt2sSKQ4B8sj3JI6YzyenXvg1KcbgpVQ65Cgc7l55HrUkRlSGH7MIVjQHhvvKSByD1AOSff8aCepWMbkCS4uH+1Z+dXXO1jyBn2GDnPWpIIiQ8ZYq5GQz5JfJ6n0UDJ4/rVuZH81AikyjcrOHK7DjnHr7/AFxUSRSoyrNDGJSS2BgFQMcknGOf1/KkVzXRC9s8jmSa4kKRDClCA4XHQkgAA56dev1qSNI5DIsYxghRuDZ6fdGRjHTryatyvLJA4eMxlydyHBQEjpx29z16VTtp0u5JfLWaZ+N7GQkqnGfmzgE/T07UWBNtERCMzgZ+T/lsSCCAcAE8YBJxnkn+SEmFQiMtrk5EbAsvX5uB07Zq953Bh2tcMy52SLs2AcFnHb7wA9Kr3MEktwYoQsJThAp52dRyfXsfSnYIu7syukqXEgbzfmJO0fMFJ69McfX2oigt57gqzSLK4wpK8bQeuQQDxx1xUGn2EirCxG7z41ZjKuSJASWI+b+hBHbitmWMGBYmtt2WACq6hOCCMHjsc8Zo5S5yUXZMy7uQhT8snTaMRgAZ6YxkAY7nnnrXmur6+thexWs0xcyOGV1Q4Zd20Oe/3uB6njvXqEtobHUhC0rNvlbbEeN5K9SuTggdDjp6Vz13pul63drLqOnW87RLiC4w2UYHGQcjIBx97PPTFVyNrTc7MJWhC7krofpfmyiUmIhlkACmNg4x1G0+/BGK2ZoybeKVSohYKeONrZxsPHQ9u9RyQwRhHQRRQQlFCRsSIZDkFSfTA65/lU58yJ5xKV8vZjPBU4yCw7UpJIwnO7uiiJFby5JTKroCAUX5XOe56Zz0qy7M8cEcmGUEiMrgdefy6mh3EySMh+RlB24wTjrwPw/KmvIkcXmS7FaMHeBnhT2B7elQyWynlUb5WyIxlmxgE8knj8O9R3Kn7UNo2q4BYnk/TNOvVlRmRch3A4ByNox+vJFD7Gi3K4kDAOm38sD0otoa+ZXnBYsoYbAowQQcEHr/ADqiUYSyySBAv3gM9c/xGrskKNHtWMBSfmUcbQO4P06/Wq8pDHyg+QRuLbc7QBwM9/8A69JCT6EE+6NlebCPv6Ec7fT8OpqtIh8tgrKQvMY6/Kec596sSMFnjaWMBAD8uc8gdPf3qtIwuHCKwyWwVA+7xTC5RvYgBMyKQq4Oxfvd6x1CCaR5BmUIAoAyODxn9a3LqJYhNK27exAz3J54/Xise4tUju5CwXJwOB97jH5VDIbTRU1MmfZLFu+TG7J+Uj2+o/nWbLCotY3AxK2DtBztHTP1yelasQeOBfK4AGIyPReDn8ePwrPVTK8nmABi27gnCHHI/H+lS9zleuhyOo2MNxKQiq3GfmPP4VlpplvcLvaB9ygqhbuMY/r+ld01mJlbEjhxg7jj8cepqrDbpG0gco4I6Efd/wAajls7gocqujiYfDMTSOVRypBO0dcg9fYYpLzwYRJIwyCF+7jsB94e1dlbq0xBiKJNtKu6jjrxVgXIZwquWKgqUIA6dcZ7VSkaOrNHml14VmRcbMH+8OnaqT+Gbox7xE6oMgnHfrg16ylyEuFDsqhQE3bsnOOB/SlnYbPMty7oXAff/CQR27Z9a0T8yva33R41Jpl5aB2jTMZBHI3cEf8A16je8lFjZWssIaS1dtjlRyhbJQ8Z4I4P+0RXrl7FaC2xNEokxxgEfNnPb2JqkujwXLzyeWrxuBhNuCMgZP6YrSM3smRLkavY8pVLKYXqs3lv5ZkhZnwNwOdmMckjI+orJC/OMeten3fhO0M6vCJIXBDDLA46YJGPXqPeuI1bRp7PdKuJIUfBce/tVXuc1SN7u59WWl/HdxBAVZsYKE7cNjj6j2oleFZ2UhQSEY/KcqQORjPT36VzWgXLGZ3fAVjtKkBunIbb+Zz+FaDzl1C+YpjC/K5jwygdec4IxngVbQk7k7tLLJEsETukWTjbngckE57e3rUlhcJdQuxdEQEgCLjBJHr0B9Pb3rPnnjWbylCmGVsxsu4+Z0GSAeBgdqzbS8aF5BbwRqxdw249SvK5Hb1yKFoaxVzqXkDM6WhiKqwAaUANkjGM9evJpxjucx+b5ICqDxGcDjkfrWfYXLTqPLjUIOq7PmyerAjggHOcc1a+0K6M64EYK5G8nPtjriixVmmTTXLvKqHYpC/3wq47Ejr70tkVjkigDFJcKBtPJJzn04rDF1BbanNLKAUlxGoB3AA8++ByTWMPE9umqb0WVmxkxJjDHuvOeMfn7VHMluzppUXO9j0hWj3ZhEYVWJ65D+x/X86ntyFk2bMgAMRjDdOKwtO1JNRmBtIrhLdeQXIOBwOAPU1qrsV3VwQ+SR5mQOBj1ptakTp8uhoSYeRzOWTaCCucngZPT1/wofesalXTDZOT0AxgD9aqxxsWGxSckljggenA/P8ASpd+4ZmUqhYAKr/MR3P+fSosJRJrKeGSOJzAWVlBK9CR/eB/z2q8JHlVEjYqqrvJK4OM9R3PGOnXIxVK3URyZjkJfYsYVOAoGecnjpn61aZ0jVHQHaMDae+MDr24xijYbWuhKh+VHdgkGcsFOTkZPP8AhV5AEyGOwsACW6gYzz+Z/SqM2QoRY0VMbyXIIAyefxA79eKklnZIWKKSuT82R97t0/zxSuS4tltAWkK713KQpBOC2TgAD884pzQqZ32x/IW5C5z1JwD2OBmqUby+fukeNMlxk4II7Be4q82zAjjiZ+CMFvvEAZP+fWjcTVhpVk2hFdTggsoAwDknn2HX6j1pxithhREgXKrsUnOMj9eR+JpF8wiWSaUEsU2IuMEEYC4PPHP5A0+NWife7jy40TMje5A7fexyf1qkiWSrbFSAwDEkskEfzBzn5n+g6fgTU37wiU+UmxwOBlmC4yNwPHbJFSwwxtMzQ2pSIsM7QCNuc4bBxknB98DpURLqGDKru7EJgbsPjLMe2Tk/4U7E81xxtDMJfk3KGKlmJ2k5zz3OADwO9VrawW0sxCWIhQ7S7FQzBOB8o5xlgCx+vFaMcXyCZ3SNFPlkB8ZBPOPxyPwNRrFMBETmPzOVToe5OD27fzpWEpPYhKeYw85JHkl+ZyzZ+XnIA9T09OPpTYYPLHlX00UqlG/0UKfJIPBAb6cY6ZHJqe2WIJ+9IuCcqYV4AC5J5/i4+vX15qVWeO2kynlxowVo3bD4J4AHvnoCOoNNIOZ7FJL0+e80T7IvlVpXYCRRjAwP4sfp9Kk8tMxFHAZgGHzb93QbTkcLxnI61bZHFtJcTyBHmZgCI8yAb+uCOT229hzzTd0FnEY1CqQFMflszL8vAPv7Dt7YpibXRGDqdhN9qtp7b7U7FiJIpFByMEMSAAQo4Pr9RVyZXLu+6Jiw3YVDvA4ySe/Iz6e2a0FjmF2JTLKJk+SU+aFUZHDcdyCOueme1RTEzrK0wdoM7EPVskE5UY49AO9JaF+0bM6e3WGTyASknm7i6lSCB0z243Z+oHFOhYTBwIiNq44OGVDwSc8df5U9SskIYCNH8rZt25+hz2Pbj0psojMccvmxqQyo+QArdz9OcnHv2qS077kDR/LIwLFlOC23Jxj+ZzwPxqC4wspVVDlYgQhAJ6dfy71bkEiyPKpVEA5ZT98ngEc/gf8ACqUyhZSUCh0BKliC209fft0zUtFx1ZEkwkjKbFDEEqSSGHv+WTVCEqob7qxAEKDwdvH5etW4m2sEYb2Gd+8Dpk59wOT+FV72aOC1KPGDjKKAdwJz0P55/Knc2WjshodndFhZipACyOcNx7/UAZrOuP3zopfbGx++vqCfw7H8qld45HLSsC20J5YBKs2Ad2PXggD8anlZGikLBWQYA29eeSTjoaTY/hKcx2rEoBfb2Y5JPTJPb39qqOYozEI2jAxl8Drz1q55UYYq6viAcBlxjPUc/nWfflIQsrhk2DDHHyE+gJ7cjmp1J3C7UeWpyofbknPGevA/Os+6hZ0KmQykrnLcM3Oen6e1T3dzHHaCXImLH5VAGUc9B+pqu0jMihYXVNuMr1HToT9aNG7GclZGFapef2pdq0ga2UHG9cK2Tgfj/hU7W0L3CMo+Qqp2sMYcE579a1pIc+cEGJSvDHqB/np71Tuw4k3KiGMgHzOvsePxqbcqsC1M+8i2h9kJDkfLnPr37dc1z8V00N0ttePH9qYFjBkYIxn+hrfv72MX6WSeY0xG7ZtyAc5Bz2/+tTX0+GXUpLj7On2navzMvbuMe2Kzkk37rNEklqULe186N5I3jAXJwe3T/AUy/iWPzHR/MkUAZIxknv8AlVvUZvsRUFSwK4AAGT7/ANKr2l00+lFpVMW8kbSc7SPf06UtE+UiUXa5mElomkKgYI+UHJGasW0h+zhWGHyysxbgjIIBqNlSGQiQjYFHGc//AK6Fcm2eF3WRVJ2v0J645qkYyQycrIxjGN2T0B+71yD6U/THk8kDKnkEAnknJ/X/ABrMiY7yFJX5c/THaprC8KXEyyb8K/7skDOcDNVGWqJldKyIbw/OzHKyZ4zWJqbxzWyK5U7mzgYAFbmpzI0LBQd7HbywyAc8Z/KvO/EF4UnQQsyE8BV7c4OfWrjuc05cx7XpjQyruSbEofKqMiRexHoRz2Oa3IZEaaJUkBMat5iHaTjHzHHYZ7e1cXp2+ScqzqADk84yc4BOeh6e1dI77EDlZ2BwX8xlIGD1BB5FdV7q5CKRubR7tY5md3Ad9ywbNwHIA/8A1VTvLlvtLLEd/O0HooLEnnrgYUimamkz3NtdW26ZMgOrIGO4dQMYx1yKWQB0kmuCDAVRS6DCnGSAfU4/Hmo3R3U5K1yTRdQgkvI7d5pGk87ap5ZM7uAAOeT2+ldDFO8k0EAtpIpcscsSoRQc4J6HJ4x1xz0rzWONl1CRdyJ6OuRtOQcc4x069q9C028kktIxKrnPPmxnJLd89j1PFEZXWp01YpJOJj6/pVzJqk9/ZR3SuduYknADoFwBg43HjGOK5u1so7zUo7iOOaC6XLKwRlxhSc/mPXscV6KbRroFx5QDMwkwNhxjAOM854P1q5YxXCwKhZjIB/rC/AA9RjpjP51m6abKpYn2a2G6G5ihRblZDcAfPvc7ySpOSecj/PetlZ0ng3KApO3IABYdPl+p6/jVOJDu3iONwoBKsmM8fexnB6dc1LFEI44Sq7uVJjZR69/x4rRkSnzal+JvLjDrFiRm6hD8wIBIyPfpitO1l8+RUDKxRvnZcBs89O/rWcBHHCpbb5m0gbMjg+34gVYsyVRA829Ayn5Mctjk/maTIequXEVvlMeQnLYLkgDgbvryePenwHEMq7gI3++56McY3AnvSTOTGXxmVhyV5z1HH5U5GSJyEj/dljkDGDx1x+HSoBPQtTK0ltLGdwiwMtztC8ckfmaltowvlFWHkIcsGJZQwztyO2RyfrVONQJCRMUYsFKcfMDxj06Zq7HIoTmRfkXAQZ+cfT3wKe+ondKwjrku5xH8hBDc4wOce+Dn8atw7RDA6SdSFXewyUJ656evA6VXikfyXiYpIRk7ccbSuMfWnWkghZo1iieIKNoGPlI4zkds89ODTRLvYsTbUYNG7guRzyCyKTwfT8fSud16/vLMRS26hULHdOy58nocjHpx74rpwQNiSKquOCofPzdz75H8/wAazLgxyWjQtHJhf9aVwMA5yS34Dr0pjpySd2rmpo91NNpdvJMtss8kQaLE+8bs9VHcH73Prj0qSDbJFAHaISK3mIQ25cFiN+M8kdTke3QVy/hmbUnbUU1i3gBEgitXQbw8ZUYxx0XgAkjkmupcealxsjk81k2sQcc4XhRwOeSffFU9TKatLQnuI0kPBkl8hAwWYk7CTyR0x3Xnnn2qZkAUybTvDswEjYde6nA5ztGPx96oXV2RfJ5iCAx5ALhixQDIwe4wcc85arNuwkEUkaSNGyk74vlJUtjax6dDj19KETZiwTbfNd94ZflD8RqqjIAH065Pfip0R/s8wuXdVjYhArZ3YHb/AGh0JOe3NVYRIlvGzyKrKxCjYCMcuMeinOCD04qyWdxsz5alCrux+UKBkgn0ycf14pWCS1HAxxIQ2Ny4wVbGSe5GSO2D9DQXcq0aGWHKMzoR0O0HAPU5A6LUMQTazwohKHY0sjAAnb93r2z1/Gm3tuZAizJIXgQNFgkuTjkHHQgc0mKyvqQ3LiCFJPJZ5Z5SSyjDBTj5iB65zjPAyOavL50eoSOXlG5dxaKPORjoMc7ueSemc1EfLitt0Jl2zs28SnHzrxk4OSM4wB60joiTMdizK5B5bDDPJHB+6SCKFoD94z5S+24jurLzHG0RMsmSyD0Hbg9feo2keAsm5pIm+bYvyleAMA9+O/8AWrYdfPdnijMSuVjIZgVwcfLntwRyPWqZjjEx3oqsTtYFA+D6Aj8c/hSNExvmh1kUSO5O7fFgKEOOME9OoyKouHVkGQ2BmQsclufvcdulWZkkQErI25yBGrndzhQGI/EjGOcCmRACKFCXMiw7mAIJPUkr2BAHP0NKxtFpK5UnuWheOaJIlIGwPuJK4yVPoecjmqjRA7o2wrn5+UGfmOSMD2Pamao0TWP2jyzDCCE3dd5GST7ADOKrb97CdXUD5CMAEquM5+vr9aRtGOlxLlS7gvF8rAZ2EBufQ9uMnrS22PtQLyKQTtVsdMccqOo5zn8qdlQjiR2CKdpIbjaxJO3tgegxxmo1mZfNaVAWRCBsbjcR+Yx9Oc4osTJvYjkdkLkhy5+ZsDoMkZNUXBkCwnhNxYrydynJB+g7VfWUw2qyAByF3I5ycnsf5jHvVdSBKkcZAB2g+ilhnPrikCZW2rGSiEZOTnoBxwf6VVBjhmCKsg43LvPX39++Me1SXL+UpaZCu0ENuI+hz+FV7nLxHyE5+UJg9hSvZaGcmNeYeYyhSu8dduSD1556UhO8SRMpLhiCAOoPTHqOtRRiW3kBmZGUHoep/GpPtKwlIwrckEE8gZ/h9f8A9dK40uxCoigl3ELkAYJxk9sf1pZbsBwigO56Bf8A63NRlPOkdZMZRs4c+vQcUzy0W7WRJG3Jwwznnnip1Cy6lC/tWur2OKZGWLZyVXkHr19ecVBPBEsQhsseQAWAOCMZ7frW9KEJjaIsAV2g89Bz19K52ZrmO4PTy2JXIXGwdsd6iyTFdszrxYynUmQ9eORjtUSARANHzIRhunzD1qaZmRdpdRg/Nzznp+XeqIl8sTFlYDbgexzzRfUh3RWkxEXSMDbxnPX1qBZx5qnzMFTnOOQPX8qlWRZEZx87BuS38qx7u58qbgAs37vA46dPwpXtZmE3fQj1a9LXDbSQqjaoA75J5H4muJ16dZb8KpyEPUdD9K1L6/mLTMoO7k56cjr/APqrmWcvNuJzk1tSXU55KzPedMiP2iR4ZThX2kt8wJOeMduOorZVvKt/tgt3ESAquwADPGc4zg9fz4rFhn8u5dZvLKndnagBQgY/mOtbrySWsAljTyVY7XhBx2HO4ZyOproT0FqmR3sluqhbQxMsq7nSNeQTu9sjGKzrlrVpHEir5gGT2zj5Tkjgf4DtV2e3KfvbV8qis6nI4UjliRj3H9OajnYT2Knk3ExKsQvyqSeTjoRgYxjikzaLRmrAhmYOxzvWQNINwKrkYz3HSttnSNovKkeKViSYYgVCAE8Z9AelY+4R3QxO0coJ8t1j5zjjAB//AFdavAmKNfs93CwH70F1P3SATyevIP5+lBvz9Datkt75doeSOTgMrRkgEZ79Dz6CtSyCrE6kFZTGEEedxOeTwe55yPyrm9Mubvb596UEh27ViOVHQcNk47E1r293hZluDEpC8hMA/U5/D+lF7jaZdtoomCiBTGy8KxyOnU56Afr60atJLBaTzQxkrn5ShAIJGePcelUDqqWvzyqPKXJP05wOeOOlS2k0Gql/KdlkdQSr/I2O/btmi11ZHRCL+J7G34avYdR0ksZZpXJPzRqcK2PzBraZQzeZ1DAH5VAIIHOD3Ptx1rmdOthZvtRWcAZDodgbOCcjPX0Ira81SsjRv9xsEjDck9v0/WlfTUh/Fo9C7aT/ALne3DBiQ3uM8Efj+tWoZY23hSGynyg8Hjnj04FU4pyFGGAXAUSLjnPIB+vr9KazAeZ5pUsG3AglfTuehxmpaJtcu5jP3VjYFifLAOV9j+nHelhvYpHSJ9kcwcqWJ4BAwB7j+oz7VlXF4qmZcqFBwW/h3D+En/PUYpbUSyo0bsrSgbgSPlYHpg9+9TctRVtTcjYRCQOfMkkxjJO0j1GOhx+JxVedivlNt/dO+1pFYkqvcc8ZHXHcZpBIVcEkLsAYKOp4/wAf8apatci2t2BZkkf5y6Ec85LHt702yoJt2Ruw3Qmji3SrIwfBmjGQScAY79uRTmK7EIklVJEAk8vBLRgncQe/ODg81ii6l+0JKhCxyFlxsGN3U429OMYwOc59qt2zM5EcTIuHZwEHp/Fj3x371RE6dlc2mDPGpbLNyGLN8spHTjqCRjrnkU97qNlhk+1SKzfMoVt0cjYAO4evAOOves6K6WWGIvklXwVlJyBk9/yPTvVkyGBswyyjedxbduKsD1PfBAPT2ovqYqPRjpr9IrtEK/uCMSyAZ2855HXBwBnjoK1HkldE35dUQsWMmw7sHGVHX72M+4rlr6QpaiTar3cQI2PGPuAZ5x164pYvEdqPD88jW8oliAaZ9wxu6DG4jGfQ9aaa6msqLaTijpPOiXfjaAMM25WAcBeTnpxwCe/41KHRHeKe2mUytklQQoJGN3HO3rz79OK5vQvENjrNt9pht1jj2LmGWTDkDC5wCcNnJx6cVtW97KCCGHnEiP7xG4jHB/hxhv1PNNMzlTa6E1lKPMmEcyOkj7PLyNiucjvz+OMfnVqe6SGRlmeVWA2gpuDAdD9egOKywreVEVTyjGW3KeRjqMHOeMj6VVKXM8UE6SxzyncxDoW2g8fd7HHPT8aGLkUnc1HDSxpMhcJ5bFopGKh15ySvft7/ANEhYEIwaMOf3UO1iGVSfm7Z/hH4GmQQfZbY2yBGvA4MZ2kZGPmHPHH4d6fbzWixu0II+VmTK7gHUckZ/l/+ugT8iOZEWJmid4wvzM2SWGOuep5zx78VE5k8uffIRFJ+8OeMOQRgr2yCo68HipI7omJh5jASkElj/H68etUorXyQ4mO+KWTGxywSM4wzDnPp174NIaVtxshwzNIPK8stlolxuA9OoIyD064qrNceTGzyuDICAGUcP2wegBGeeO5rQmVGQIyeW4xliSARxnk98AmsO6RAJ5V8tuRv5OQhyWye5JxnvSasbQszAvZppr+G0hslkkuGMcsb3Hlq7BSSVYA7cDHPTjnqao+BWnuNOu0Y8IqR2qyk/vIiXU5Pf1wOBg4rV1HT1uishLxzxfN5ynY6kYPHUZAOQe/NJp1gtvZ2yO7RSrM3mxqAvyq2QSOpzndweeRUpanc5x9nZE8aLNG0ccXmRqm7aTtOO5GOTg1C7ApG0aeXiH1Geg7dv8aj0qWVWnEv7wCQ7Bjjg5z7juKi84NEFiDNGymMqxJB44OfxxSuYNWdiaVd8cRDNHGNqkYxtXr+o4JPXHamIApYb124xnPQjO3P+f5U1XkiuGj3LJgAqNo+ZeTtPbHNI0qrHtUh8AqOh4JPI/zzSIdzPnyY1RQdwGGXOMj2P58022Vli3BsOBgIR6jtmnzDy5Mklmzg7T0IAJ/LA6e9VbfUYpb14hcRSEpvVQeo9QPy/OloZz1WgXDOsqI0Zdi+AGGMH3p2YPMMMmUyMyEDJB46frUkwZZN3JkbDZ3dRnt+lPvIh5ayoM8Atk4Pvkd/pUu4R7FKNSJCVZSBwSBhiccjigOjAtlW6fcA/HP6UgeMRh0JCDkcZLE1BdNtJcqSGXjAxj3/ACqQdxtzOCMxchVwQDgH6frVCRi8swUBiMYJXhc/0pshKeWkZ2spB65JyODTpXPkJnb2BGcY9vp0oBqyMzVopju8uNc5H0P+elUbrYbUsB82e/8AD+FWba/N7JPiJlaJtp3DGff6c1Tl2iWTzXIH8RHJApLXVdSZLozm47cWMJVJGLyPkgkk89Tntjj86ZqhBh3cAADJHWta9gR1YA59+uKwdRYRWBR3Chh1U5xUONnY56ruzktTYIzI4IQ5289emD+dZCffH1q1fs0lwd33lABPrVYDEgHoa7IKyOeT1Poa+AtLlLqG2MiEsRKj4ZTkjY474wRn+dXbOdZYvLzHvDblUZCvnnPy/LnHpjNJPcH7SIFgSSQASbgfmLZ5UjOGUjBzU0MkUcabJApcKXG0AYznJ6cqeM+ma0W+gNEZeQ794iXzckB8deuc+3cHjNUJITbRkSqqDl/MT51J6ZOOOM9fQ1rubK/0pppWjL+a0YEbkkDjLYzycZ+v4ViyMULW6bvLdshnBGSRt4GcfnSeg43uMmiQQfaBPtgYEfKjKeC2GU+nX8zU+6BYGElzEXGGXch5IOCMjgZz29aiSb7TA8LqRPD87MnK7Tg4JPPcfjVaPULeWyiaRz9ojLLKkiFSpX3+oz9aWxutdx+v381nbxfYxG5UMRGjE8EcqSP0PJq3pMqSCQuZAGwQWXGc88+o4/wqCRUlEckkls4YnBVlJ5HrkHrntmtEFUitYvNiKLFtMe7kc5wx7Y9+Ofeps7s2hU5Y8osUm6RVDHyHZsYPQEYIIPHbHvxWvYW8ltAsbyNGsYygaELtXjA77qxI8SWiSzrI0eMbAMlcZ9Tz6c+laNv5k0wQT4OMkRlg2OOqHr/+unc19r0OitpQAisUlQNuYpHtK+ox/nirFnGieW0Pl7VLPg5AwxzjPbnGKoQXiMPJeFZC7b4pAAu3nGOnFWXvY443jeIpIDgK3JZvZR9Dx2zQzNt9C+A8FwfJRXRo8GJm55/u54z/AI4qQ4CDJCBBny3UgDng4z0OfXqKbaSJKoVSjxsQyFRyPb9agfEEbEsA0Z2hgxAKn+WKGEJdxZBJJC24LvY4YSDduGR+JHGMe1W40AbbvEcgO5QJN4HuD3Bz+FU0uFF00atk4JznIweAc9O1XIiWQtuMRGMg8AnufoPX35qbFykSRzy3W24jZ4n8tWKbiSVxncDyOlVboS3MbB49jZGyUno2ORjoOOeRg5xSRyxrIQMxgDKqSPkBJ6deKh1H99bSornJ6MBtBPq3H5560nsbU5crRJYyXKuqOVhijiVoTxuZfu5yevPp0BrXtQYn8suFKjBG8jGehPH9PSue03U5LhFgYQbYWLKpxnA44PYdPathJQWZRuB4JDHGB9P88U7roKrK+6saJYxrJJtyikO6SMcKPU9+f61csZ2jYNt+XOSo525PQnv6Vmx3CLJnLIqNnfncG/Pjp/nmmJPD5g8t5FyCOVBXPbjPcU+phbmNcvC0Syhh1PCHOG/Dp+NVAkZjMEisYZQVcMmVbvtPsPes8TK8rfuwGJBODtb6H1+vuauiQbmYB1bHJDFs+v1+ooNkuXQnsIbe0lk+x2kEZlG4soHy5bP9T1q+SJoAWjRdyNGFCncrHJyPoQT/ACFZjMWdEmbcgO7EPyHJP3gPXjoTzRFIHhIeMwsWGHONrYY4IxznGBg+/PSmvIhq+ppJIrqDBkpMwYytGAUx16/ePU5x+FPtCIh5kvlRfdeYOS38QJIweOo469aoiCM+XiZeBwCgJDe47emT2p8Mv747iWnRtwKor4GMZb1z9OlPqTbQ0o5sldkKLjABWTaCu7duGRwBjr35pTLtEk6JHCA3zbYwQ+RgnJ9yOfckVUa4kjS2R3icQ/cOG4wDjoc56cVXa7ljBDo3BO941QueegzwOSOBTRKhc0jctFPIDh4ol3lgOCSMDBx1PT0HpzWbcakYr1EijQs8S5D5+VdpbA7bccZ65rQS4AsxHG2YUUHy2Yhduck7u5z1P51UMsm9GQOFcohJHK5P3sr06c8/jVCS8gnDlZJZVfbKoDSq4IY4J5B7njPTpWTcW0glhWMtJK+ZncR7GfdkHr0OCf1rWuNxhlaNQXj3AryAx55HHPy965m81XM0kEUkywykDaylSHXBJCk5A54H41MjelFtaFq0z5iyNGEWNBGfSQA4BA7ccGodQHl3MSzHaFKqjqMb1xyoPr6VaWMLBDCHdN0h2sy7gAeCPfnn86jdke2jKqBLH5Zf5ehzhuvOCBgD3FSXfW5WMqW1xI4MbPI5RZC3UjHX2zxVK8dYpYvIJEZYDdnI+Y5GfXjH0rRe2SKWaUDzIDtJiXr2/HnIOR6jNVYIS0SxyGIskxKrL1XIAy2e+cfhmpauLmW5E5DOwO4iNON3JC+v168Vk63qdjayqk91HE558pm+cliMEDr6dK1ZvOE4ecReXN8hbYcFQ2MkEegHHpXC+PfAkOvalbX9nJJY3UaqGiQ7wByQcnnIPH0AHaoldK6M76nTSXMbFZIzlWBIcSBjg9896x4NGt4dUuby3IDSn94d3U47VetbWO30h7PpNGwO7Py7SOfxzgg+pNMWOQLFB5kpU7huXH1GB9c5zUyV0roa62LMUcjNbiMl41GB0+YAetRXZmmcvC3ysQcj069PerUMRWJ8FypwOTkrVabelz5agsv3d/I68Z4+lALRldN23aI1Mu0naOhzUN1ujAkkXagGSH6CrUhHmqJOX5yw7cdf5U12EqvyTjA5HBIGfp+HQ0rdgeupkBGSXzGXb0ySc4Pp9KgUl4SSfLZQ3H4960fsu+PMjnauSAvJ/H86oatcLatkxM0ZIQ+WOvp+tLbV7C3djPuV2xEImHHyu2cNjJrK8qR0JYE7uzHsO9a9y0jsWjXggAsRwfwqu43QFJCm8jqOOM+lFriehhzI0SNuBQDqCc5rDmLTO4lAB3YU+vFdDJHtVkIdgf4T6+1Y9zFvuZVKkoMHJ4Gfas5X0MKsXI4rVbQRbjlck8+orJVcMAfWuvvmiYSjy2Lg4ZSOvFYF/ausiuMYYnjvkdRXRSndWOeUXbU+iZ/ku18xPs8jRFAFBIG5cfKR0/xFILxJw8lo52wktGgwxXOMDceSD6dOtQafPdSXbxRbpPs3O0uFYL3XB69SOKvwRyXMVrFLaxzzFHiy/DkbgQhGPTDD0Ofeun0IXmVjDbOGuYYImaUgyRSKAyHoOoHcHqKx9djPlGWaEJcq2FRW2fpyO+eOtbxeCSOWOXyonQkMQN+Dj0647H8OlVHa2h3pDKkkXynb3HfByPqCfTFS7MpaO5zUjmNre5WJlJRQUTnufm56Hg8DjgVUm+0rcFlUuJASyyyZO0nqPfHc1uPb+RcGIO7BtzY37Sw7kE9CPX26VnPbskqoWhhuEyA7EYbqMMOo4z7fnUS1Rupq2g+WSNkYhNuCB87bsDA5OBg9iTjPFWrO+haCN5S0RbKsDhlBI6D2x0/GsW4kkAdJGiIixglsdMAggDJ49PrSWGrREuswe6h4UsG8vYc9CSMHpx/kUrg02jpY72OMHbCpRk2t5mfk7DHqM9OpH5VcjaK5jgXMoljAHmhfvLjg9eo9QfqK56KVJI0S2kdkHMRkUc47MASD39KsSzT+chlZVkHOR8oIPdee3p+lG+jEpJM6mGMzKB5qupwytIOpHGV9D61ftr4KALm3Zk34Yr8uT6+oP+FYOn34VlR/Jl3yBfn+/wAjGTjqv4A81dura4idvtA6AxuRIcHHQkYOCfp2qrdUUpp7nSQkRwho380M2TtHzdfTjvg06YreK7FQyFsSFeM9gT/iO9c+gbyfPt9yoxBYqxxz0IPr7e3rVoSRO6OijzXHO7qTx3HI+uKTKjK2qNaOTDvE6OJUOFyMDHH156U6Rt7N5YZWBONjDZn0KnnPv3qpbXZV2DljtH8RLEcAcn1//XQtwspSNwFwoIG7hxz0BIo9ROWpLZzq5LSRyIwbadrjZuxnnPQH0/lViVZGuRzIkQyVB5Ck9eD249azY9QiDmBVjXIIbedgPt9Ocexq95ssKKWWR9xKnGM/jjr9aRbqWZYJXl0B3ZKFsYJ/Cp3lG+NywfZlHBzjBHfHpjgisJbh0lVUR1iYdH6n+hH6+opmo3rSp5EZeKdBjf5Z2qAe/Tp6UlKwPVm0b+OQhCWRkBKsTwwHv0xgj69aI5ZIpFlfDxoCSCCCv0I/nWK+oXt4YVnuMzhsBlHGPyzg9Pxq8988QeUqYyG2yYI3Y/Pn8qd9TaOmxqTTJE6F/nRjkuOflPrjjjP86tJKyvkLm3bG2RM5Ttz6Vz32lAiRw3IMLHHllckj3U/kfzFT6dLEVfMhZlwCrEq0Y6fl9fyoT1NGtLs6MSbcM5UoBwTjPPpz146U2J1Cfu13DHfo309+hrLS5cHypGj3kEKw55B5z69jipFvnCokilh0E0ZyCO2AenOPyp3M7M1fPLRyLzgnk78nPHIHepfPmeKH5i6r8oYnB2/Xt6+9ZUN64VXVVeSN+d5OT9cfzqx56yxhJUB3KNuMN16E/T+lFx2sXGuCSQ2drcnnaykHgjHb1p8FzGzqZcMGwoIjJYHjdge5A4NZ6XLO0Mdwd0oyg+UAg44wR1GBjnpV5fMmeSNlWTZHkjd90A8n3HemvIUrIsCQSzFYY5DKF3eYsbDaWLdxjk49OOKntXMhV4GVJBljL1UccE+p+uOay5ZpI7hmWSKN2eMrCUIztGMh+hBB6duvWrZlWaMSSoInyM+W+QQc/TPT/CrTMmSugZ2TzIyFVo/MmG4vgc+wySTk/jWVBay3F+93sWaaNP3E6jeyoR8wY8fOcYBA+nFasS4Cl8BJG8uQFQ2WA5HTlj7dPzqMo0ckSW8RQuQNyhWOCDzk4BOePTpim0XGbirIrSoJtsSSbWB38kbl+XOwjuc+n9KZeOvm79+VYb5S+Mgqc9eTgc881bvM6YEknePJID7Mbg3PzMO2QcH+nFQSQyWskcaKwj3glSMlV6HPpyScelS1cXNczokCWkgZZFkkI5kbbzwQT37Hj1+lM8m3ExcrgSfNyCfujDE9hzxgdK2Li3myEOXiaMiQqvQMMNtz0J7AeuKoFHj3vKN0Ck5gUlk3joEH6kZyTn0pNBz31KKDzI7IylvLy2TCrHeC+MY9RxjHr6VTj8xrECURsMBhg4U47j3rTIilS3jdWimjddoIOdgH3c9CSMc1WaJlI35O9/kLIMAH+Entx1PTFJoDJuERIpGXPHzcHH0H+eKrTsxBKjMYIDDoV61pX0ccl15K7y0YEeAAPm9Pp09c1BHbBy8gw5Bwy8BWI6j61DXYq9tSK0kzbg8srcAr6D1/+vTrjKbd0oUDjdjt249ahty8A8uNDhstlj/n8qbNcBJVYAj5eSB0OPQ9Dx+lJDSuyCJTKwdGyNw3BjkE9ePb3qGVZACwc7Qv3R2akGoB5FWbIxJtXYp6n8vrUiTxzR+W4J3fdwM578+h60kkW047mRIlxG0MsToQzEFWBzwM8jqa5bTbrWJdRlh1WJSEbjyRuUA/db8P8iu8miV8OjJvj5YKchR3/wD11XGzbhGBRsEsBkc9cVEqd3oxOS7FSQeWE4DTNwOg6dqzbm0O0iJWZhyCw/z0/rV+7jSUJJGdrspYALgn3+tPt5SY0EiNsQsMhMKWxnv35quUyemqObEUU0BLb1ZeCz9celU7m2VZFUj5T37/AFreuEfH3CcDJA5/H/GsiWA/ePCA5J9efzqeVEPXU5u9tWi2mRfMKgofUj3PfP6Vh6lbxsltIhBIYgDd14rtLxGeFkiHz7TkE5zXL3yoZhHJnJfCnjIIqfhZjJM9QiRPIijguFJbDNHLFjBBOMsOTyByPrWyoN2fMjfybnCtGkucg5IYbhxxwR7ViPavFqEkDJgKMoG6FTj5GPUYGCG9q07O6CQkhJ454TvYMCVQ9MgdQc4yPbjjNdyZg1Yme4N3bedJ5byglXG0K8g7hj/FwOtJJFEqStPGsRkRcTMoOeflPU9MHoKZNLHMgliZrZZcElYw8e/uQDzgZHA5ANVJ1vAqiTy/NQBVzEcHB6gep9DmpbKs3sTtsDrHc+VLMMPHIDhSc9AR6jqexFYus2bJcpcKFljJI2uoZwvYkdD7Efzq1axwm5TcHzGe/wAwYEcjqCB1Ptn0q0sckT+YkV5aSJmNipMgAI68npgjgik9Rr3Tn7iOC6t9lxujlbCFkHmAEfxlcg4I9/5Vzg06SO6KQsxlbhmDtHk54JU8duv8jXXTGPzgGZSc7HRosAeh+XH14/xqrIBJDuuYVYhiiS4zt9RtzjB9PfioduppCbirGZFbz26SySxKu9iJElG4Aj145HHb+tTtPGGEaWZRdoyVcyDsc+3XpnoaIEEMivFcS7VGwNyFwCce/FPZUllKF49wYZk4Rec9RjaevXj8Km3YylLXUrSbZGUwq8UiHAyDwfbHOD6Vt6Zq969uyT4nljGdpQbxjuN3J/WsS5DW8DSIzBPuOQWG09unTPY59RUUMsQCyIWklBAwjYZT/eweG+lCdnuLmudvY3vlv5k0cgjkbk7AH56jrgg9cHHrwa07iQSbfs5UI+UDp82QeQAe3+6f0rg7K+2OrRjYzfLgyALnuOc4B9OBk8YrQg1YrflLhZF+Xkhh8re4b5s+nP41aasLms7nR21y6Rss6sqbQPmBDn0yQex744/So2nYbo3QvGD8illBB9QM7WB9s/QVh/2pNueQPK0q8k7twHbBOcqfzzVeXXTgosaxeW2dqkE5+jDp1pNpdTVSbeh0i+SyxmYrukONgYkvjngAcE+h60+3v4jtEM5EbErsl4I9Aex54xmuXfWImZv3ETRsmQUZkwSe+D7dO1EmriWBldk2MB8zAll+p65qOeI+Zs7G4vQsB2pA57Mj8A4x+BH9ahl1Yo4Z2DSqCDG3G0+h9vpxXJw6kJQpglgAcHO/Cnpz9foami1GTPkyrCyxAhvLAZ1HsT1HtQnroNM6Vb145DEySFWUN94KMDpggZz17/4U+W/dyht5o3UgAoWB2Y7nPf37965SG9jeBWgSMFR/rWZij89MZ461qWWqSMGia5kt3XLJIBuDdthB5wafMmbqVtTYa6u7aSUGVfsMzDcMDgg5+9/Wr1vqoZyJSYDINqCRvv8API3DqKwo9SCxxoZZAzja8QTcpbHAAxj9alEybgpMoiI2GPcuIm9s8haEX7S61OmW/XoAGlxg7gM56E/yqe1vBdRrsk+ZVxskO4N7dPyrlJb2U7UldVuMhY2Xk5HGT9R/KrNpq3mb4bweXdKCHO049mHoapML3Wh1ouwFYS4YdCWHTP8Anv3pAwkVFYqig5w46j+9iuds78SOSHJIxuEanB9uemR271NFNHHcA+ZtjdSAVXcp/wB4E8fUUaMtaHSbi+0sGjhAyrIm0Y9MA5NQPfzWdwJrG6jR1yrBehU4yvPbjpisuW5CrCm5QUICsO47/pjFL5+ZgiPMy4Pytg4zycHvTEmnudINQaSRv3vzMrZYnZk8ZGCP0AFKsxt8Bo4pCz/cPO4Y569TzxWM1yV2kOGQjBJYg/jz09qspKI5WaRQyOgUhiAcdQQe2Kq4rI0oLlljLlkfc3bO/HYZGcYHXFX0iJJMqJIuwhdvy5PqCee4GOtZMdy8duroI9qgKy/xD/d7fyqEahJY3WLR48tu3B5D09f59OuafqS03saMli5u0cqZmwELNKJASBgbTwMYOcY7dasmWGKZlZi+1CN7vkO3c56e3fA/CqIulnlHQ5O3ccsGJ/uqOnHrwePSqc9+hV4LPUJ4J2KwyBcEvGfvZyOmCcY9aasGrWprRSyp5MnnI3kRu+Ec7g5Hyjd9MEL1/Wl06J4Z5pNjYeItLbhjjOCAQSM5J5z35rPsFNuXt4k3LkyKRt2BeCR9TnBxnitKMSNcySL/AKtt8cZkc4KDgY6/IRxzzwPWi1yJaXFghMrt8vmKygIc/MWwPmBBxt5xnocYGKyb13g1H7I0cgkiYFBI28bWOew5GOPzrXgBUiZVMZj5kKkjPOAD3zngL6YqBbcLMJLS3IMjbS5ZWOcZGfRh1PbpjvVOJHPYwbeziS8eSQ+Yly52lSSBz9wc5HQ/yzU9zGqRSyllWR2Ayse3OenHRegq6LWFZrzLkRzKIwxQLtKjLHByV3f/AFxUeoxzS5MzSRzBiSip/DgE5PXGB0HcVny2Q+a7uYjYyN65cvzyep4/mKqagEdZIZFKyocuq/pn3Pp6VuNaxRIzxyCIgg5IGZAR2H9az0tEjtkZt8bbiZTu5Zc4DE/59DUuJtGS3Me508+aku7btBCkcYz6nvz2q9Eiywp5ZK84OTj7vHbuetTNBJn92AryEcHgNz1P07VHNPDaRP5sgiDDhiOT2z9aS7jc3LQZLbBIFMahXf7ysBkeuPc/rVEw72xE5ZkzwCAcemew6jpWwUzbhkPG0Et3bPBx+n51nNH5eGljIdUIUDjPr/OnZImMuhzzB7cytuBfOWUcAZ6nPPaguglJVwccgg+vTP8A9anbobmdVkbIUfg3GMVLeMWhCIYok2/e2jg+uPas+hcipcBPIjZiUJ+YhT0Hbj8ao3EBYOHBAjXJc8EE9P6VslVlttpVt/Yr2PYfzrJ15z9mzFIGOQgQry5GM9Ow4/Sm9EYrV2MW6gwHdmQ4B3+gPb8a5W5heO8gkm+bP3m25yNuQR6H/Jrt5IZo7EA7vnIbB4/h4+vFczqgjCchf3YyBydrE4JArKS6mMpHpd/BbNcq1vKLaCVB+8yzI+Dg5z0I5BX6e1VkW7heCdpBtJ8iUh8DI+7uGM4YAFW/DrW9rNpDApcfLC0u1o2DDarDO4+49e44ryzw34gkm16eyuGgHlZSJpZtnmc/dwepx09cA12bOxlK256J5xljlWREE0mcpIQvI+VuemCOO3I7Gsy6uNQ0m5hclS0b7SoAZnjYcg84OPrng1qNDuiRpIDN5UjW7I3+sTPIDY6+zfSqk9layhFSc2ly6nPAK+YP4Tx0OCQffFNlU2ixGLLUJnlt5RGm3y9kgPyn0OPy3VXaOVLtk+0TI0ozmEsBJjtgcj6jP0qxb5t0MflrBHFtCyfdXLjnoflPH0qxcursjCePzUZZJJYGHztwCU7DpnHHqKT7hLcyGgW8ixA8N1Ig+6wC5I/iVujD8j7Cqc1t5gHlxTyRsflRmKnpzgkZwCMY/WtiazkldTcQxsrgz5z82CQS2PYg+3NNhLWkEbN5kMDAmExybsMCDnjvg1Fu4vQxCzIGmffBP3imXJdSMcNnnI4wfSqNzGt46vbeW5CjdAFAK/h3+vX3rpViMhk83zXY5URkMDnqDjt6/wCNRX1h9rniW5S4Z3IMQ2EeZ/ut0z7gA+tDWhDWpzl2jAlfLhiYghSzEvtx0Ybjnp3HpWddAMzMXQOWxJE643DH3gwBPH+HJrpHt5VlWOOQiINkecUbn03OOO/tVGa3kWRbd3gMcjhkXAXaSfugjIUdazaIszCYyINyXKGN8mU7w5994PJ+tV2uAkqxXDFolHBQbsD2Hp7Vt3ujzWc0o8q6huo87WQgFx3yOoOM5654PSsdnSYKlzseLna7RjI9jtI+vH8qhq+4JvcWK7gmUfZ5I4zHwuXKn/gWfy9qV7lkibDqVHJj3hjH7kc8ehqrc2cDuzRzp5oG4FADuB5znPPp04qvGHhib/SDsRspkAhD3BGOM8d6VnfUOY0H1E7GBbeJDuGwAkH/AHhUO64n/wBQC2cbyE3qPQnjnH51kGRCcTsVkJLh/L4H4jp+NREbX3KDIwzyTjJ5+7g8/Sla+5XNy7HQxzfZ7oxywWuxV+dlMgIP0zkfXpST6iYclIl81Pm3o4faPTaef0rl3uJoVZ1QxWwbKFCcg+gPY9eO9TtqGFDkSxzMoYHJwwPscE/rVW7D5ne50djfKJeI13uPmKgqD+WCK2IdTCeQzAMflyokOd3c5bP/ANb0rgjeRi4CDejdAc4KOfUdMZ961EvZVaNJhhQQjfJuUn6/061Fmi3O52c2pQuyB2ERU7Wwu4geoP8AF/nFQx3aO8i/a4DGQMkp19CB29652K5mNukLR/u9xO4qQrZ6AdxUsOpRblS4F6uwiPjqCPY8YOfzou3uXCrbQ7C0vIUgRLl4ynUSK+cZH3D3FSQ3SiIRwbROpKKAfvA+jH/PvXLQ3SuflLJt4YD5wePvADB9OKnmurny8LDCcYYENgv7465781akUpK50pvf3savIgJOMOrAuRnjjqa0bW5ZxuhZWtmI+VhnnPTJ5A9q4c3JubiOSSK4WRDkll5X/wCK9q0LW6aP5l+TICpIjElsdRj09j0oUjZz0O3W6SFnSFTg5EaseOOcf/WqsL2MSsjq6zHI8uRcYx3GRXNG9baqG4X7MxIkYDKk46Y65H4VZsrzY8aPEkwAJwOFfvkk89M1aYKXU6+xvWfbHhFUfwsMg/mf6VajuponKquHABO9gTjPbtXHHUbeIlJCEVstsWPI/UirttqqhQUD84IwMevT1HtS5i79TqL5zKisokQMCoZG2/r/AF7UlmzQSYlct2BIGDkevrXPnV4pXCR4JKksQ/r6A/xdatXc7iBpLWOVoQQW3jCZXrj/AB96q/Uaeljp45pBDscxTRjgkN8xUAZ579uBT7CZJEBETo6jaDP8hUDJB9+319qwotWiDooiCp1DbtoHtmrUWo71ZkinCqMh1fO0H1/PtmquZybtY3J3nVGSU79yfMG6nHOcjkAZzx14pLO7+yQs8e9rdSRE6yZ2c7huz052nPOce9ZQ1ZcFypK7cFIydxH97Ht17jFU574LOLlXkbzMEgscEjqWx09P5VSlbVEJN7nRpc3VxNO0BhkbA2DaU2xbsliTnk44PGMds1e+3ShSoijW1aIvuVmUE+h9hkcg9PxrmJ5YJgpn8pWT97vSVk+bII3dR1HU/lVy31MqpmnlVhjKiPhEP97B65B5OPXNWn0IaudPEyyu73DWojjw2wyjCqFHzLkY3EcD8e9V7iQvAoZBvkYsDtwc4AyCeWOePoPWsdr/AM2KErPbyruG0Kuc89RkZzjOCeOc4FW5dShnmE7osMBwskikNOyBicA85zwA3GOeRmrvcVmtQ1PJvovMjDTRFY1YD5VP3t34cHHJ5x1pixfJcTzqWdcRhDwSc8gA8rz/AD5qFtSSEzytBIk27KRY8x884U56Nnks3OAABUxnKOJIZY5bx23Z4yp5yGXHOB3OOc5qLXY02kVZLYOhdlclztKqo4I5x+FZmu2kt5AbVlwQW+T+HHQk+reh7Y96vrG/lx20ltuidiBIrk+aSOWOecZ4HrjnimRj7X9p1BkaMAmNVQhiMYx94/dYjjg8ZJ7UpR6GydtSjDv+wbGBjCZQM38WQOnpVO4KlYw+9lAIBBOVJPGfwGfxq5I0jeWGcMGA+XgDb7GqupRF5RBGmUYKUIPDc4JJ9ODgVD2Hc5s2KG9Eycyk7PmHTPrVqdHWJGERy6YcqPu+v8quIIzceZMVePj/AGcEd/YYx+tROwlnjbzN9vjeMDgJjqB+IP8A+us+WwSqMoJIywOpAw8qnI6/Xj36VR1OEQOFhBbYeQCTgHnnPc9TRrMksLW7QN5bvJlip4x0P4f57VFqBP2JWYASAlCc9QOf8+lK5nJtWkUp3eSGQuyLgg7QMc5Gf8+9c7quBcJKg2R/fDHpjcRnHseveugfJs3by1LkjcSeAD6+1cnqTmO9EDq0Mch3nJ5Rxz37YyPpSkrnPJ66HvGpFncymEy25i2OJDj5geA579ceorzDXvBkU2svc2NvIWiZmngulw8Dg52gr1XGcd+K9gv7WP50FwZYy+JUYf6vdxvHqO2PSs1ojP5bzpGLwOSkpkJEm0cIx65O3r1H6V1yjzF2Rhx21wmzMf7slYzJGw2tx8nuMHOM44NPs4poUNi08U9rKiuv2jaQQoPyluzDnBz7HHFWEtfMncRuhGRMjLj5VbAwT0IBII9cdBTruxjuEdbNYTM3AVSVCMvB+Uno3t647UNdSFaOgbl+0/ZbuI7YgwV1XaQQAQWPdSPr1zS6lKxYwSxmVVxtkVRvIxwQRwR1+tS2i3Q0wTgy/ZVkC7Sgcx8cEsDkqBkY74NQ2zztALdZ4oXVWKz5yHA6DGOSezUnqCWpntLBbSyTWciqFTCq0Y2tkc/KenfPpWpHpvmCZ5EivNkeGZEKq2SMEH15BHr0qOa0iS4O63ki+QeX5gDlj6NjjoB2B61mr9ptrhUtJI4UmwZGAIVDnPy+gqNFuN67Fu7gaO7iLxOUO4TNvG5s8fxEDIOcc9KgvrMhGhSXMeQYgzFXVj2wegPP9K047m4ffK5wrnZOPlYE887ecg55IqOG2hSB3thDcWrjAGOYzntznj2pNdB27mSsRjZVvUkIC5Z4pAzN6MQ3X+RA9awdU1PTZb6301dVlglfcu/zSpB6jPtn+vFda1ssztM9288I+RZEXB49c9O3OPrXIeJ/BFreXC3SSmF5PmYxRDPOOcdz6kGpk2hciuIttdlgL+WWcx4AuFYNxngnB6dOQaranp8U0G6M28kvUqYyHHPBJ6fj+ddPZWBs7GC1dWaBYwsc4BAIBwcjoeuPx7GibTkBk8y2bzo/mWfzDkDttYf1pON1YhxsziZtP8zKwBVYLl0dQCjezHtz7VFJZThsi2ilG0bllTqMex6V18kA8piuyfZn96/IYe4wDkdMjI9h1rPNmVlKtCqxhs71blcn39PrUOJLRyX9nyLGcR/IP4ljyAT7CqElm+1t3mLKucoEXBX8e/612d/aWqs0kSu0Y5PAEg56kA4b3/pWbPYJOjBhMzKSfPR9xTnkkd+KWqI5b6nFXFvKitIqTSgt1PIPpuHY9eTVVow0SkCGNgNuHGGIz0IPcdePwrtHtUHzTRDgBSycJLnpyDwR7jrWXdWkcTuhCTKwLIORJnoMZ4/mOKadtw8jl/MVJNu7BVfvKS4I9MHsfSnJOsfmLb3G+POQMEZHcbehx/8AqrRvbZ/KKK0nlKd4UorYPU+/rxWVe2U8bs/l7VHBAG3B9h6Vasxl9ZzDNsluI3SRSrjc5C98kEZH5EVZE7Msc0aMq7cGdGDbeeQw6EdOKwXjnibz3MkYdSVfBG7tioEkKN0UsOASART5VuLU6KLUwzsiKq5GHBypHPBUjt35qb+0blVV5/LyEDyDzEHnLnqBnOf1rAjdoJ8S2wLn5lZGKEZ6EEUqXY8kkht7cNuIIb0+lJ00UpM6eK8+0IZZHfyBhcSSDchPQE5/StG2uxtiErS/NyDj5WHbn3/pXDpcCNEKAeY4wWOGyOmDnpVuG7uJId6SRSScja7chcYzt4H/AOrpWbp2d0Xzdzspb6RA7wkrMCCeeGXHQj/CtG2vpCm1SjBlHGQQvtnrXnpvpC0PzyK23BO/AOPQ45+lTQ6oYYUjO9SmPmHc8Z5BGKVpJmidzv4LxIRtV9oRuhfcD7HtWlHfILcLGIyGIQbScE/3lbtjPNeenU3LCSWZXlYkhI+RgHnf6mtGz1FWVmYiVeDwrHJz2bsMmpTaL53uddb3skU0ZDBlCl2TGAex3HGT1q3bz/u2Lhz0DqzsB+K/41yUWpExjMp3KMbc4Iz29T0x3qxBrDqqFGDt2/enOfTnv7U1K5TqnXpdnaqNJsK8BFbPGRwRmr7TxGUCUqqhuGXghs44x7Z7VxT6oFYjGwP2G1weOp9+9OGrGNMPKyoq5yY++ep9PxrRSSIdS52kksh2rHC8xC5QvLj5eg+bt/Kqi6hHHcr5a7CwyqgFjk9V5/pXNpqUrxRvNIfLRgQGGVP1x0+lTLrDyssZcKqrlSWwwPU4zxz/AJxS5lfUqMrnX2+rMYU8sBlVifJz93seCO/rz7Voi7UR4nkkjSQg+Vgdex7Z9/p3rh470syNK58whcMHCKw5BFW/tcvHmShvN+UqCpYMMDkD+dWpl2R18mopCfnaRpflUEDapHXkfTp9c02fWpEnt4UiR3lDRg4y/Bzn2UnAJP4VzUN8X3qYZY4cc4c43dOP885xVqJy0u5RkbCd45fHv6cVakK6W52kUl1A5kfy2YHmdVJVW/2cjnHHPY/SnxXUTPtZXLAEMwbcxb/aJ7Yz1/SuUiuiYFUPJIM5CSPgEkfz9vQVZa7uBGPs6B5jkbX5wSMdfWrTIujoxOZCJ5HkZtxwAoBAPGN3T1HbjpUUsss0KxRB4oyu5guZBIRnGcDjrj8PQ1jw3JZFiCkRKqu3zEAnvn0rStr0RqFt2V3ZQhcKV2gZPAPOM/mTVbg5WJbcrE0ElwzG4AxHtXco6gHAHP1+vSq15LGbaadZt5XesacjDYz8vY9jn8+gqsS/nf8AHw8t1u2lFUMuB2/MD6ED6VnXF9EZViFuXtlJWVpP+WuGHyDH8I9e/OahuxSdxY0RLbKt5jE7Czk4YYyTzzjOR056etVbo4njuWTaqhgoUZyP/wBdTLcliTcMs85DSFmbKRhh8vyjox6L643cCsi7kdbiYJGwjjACiQ8l+u4Afl6DBqNg5riXEkkhkzGEfadxj64PYD6dfxrLe5/cLcRlCoBVVLcj/PrSzS7JVYuxTy2kJxgnPH5YPPsPesecAtsEgyw+VN3AO48/lzmobM5NbE8k5+yFcHkKyseF29z/AEzXIa3cSeeJIvngR8F/vYA4HHtWrdXckpkxJ5aucpg8AAlc/iefwFczq13svQpVwhBBOcNzxx7fzpJXZg2fWU0IkWbzIXRbfDnbwSrnbgemOCKzLiwvYkmik3SW8conTfjKliMMCOxwuefetS4E0NwJ4oxNCymMIzHKKBna49M4IP0pLmNrbS5jFKocOszKjcOD6Z9OldjXU6b22MKW3tm1KZraUpIzM6pIhJJ7ptz78kdAagHKmRY5RKEwwzwZFx8x9DxkEe1a12baO5ciOSNGaPyWflomB78Zx2pks0oWR5srEIzv2jKbgVyAO4wQcdO9FiGZrTwF7praY27qwcpnJXuX46gnkgDAJ7UBcS/6SCkbybWdVBCOeMD2Iwcjj8aJ4EhvJDK/mRXA/d3cfPygE8Y9M4I+lWNssYkhkMSRS8MJBw5A6kdO46Y5OaiwloRh5bkDzSht2AWFHP3iG2lePXr25qOWSS2liZ1eNRjyZZUEibgfmBI6jqD6EU+RUV5FYNIxwyNAQSw5D++eFP1qaBU8xxFKJIcgrE7biwYc4HY5/wDr0tSlYz1MvlxI8sCZAy6x8Bs87gR0yPpVhYo5y10JLZLgH5v3WAzDI7EY6UpSP7FJG0cgZHAZyuY24GQSOnGDx+VWbG8hhlmjvonjztKEDcC3Pc+o6jip9TTZFeBXLFWM9uyNvDoADuI4wB2/PrxTJlS1ALRSRSFjsdMlSPQjuD09RUuZXVJ7SQtcBSrJIOSOowfp/SpzNHJLH9nkaHkfup1IAYj09T2x1qegnEgjjYbgjG5sy/zFBnax6kfrx+dQzQujBrXcwViAxwMn8Oh9BVhbR0uI3hLK0mWZR0Pt+XHPvTbyZl/fxJJLCP3csa4zj6Hr+PTFBk4u+hTVIUjdo8wMrEsGGQx/zmqbwW6lmaBVJClo26j1wR24qyQHLbLthAzbRGxBYDrnHbHv6UyW5nidmeQtlSCwTKycdPTFJ6D5bmfcaYJrmBUEbo2ShVsMcdQrdj7GqVxpM6sxcNuz/AgTjOMH/GtV/s86SiKNJomyoMWYyMD9eexqsqPNzAlwJ42AbzeVI65Ujpx2NJmfKzFurFU3faI5ljICjcv3c54Of196zJtKkwElCx/3A6Fdw9CO3bn6V2U8LnBuF+0F+rbs7SO/cYqmERE8wy/6PJkvGT5hjkHQ5xkD6cijlRNrnHSaZ5aq/wA5iDYO8ZKtySCOvryODWSbZoLnYjRhDnl+VIPsRz6f4V3l3bhZo7pTOkzLzv8A3iyj13ehHPP4ZFU7qwlljCok6RgNJH+7Hy+vXqPWs2uwcnc85uNPhjmVJ5Db2/3WcgyR89OM5Ws+W3SGUt5m9eQzKu5ZB2x3r0K5sneIMqhg4OQU27fcf1rIbTVjSP7I6i327ZUCng/jnj3H0o5mgsefSwuN+1WwvJIXGB71HtYx5ByF5x6V3c+nm43hEXdGoYMkpBdfYf09qy7rRlhEjtEBGD8x8ssy89xn0zyM1aqCdjmEIV8yANjjb60MeULKFG3jaOvvWrf2cjxl4I1e3jA2eUucZGcE9cj3rOaOSbLnB754A+n19q0uhDGnkaJYi58oHcF7Anqf0oxJIjMFZkTGWA4XsM0r7mjjL8IowMAev/16YGdFZVZgrDDAHg/WmHoSebuDMGZZOFCr3H1/KrMN+YVbYzhiF4X5RnvnnnpVFhhEPyjOeh5/GnTQ7Nu071ZA2QCMZ/8Ar8UrIOY0ItQuHTbGEADYLKih+T2PWrCahcNeFCQ0cg5V1Chx6kc1iDJIABz2FPWUhSpHy4xjqM+vNLkTHzM6Fr2IOkZiiZAvLI3DZzyFJ5xVyHUI4wVM8nlq3AAyMdOQTng85FcvBMYGykmGC8bkDDPBxz/OnRXUrM2XKhmBYqABn6dKXIhX7nZpqag5zJh1BEjSBVI9fTHHQ/zoNyd0bCVfP3lWWQ/Kc9vTBHauPE0lvsPmqQeSqkcc9KfDfyEAZby1BAUv3Pfkc1nKk2axmlsd9aXWw4QjcHwkeeSD1x/+upFu34d4whc4JD8Mew4ribe7kmiEcciROx3jLYXPOO+F9KkGqXKkhioZmBwxAOPYjsM9sVPJKxp7XoegxamYCqMzqD86pwACPr1q8l3JM8Mh28HgkcN7HFebQ6g5ZYtpw+NhlJIA9PoeuTWpDrUQu1VDtRhtVA27JJ65/wA9atX2IlM9At5mimRxEN+RnsQOvGakGpPEczXG4s5+VTtXGD+fBrkodT89nJ3GTbu3O3UHjdn/ABp6XSSyJtKnbyATux/9f2qubsRz9ztbXU50wXmCK2flLc/Xj2qZLn7RuLcnO7OQCc9sj0Arg7i9eAOJZCyZ5QHBwDwTntVqHVWmj4J2MAAFO1R7E/5/nVqQc3VHUS3ivOL0FXlj+RZRlSFzjnnvxTHvkZ3hDbVw4Z2X7o4OR78EAd6wJb0bcxMikgHpwvHT+Z/Gqst0yhZQ5Lj7rPnFJ6FKombt7rlj9qjCxurq6lnIDysvGQ2eCT6dBnGMAVVm1eMsY1TaI0LNliWzjggeuSST0J7DpWVNdO8CiMruK7d3AIyDnnr61y+oXkKTkxB2jCEDLBcZPBI7nIOB2wKhuVyrqSsdTqGox3BncuY0YiMEkZbgkgEfn+VZWpXm+RUdhHGiZHr0wenU9setcj/aZjdUDSGBOEBIBHPUD86iivpXuD9odMsd+5hn5sdc/wBaTg2ZysnodFf3bWtvCIkMjByxGM9gcD8AcntXN3k63dyrqNis5CB2J2ruyASfr1qWfUJXWORSEkRss643dAOfXv8A5NZ7PvlBLFjwMn26fpitYqxlqz7XILGORJnVWOxWjGWPI5btgjj159qibIaOWI4hklAJbgRkcdD0J/LNFFbnSmGIriO4DHerIYmEgK45AIz1GQOMcZHpVdLVYGkjkR0twCGVhuHI646jjA49qKKOlyZOzsUEswbRXtWO3Zl8AkBguDx34yD+dQ6JCup3YtEt1gjt8GRZXHzHcqqFHqeeT9KKKErtIfM0mye2VrOTzTGmWkMxWdN0iFRtZD/skVMInBFwm1rdnXABCshHGF79cfjRRUFMquAttMtzMySyyBzFyASF45Hf69sGpjC8ssjEwySxLlkLbGkUgDK9OntRRUrV2L6XHzwEgW94kqvEy7HwWYgc5U+3+NMitpCj7pRJH8uFOXLf7WfxFFFFg6DXAjePEkv2csfkJBaM4O3nrgnr+FUp1a4VZvJzOhJcKMb1yOcd6KKhgtireW6b4XSIrKG/1mNy7D0H4c9TToYJGGbCfMRO5oguFJHfHr7CiihLWwSfu3KbLAlwkYtZYPMYIWUgrntg9MU6UXMWZbiORo4uC8TYYqTj6f8A1qKKOjMn0HyuIArJttkZwqyPkAHp74P6VC8AtpzNKyxvI2DcREMshHU9Op4+lFFD29CYoqNDHcyPE0txHdAfuzt+WQe3p/iKgv8AT0CBWd4JDjMgJ+bPOR6Z7iiipsmmymrWKEllMksBiljclgDJE+NwJ6N7+vamT6csRkRwEmQlgUbtnqFP3hRRS5Ulcl6tFO8smBLgI4RQTKkRHB9eORWO9tKsu14cOmeNmFx35z0+oooqJ6aiSKc2lRMPPgSV9gbeuclB2IOee9Yj6ajExh5AQ/O5xtAPQ8ZPrzRRS2sxXepBNpdtbjeVnBzgJGgbjuQT95f15rPuNPAjZQds2chQuVfP90/X+VFFbRdzKxXexlUTRYjZ1wQCTn3x0FU5IZYzhkYexHP5UUVYRY1Q6kMAwI7ikKN/dP5UUUFi/Ng/L+lCxs2AqsWPYCiigGLgEHKNntjpSYbOcNmiigCWGVoLlZYlI2sCA3Q+xxUrFppWCyNtY7i8g/z+lFFFri8xZJCsvmRwNHC427Mkg8c80zO5TiMrICCMDIPHNFFFhouQ38gjKNFEWPzb2j3HPXp0A496tpqzBW+VX2ncCwKY9gB/LpRRQkJlg6m8si7FMh+6cJnj2A5/Gnw6lJKgiCyKgbDSPkCNPYdveiinyol6LQmXUxIruLdkTocngLnHzHrycdcVTZnMHmyTl4QzEpvwTgDHPryOPYn3ooo5U1cSk1t3Kk8xngnld51MeMDB5ycgdeOKoToThU3sASNwHHrgCiijlSL52Vny7Z2kH0A4pZY9shCEuvY7SM/hRRQhiMpJ4U5+lIqtuXg9fSiigR//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Characteristic location of acne along the jaw line in a woman. Multiple papules have been excoriated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_565=[""].join("\n");
var outline_f0_35_565=null;
var title_f0_35_566="Miscellaneous novel therapies in rheumatoid arthritis";
var content_f0_35_566=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Miscellaneous novel therapies in rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/35/566/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/566/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/566/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/566/contributors\">",
"     Arthur Kavanaugh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/35/566/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/566/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/35/566/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/566/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/35/566/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the late 1990s, advances in molecular biology have led to a variety of new treatment approaches to rheumatoid arthritis (RA) known as biologic agents. New medications such as those designed to inhibit tumor necrosis factor-alpha (TNF), block T cell co-stimulation, and deplete B cells have significantly altered the landscape of RA therapy.",
"   </p>",
"   <p>",
"    However, therapy for RA remains far from ideal for many patients, leading to a continued search for other treatment approaches that might improve patient outcomes. Non-biologic approaches to the treatment of RA still under investigation include the use of statin medications for their antiinflammatory effects and the utility of stem cell transplantation. In addition, immunoadsorption therapy is approved by the United States Food and Drug Administration but is seldom employed for the treatment of RA.",
"   </p>",
"   <p>",
"    Newer non-biologic therapies for RA are reviewed here. Discussions concerning the general approach to the treatment of RA, the use of biologic agents in the treatment of this disease, and experimental agents, including small molecules, to modulate cytokine networks and signalling are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16746?source=see_link\">",
"     \"Cytokine networks in rheumatic diseases: Implications for therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STATINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statin medications lower serum cholesterol by inhibiting 3-hydroxy-3-methyglutaryl-coenzyme A. Statins are widely used for the primary and secondary prevention of atherosclerotic cardiovascular disease. In addition, these drugs may have antiinflammatory properties, including lowering serum C-reactive protein levels [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data from a variety of laboratory and animal models have suggested that statins may be effective in inflammatory arthritis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       Atorvastatin",
"      </a>",
"      reduced chronic synovitis and joint destruction elicited in mice by immunization with collagen [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of the collagen-induced arthritis model in mice [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/3\">",
"       3",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      reduced the number of inflammatory cells in the synovial membrane as well as the expression of monocyte chemotactic protein-1 mRNA in the joint.",
"     </li>",
"     <li>",
"      Apoptosis of cultured human RA synovial cells has been proposed as a possible mechanism for the efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      in reducing inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A cross-sectional analysis of patients in a large observational cohort study suggested a beneficial effect of statin use on the inflammation of RA [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/5\">",
"     5",
"    </a>",
"    ]. Among 4152 patients, 279 were taking statins. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients on statin therapy had lower levels of C-reactive protein and fewer swollen joints.",
"     </li>",
"     <li>",
"      After an adjustment for glucocorticoid use, patients on statin therapy had less RA activity as indicated by an assessment for pain, the clinician's global assessment, and swollen joint counts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a randomized trial of statin use in RA (TARA), 116 patients were assigned randomly to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/6\">",
"     6",
"    </a>",
"    ]. By chance, more patients who were also taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) were allocated to the atorvastatin than placebo groups (50 versus 26 percent). At six months, the following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Responses that met European League Against Rheumatism (EULAR) criteria for \"moderate or good\" improvement based upon the Disease Activity Score (DAS28) were significantly more frequent in patients assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      than placebo (31 versus 10 percent, respectively, odds ratio 3.9, 95% CI 1.42-10.7).",
"     </li>",
"     <li>",
"      The difference in the mean change in DAS28 between the two groups was -0.52 (95% CI -0.87 to -0.17).",
"     </li>",
"     <li>",
"      The number of swollen joints decreased more in those receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      than placebo (mean change of -2.69 versus -0.53 joints).",
"     </li>",
"     <li>",
"      Reductions in markers of acute phase response were significantly greater in those receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      than placebo (by 50 and 28 percent for the difference in the mean change in CRP and ESR, respectively).",
"     </li>",
"     <li>",
"      Adverse events occurred with similar frequency in both groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The randomization imbalance of patients treated with MTX underscores the importance of confirming these results in other studies. If confirmed, these results offer a novel approach to the control of inflammation with the added beneficial effect of a possible reduction in coronary risk.",
"   </p>",
"   <p>",
"    Because an increased prevalence of coronary atherosclerosis may contribute to the elevated mortality rates of patients with RA, the combination of lipid-lowering and antiinflammatory effects provides the rationale for a randomized clinical trial that evaluates clinical outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31433?source=see_link&amp;anchor=H8#H8\">",
"     \"Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications\", section on 'Lipid lowering with statins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=see_link&amp;anchor=H11#H11\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\", section on 'Cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC STEM CELL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anecdotal reports of RA remission following either autologous stem cell transplantation for malignant disease or allogeneic transplantation for bone marrow aplasia prompted the evaluation of stem cell transplantation for the treatment of patients with refractory RA [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/7\">",
"     7",
"    </a>",
"    ]. A summary of the reports in both autologous and allogeneic bone marrow transplantation is provided below.",
"   </p>",
"   <p>",
"    The degree of synovial infiltration by T cells prior to transplantation and the degree of synovial T cell depletion following induction therapy both correlate with changes observed in RA activity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/8\">",
"     8",
"    </a>",
"    ]. An increasing proportion of synovial T cells correlates with recurrent disease. At baseline, many RA patients have a marked contraction of the T cell repertoire [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/9\">",
"     9",
"    </a>",
"    ]. Ablative T cell therapy may further compromise their ability to maintain T cell diversity, leading to complications such as overwhelming infection.",
"   </p>",
"   <p>",
"    We suggest considering the use of hematopoietic stem cell transplantation in RA only in the context of a clinical trial. Although some benefit may be observed with these treatment approaches, neither myeloablative regimens nor those that are less than ablative result in durable remissions in most patients, and the future role of stem cell transplantation in RA remains unclear. Given this lack of lasting benefit with current protocols, the significant morbidity associated with such regimens does not justify their use in routine clinical settings. Additionally, the need for considering such an approach is now less than it was before the growth of biologic interventions for RA, such as TNF inhibition, B cell depletion, costimulation blockade, interleukin (IL)-6 inhibition, and other approaches in late-phase development. Nevertheless, improvements in the safety of autologous stem cell transplantation procedures may lead to wider consideration of this therapy in some patient subsets [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Autologous transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from small uncontrolled series suggest a short-term benefit from autologous stem cell transplantation, but most patients relapse and require additional therapy with disease-modifying antirheumatic drugs (DMARDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. In general, the regimen used to mobilize stem cells for harvest from peripheral blood includes either a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and granulocyte colony stimulating factors (G-CSF) or G-CSF alone. Similar results are observed whether or not stem cell (CD34+) enrichment is employed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A summary of international experience with autologous hematopoietic stem cell transplantation for 76 patients with RA from 15 centers was published [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients selected for transplantation had an average disease duration of eight years and had taken an average of five different DMARDs. Only four patients had used tumor necrosis factor (TNF) inhibitors before stem cell transplantation. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality &mdash; One death resulted from sepsis.",
"     </li>",
"     <li>",
"      ACR responses &mdash; The proportions of patients who met criteria for complete remission or ACR70, ACR50, or ACR20 responses were 4 percent, 47 percent, 66 percent, and 84 percent, respectively.",
"     </li>",
"     <li>",
"      Recurrent disease activity &mdash; Disease remained active or recurred by 12 months in 92 percent of patients. Three-fourths of all patients had resumed some DMARD therapy by the end of one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Allogeneic stem cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only anecdotal reports of allogeneic stem cell transplantation exist in RA. The myeloablative regimen required for complete reconstitution with donor cells in allogeneic stem cell transplantation is too toxic to the recipient to be employed for RA. However, a nonmyeloablative regimen may have beneficial effects on RA.",
"   </p>",
"   <p>",
"    This approach was illustrated in one case in which a 52-year-old woman with refractory RA who had previously failed an autologous stem cell transplant. The patient received a minimal conditioning regimen consisting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and the T cell depleting monoclonal antibody,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    , followed by infusion of her HLA-matched sister's CD34+ selected allogeneic stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/18\">",
"     18",
"    </a>",
"    ]. The result was a state of mixed chimerism (hematopoiesis by both donor and host), reduction in clinical activity of RA, clinical resolution of rheumatoid nodules, normalization of the erythrocyte sedimentation rate, and conversion from rheumatoid factor positivity to negativity. One year after the procedure, the mixed chimeric state had persisted, all immunosuppressive and antirheumatic drugs had been discontinued, and the RA remained in remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IMMUNOADSORPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted, immunoadsorption is an FDA-approved therapy for the treatment of RA. Prosorba, the approved product, is an immunoadsorption column that consists of purified staphylococcal protein A (SpA), covalently bonded to silica particles [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/19\">",
"     19",
"    </a>",
"    ]. Small amounts of immunoglobulin are removed at each session. Two major explanations for the apparent benefits of immunoadsorption have been offered [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Removal of pathogenic immunoglobulin or immune complexes.",
"     </li>",
"     <li>",
"      The action of SpA once released into patients' circulation. Binding of circulating SpA to immunoglobulin on B cell surfaces, in the absence of auxiliary signal, may cause B cell depletion, leading indirectly to a beneficial effect in RA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized, sham apheresis-controlled study evaluated the efficacy of this column in 91 patients with chronic and refractory RA [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/21\">",
"     21",
"    </a>",
"    ]. The patients had failed an average of 4.2 second-line therapies for RA, but the trial was conducted before the availability of biologic agents such as TNF inhibitors. Patients received 12 weekly treatments with Prosorba or sham apheresis, with efficacy evaluated approximately eight weeks after treatment ended. ACR20 responses (",
"    <a class=\"graphic graphic_table graphicRef64036 \" href=\"UTD.htm?25/30/26091\">",
"     table 1",
"    </a>",
"    ) were achieved by 32 percent of patients in the active treatment group, compared with 11 percent in the sham apheresis group.",
"   </p>",
"   <p>",
"    It should be noted that the degree of improvement required to achieve an ACR20 response is difficult for many individual patients to appreciate, and that the standard for judging improvement in RA clinical trials has been raised significantly since the time of this trial [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/566/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the era of biologic therapies, the role of immunoadsorption (if any) in the treatment of RA is not clear. Immunoadsorption is an expensive therapy associated with a high incidence of complications and uncertain efficacy. Unless there are compelling reasons to use this modality and all other alternatives have failed, the cost of immunoadsorption outweighs benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-biologic approaches to the treatment of RA still under investigation include the use of statin medications for their antiinflammatory effects and the utility of stem cell transplantation. In addition, immunoadsorption therapy is approved by the United States Food and Drug Administration but is seldom employed for the treatment of RA.",
"     </li>",
"     <li>",
"      RA is associated with an increased prevalence of coronary atherosclerosis, which contributes to the elevated mortality rates of patients. We suggest that in patients with borderline indications for statin use for the purpose of primary atherosclerosis prevention, the presence of RA provides enough indication to use these medications for their cardioprotective effect (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, we presently do not suggest the routine use of statins in patients with RA for the purpose of treating the inflammation of RA in the absence of a clearcut indication for their use in cardioprotection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Statins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The future role of stem cell transplantation in RA remains unclear. The need for even considering such an approach is much less than it was before the growth of biologic interventions for RA, such as TNF inhibition, B cell depletion, costimulation blockade, IL-6 inhibition, and other approaches in late-phase development. We suggest considering the use of hematopoietic stem cell transplantation in RA only in the context of a clinical trial (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hematopoietic stem cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunoadsorption is an expensive therapy associated with a high incidence of complications and uncertain efficacy. Its role in the treatment of RA is not clear. We suggest that immunoadsorption not be used for the treatment of RA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Immunoadsorption'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/1\">",
"      Arnaud C, Mach F. Potential antiinflammatory and immunomodulatory effects of statins in rheumatologic therapy. Arthritis Rheum 2006; 54:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/2\">",
"      Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/3\">",
"      Yamagata T, Kinoshita K, Nozaki Y, et al. Effects of pravastatin in murine collagen-induced arthritis. Rheumatol Int 2007; 27:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/4\">",
"      Nagashima T, Okazaki H, Yudoh K, et al. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum 2006; 54:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/5\">",
"      Okamoto H, Koizumi K, Kamitsuji S, et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 2007; 34:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/6\">",
"      McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/7\">",
"      Jacobs P, Vincent MD, Martell RW. Prolonged remission of severe refractory rheumatoid arthritis following allogeneic bone marrow transplantation for drug-induced aplastic anaemia. Bone Marrow Transplant 1986; 1:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/8\">",
"      Verburg RJ, Flierman R, Sont JK, et al. Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration. Ann Rheum Dis 2005; 64:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/9\">",
"      Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci U S A 1998; 95:14447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/10\">",
"      van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006; 45:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/11\">",
"      Burt RK, Georganas C, Schroeder J, et al. Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis: sustained response in two of four patients. Arthritis Rheum 1999; 42:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/12\">",
"      Snowden JA, Biggs JC, Milliken ST, et al. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis Rheum 1999; 42:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/13\">",
"      Breban M, Dougados M, Picard F, et al. Intensified-dose (4 gm/m2) cyclophosphamide and granulocyte colony-stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis. Arthritis Rheum 1999; 42:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/14\">",
"      Verburg RJ, Kruize AA, van den Hoogen FH, et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum 2001; 44:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/15\">",
"      Verburg RJ, Sont JK, van Laar JM. Reduction of joint damage in severe rheumatoid arthritis by high-dose chemotherapy and autologous stem cell transplantation. Arthritis Rheum 2005; 52:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/16\">",
"      Moore J, Brooks P, Milliken S, et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002; 46:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/17\">",
"      Snowden JA, Passweg J, Moore JJ, et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 2004; 31:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/18\">",
"      Burt RK, Oyama Y, Verda L, et al. Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism. Arthritis Rheum 2004; 50:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/19\">",
"      Ault A. New direction for treatment of rheumatoid arthritis offered in USA. Lancet 1999; 353:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/20\">",
"      Silverman GJ, Goodyear CS, Siegel DL. On the mechanism of staphylococcal protein A immunomodulation. Transfusion 2005; 45:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/21\">",
"      Felson DT, LaValley MP, Baldassare AR, et al. The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial. Arthritis Rheum 1999; 42:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/566/abstract/22\">",
"      Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998; 41:1564.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7965 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_566=[""].join("\n");
var outline_f0_35_566=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STATINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HEMATOPOIETIC STEM CELL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Autologous transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Allogeneic stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IMMUNOADSORPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7965\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7965|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/30/26091\" title=\"table 1\">",
"      ACR RA response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31433?source=related_link\">",
"      Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16746?source=related_link\">",
"      Cytokine networks in rheumatic diseases: Implications for therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_35_567="Junctional nevus";
var content_f0_35_567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57022%7EPEDS%2F81931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57022%7EPEDS%2F81931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Junctional nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flat junctional nevus with darker pigmentation in the center than at the periphery. This lesion is symmetric with a regular outline.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Compound nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Compound nevus with central elevation. This lesion is symmetric with a regular outline and uniform pigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_567=[""].join("\n");
var outline_f0_35_567=null;
var title_f0_35_568="Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults";
var content_f0_35_568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/35/568/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/568/contributors\">",
"     Peter M Mauch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/35/568/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/568/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/35/568/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/568/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/35/568/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hodgkin lymphoma (formerly called Hodgkin's disease) is a group of cancers characterized by Reed-Sternberg cells in an appropriate reactive cellular background. An important clinical feature is its tendency to arise within lymph node areas and to spread in an orderly fashion to contiguous areas of lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/1\">",
"     1",
"    </a>",
"    ]. Late in the course of the disease, vascular invasion leads to widespread hematogenous dissemination.",
"   </p>",
"   <p>",
"    The clinical presentation of the patient with Hodgkin lymphoma and the patterns of disease distribution are reviewed here. The initial clinical evaluation and the development and use of staging systems in Hodgkin lymphoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=see_link\">",
"     \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hodgkin lymphoma has a bimodal age distribution with one peak in the 20s and 30s, and a second peak over the age of 50. The majority of patients present with overt disease, most often as an asymptomatic enlarged lymph node or a mass on chest x-ray. However, the presenting symptoms and signs may be relatively nonspecific and more compatible with infection than malignant disease. Occult presentation of Hodgkin lymphoma is unusual, but the incidence of clinically occult disease has been an important influence in the development of therapeutic strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Asymptomatic lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hodgkin lymphoma presents as a painless mass in approximately 70 percent of cases. The involved lymph node is usually nontender with a rubbery consistency. The most common involved site is in the neck, as 60 to 80 percent of patients have enlarged cervical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supraclavicular nodes (",
"    <a class=\"graphic graphic_table graphicRef51115 \" href=\"UTD.htm?27/63/28668\">",
"     table 1",
"    </a>",
"    ). Enlarged nodes are found in the axilla in 10 to 20 percent of patients and inguinal nodes are involved in 6 to 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not detectable on physical examination, the mediastinal nodes are involved in 60 to 70 percent of cases at presentation, and retroperitoneal nodes in 25 percent. Exclusive infradiaphragmatic lymphadenopathy is infrequent, occurring in less than 10 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mediastinal mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second common presentation is the discovery of a mediastinal mass on routine chest x-ray. The mass may be fairly large without producing local symptoms. Less commonly, the mass produces nonspecific symptoms such as retrosternal chest pain, cough, or shortness of breath. Small pericardial or pleural effusions are rare except in patients with bulky mediastinal disease. Superior vena caval obstruction is also rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=see_link\">",
"     \"Malignancy-related superior vena cava syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with early stage disease, large mediastinal adenopathy (defined as more than one-third of the greatest intrathoracic diameter of the chest wall) is an adverse prognostic factor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2792?source=see_link\">",
"     \"Clinical trials of specific regimens in favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Systemic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant proportion of patients with Hodgkin lymphoma develop systemic symptoms prior to the discovery of lymphadenopathy. Typical symptoms, called B symptoms, include fever (&gt;100.4), night sweats, and weight loss. Fatigue and pruritus also may be seen, but are not classic B symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     B symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;B symptoms are present in less than 20 percent of patients with stage",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    Hodgkin lymphoma and up to 50 percent of patients with advanced disease. Among the latter, groups of patients who have B symptoms have a modest reduction in survival [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic B symptoms have been formally defined as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever &mdash; temperature &gt;38&ordm;C (&gt;100.4&ordm;F)",
"     </li>",
"     <li>",
"      Weight loss &mdash; unexplained loss of &gt;10 percent of body weight over the past six months",
"     </li>",
"     <li>",
"      Sweats &mdash; the presence of drenching night sweats",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fever is similar to that associated with infection; it is more noticeable in the evening and becomes more severe and continuous with time. Pel-Ebstein fever is the characteristic, although uncommon, intermittent fever associated with Hodgkin lymphoma. It recurs at variable intervals of several days or weeks and lasts for one to two weeks before waning [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not currently defined as a B symptom, pruritus may be an important early symptom, preceding the diagnosis of Hodgkin lymphoma by months or even a year or more [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/5\">",
"     5",
"    </a>",
"    ]. Pruritus occurs early in approximately 10 to 15 percent of patients, but the great majority of patients experience pruritus at some time during the course of illness. It is usually generalized and occasionally severe enough to cause intense scratching and excoriations. Severe, but not mild, pruritus is a poor prognostic sign [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other nonspecific symptoms and paraneoplastic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In occasional patients, Hodgkin lymphoma presents with one of a variety of nonspecific symptoms reflecting organ involvement or paraneoplastic syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Intraabdominal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retroperitoneal lymphadenopathy may give rise to discomfort and pain in the paravertebral or loin regions, particularly in the supine position. Other patients present with abdominal swelling due to splenomegaly, hepatomegaly, or rarely ascites. Advanced intraabdominal disease can be associated with ureteral obstruction or compression of the renal vein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cholestatic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jaundice or hepatic failure with intrahepatic cholestasis is an extremely unusual presentation of Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In one series of 421 patients, for example, six (1.4 percent) presented with liver abnormalities that led to a liver biopsy and the subsequent diagnosis of Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/6\">",
"     6",
"    </a>",
"    ]. All had fever, four had frank jaundice with or without moderate elevations of serum aminotransferases, and one had hepatic failure; none had pruritus. Fulminant hepatic failure can also occur as a paraneoplastic manifestation without hepatic infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Alcohol-induced pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, patients with Hodgkin lymphoma complain of severe pain following alcohol ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The pain typically occurs within a few minutes after the ingestion of even a small amount of alcohol and is localized to areas involved by Hodgkin lymphoma. It occurs more often at sites of bony involvement, but may also occur at sites of lymphadenopathy. In one series of 35 patients with alcohol-induced pain, nodular sclerosis was the predominant histology [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/9\">",
"     9",
"    </a>",
"    ]. The mechanism is unknown.",
"   </p>",
"   <p>",
"    While this symptom has no prognostic significance and is not commonly present (less than 10 percent), it is highly specific for a diagnosis of Hodgkin lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of skin lesions have been associated with Hodgkin lymphoma. These include ichthyosis, acrokeratosis (Bazex syndrome), urticaria, erythema multiforme, erythema nodosum, necrotizing lesions, hyperpigmentation, and skin infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link\">",
"     \"Cutaneous manifestations of internal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Neurologic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hodgkin lymphoma involving the central nervous system is a rare event, occurring at a frequency between 0.02 and 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several rare paraneoplastic neurologic syndromes have been described in patients with Hodgkin lymphoma. These include paraneoplastic cerebellar degeneration, chorea, neuromyotonia, limbic encephalitis, subacute sensory neuronopathy, subacute lower motor neuronopathy, and the stiff person syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/17-26\">",
"     17-26",
"    </a>",
"    ]. Paraneoplastic cerebellar degeneration does not correlate with the severity of Hodgkin lymphoma and may develop while the patient is in remission [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26983?source=see_link\">",
"     \"Paraneoplastic cerebellar degeneration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/41/665?source=see_link\">",
"     \"Stiff-person syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrotic syndrome can occur as a paraneoplastic syndrome in patients with early stage Hodgkin lymphoma, possibly due to secretion of a toxic lymphokine, such as IL-13. The usual pathologic pattern is that of minimal change disease but focal segmental glomerulosclerosis, which represent a more severe manifestation of the same pathologic process, also can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=see_link&amp;anchor=H7#H7\">",
"     \"The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma\", section on 'Interleukin-13 signaling pathway'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other manifestations can occur in patients with Hodgkin lymphoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypercalcemia, which may be due to bony involvement or more often to increased production of calcitriol (1,25-dihydroxyvitamin D3) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"       \"Hypercalcemia in granulomatous diseases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia, which can be normochromic and normocytic or, rarely, a Coombs' positive hemolytic anemia that may be associated with immune thrombocytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Eosinophilia is a relatively common finding that may be due to production of chemokines, such as interleukin-5 and eotaxin, that stimulate eosinophil production",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recruitment [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leukocytosis, thrombocytosis, lymphopenia, and hypoalbuminemia are also seen with Hodgkin lymphoma, especially in patients with advanced stage disease.",
"     </li>",
"     <li>",
"      Other uncommon presenting symptoms include chest pain, bronchial obstruction, abdominal pain, bone pain, spinal cord compression, and peripheral edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PATTERNS OF DISEASE PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is widely accepted that Hodgkin lymphoma starts at a single site within the lymphatic system, usually a lymph node, and then progresses to adjacent lymph nodes via lymphatic channels before disseminating to distant nonadjacent sites and organs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Noncontiguous spread and hematologic distribution are more common with recurrent disease. It is likely that Hodgkin lymphoma can spread via the thoracic duct, possibly in either direction, without clinical involvement of the mediastinum.",
"   </p>",
"   <p>",
"    Clinical studies of disease distribution have supported this concept, particularly in younger patients with classic histologic subtypes of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. One series, for example, evaluated 100 patients at a time when surgical staging was routinely performed, thereby permitting documentation of disease distribution patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/37\">",
"     37",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is rare to have Hodgkin lymphoma in the neck and the lower abdomen without disease in the upper abdomen.",
"     </li>",
"     <li>",
"      It is unusual to have bilateral axillary involvement without disease in the lower neck areas.",
"     </li>",
"     <li>",
"      It is extremely unusual to have hepatic or bone marrow infiltration without disease in the spleen.",
"     </li>",
"     <li>",
"      It is uncommon to have pulmonary disease at presentation without Hodgkin lymphoma being present within the hilar lymph nodes, usually on the ipsilateral side.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19852433\">",
"    <span class=\"h2\">",
"     Variation by histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of disease at presentation appears to be associated with certain histologic subtypes. This was illustrated in a detailed study of 719 patients with Hodgkin lymphoma who underwent staging laparotomy; the following patterns were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with nodular lymphocyte-predominant Hodgkin lymphoma presented with localized peripheral disease often in the upper neck, whereas patients with the lymphocyte depletion subtype usually presented with abdominal nodal involvement and often have extranodal disease.",
"     </li>",
"     <li>",
"      The majority of patients with nodular sclerosis histology had disease above the diaphragm and mediastinal node involvement.",
"     </li>",
"     <li>",
"      Disease in the liver was most often seen in patients with the mixed cellularity or lymphocyte depletion subtypes and systemic symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lymphocyte-depleted classical Hodgkin lymphoma is the least common subtype of classical Hodgkin lymphoma and accounts for less than 1 percent of cases. This subtype appears to have a different pattern of presentation than the other histologic subtypes. In an analysis of 12,155 patients enrolled on prospective studies, the 84 patients with lymphocyte-depleted histology were more likely to present with advanced stage disease (74 versus 42 percent) and systemic B symptoms (76 versus 41 percent) when compared with patients with other histologies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Risk factors for splenic involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of prognostic factors has made it easier to define patients who are most and least likely to have splenic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In one study, for example, staging laparotomy was performed as part of the routine diagnostic evaluation following clinical staging (CS) in 692 patients presenting with supradiaphragmatic Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/41\">",
"     41",
"    </a>",
"    ]. Factors that were statistically significant for predicting disease below the diaphragm included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CS III-IV disease",
"     </li>",
"     <li>",
"      B symptoms",
"     </li>",
"     <li>",
"      Mixed cellularity or lymphocytic depletion histology",
"     </li>",
"     <li>",
"      Age greater than or equal to 40 years",
"     </li>",
"     <li>",
"      Two or more supradiaphragmatic sites",
"     </li>",
"     <li>",
"      Male sex",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    B symptoms and the last two factors all independently predicted for positive surgical staging in CS I-II patients, while the second, third, and fourth factors all independently predicted for positive surgical staging in CS III-IV patients. Four subgroups were identified that had a low probability (&lt;10 percent) of stage or treatment change following laparotomy: CS IA female patients; CS IA male patients with nodular lymphocyte predominant histology or high neck presentations; and patients with CS IIIB-IVB disease.",
"   </p>",
"   <p>",
"    However, these predictions are not absolute and for a while some believed that staging laparotomy remained a relevant investigation for selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In an attempt to address this issue, a decision-analytic model was constructed to compare laparotomy versus no laparotomy staging for a hypothetical cohort of 25-year-old patients with clinical stage I-II, favorable prognosis Hodgkin lymphoma using studies published in the modern era [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/568/abstract/44\">",
"     44",
"    </a>",
"    ]. The life expectancy was similar in the two groups: 36.7 years for the laparotomy strategy compared with 35.9 years for no laparotomy. Despite these arguments, staging laparotomy is not a benign procedure and the use of modified and safer chemotherapy (eg, ABVD) and more limited radiation (eg, involved field radiation) at reduced doses without staging laparotomy is the current standard or practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18059316\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hodgkin lymphoma (formerly called Hodgkin's disease) is a group of cancers characterized by Reed-Sternberg cells in an appropriate reactive cellular background.",
"     </li>",
"     <li>",
"      The majority of patients presents with overt disease, most often with an asymptomatic enlarged lymph node or a mass on chest x-ray. A minority present with nonspecific symptoms and signs that are more compatible with infection than malignant disease. Occult presentation of Hodgkin lymphoma is unusual. The most common presentations include (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nontender lymphadenopathy in the neck or mediastinum. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Asymptomatic lymphadenopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Incidental finding of a mediastinal mass on routine chest x-ray. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mediastinal mass'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic symptoms (fever, night sweats, and weight loss) are present in less than 20 percent of patients with stage",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      Hodgkin lymphoma and up to 50 percent of patients with more advanced disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'B symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In occasional patients, Hodgkin lymphoma presents with one of a variety of nonspecific symptoms reflecting organ involvement or paraneoplastic syndromes. These presentations include symptoms related to retroperitoneal lymphadenopathy, cholestatic liver disease, alcohol-induced pain, skin lesions, neurologic symptoms, nephrotic syndrome, hypercalcemia, and abnormalities in blood counts. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other nonspecific symptoms and paraneoplastic syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hodgkin lymphoma starts at a single site within the lymphatic system, usually a lymph node, and then progresses to adjacent lymph nodes via lymphatic channels before disseminating to distant nonadjacent sites and organs.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/1\">",
"      Mauch PM, Kalish LA, Kadin M, et al. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer 1993; 71:2062.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan HS. Hodgkin's Disease, 2nd ed, Harvard University Press, Cambridge, MA 1980.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/3\">",
"      Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/4\">",
"      Good GR, DiNubile MJ. Images in clinical medicine. Cyclic fever in Hodgkin's disease (Pel-Ebstein fever). N Engl J Med 1995; 332:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/5\">",
"      Gobbi PG, Cavalli C, Gendarini A, et al. Reevaluation of prognostic significance of symptoms in Hodgkin's disease. Cancer 1985; 56:2874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/6\">",
"      Cervantes F, Briones J, Bruguera M, et al. Hodgkin's disease presenting as a cholestatic febrile illness: incidence and main characteristics in a series of 421 patients. Ann Hematol 1996; 72:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/7\">",
"      Qureshi WA. Intrahepatic cholestatic syndromes: pathogenesis, clinical features and management. Dig Dis 1999; 17:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/8\">",
"      Dourakis SP, Tzemanakis E, Deutsch M, et al. Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease. Eur J Gastroenterol Hepatol 1999; 11:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/9\">",
"      Atkinson K, Austin DE, McElwain TJ, Peckham MJ. Alcohol pain in Hodgkin's disease. Cancer 1976; 37:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/10\">",
"      Cavalli F. Rare syndromes in Hodgkin's disease. Ann Oncol 1998; 9 Suppl 5:S109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/11\">",
"      Lucker GP, Steijlen PM. Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease. Br J Dermatol 1995; 133:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/12\">",
"      Perifanis V, Sfikas G, Tziomalos K, et al. Skin involvement in Hodgkin's disease. Cancer Invest 2006; 24:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/13\">",
"      Re D, Fuchs M, Schober T, et al. CNS involvement in Hodgkin's lymphoma. J Clin Oncol 2007; 25:3182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/14\">",
"      Morawa E, Ragam A, Sirota R, Nabhan C. Hodgkin's lymphoma involving the CNS. J Clin Oncol 2007; 25:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/15\">",
"      de Castro AF, J&uacute;nior AS, de Lins e Horta H, et al. Primary intracerebral Hodgkin lymphoma. Br J Haematol 2007; 138:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/16\">",
"      Gerstner ER, Abrey LE, Schiff D, et al. CNS Hodgkin lymphoma. Blood 2008; 112:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/17\">",
"      Graus F, Dalmau J, Valldeoriola F, et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol 1997; 74:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/18\">",
"      Graus F, Gultekin SH, Ferrer I, et al. Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system. Acta Neuropathol 1998; 96:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/19\">",
"      Hammack J, Kotanides H, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease. Neurology 1992; 42:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/20\">",
"      Batchelor TT, Platten M, Palmer-Toy DE, et al. Chorea as a paraneoplastic complication of Hodgkin's disease. J Neurooncol 1998; 36:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/21\">",
"      Caress JB, Abend WK, Preston DC, Logigian EL. A case of Hodgkin's lymphoma producing neuromyotonia. Neurology 1997; 49:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/22\">",
"      Deodhare S, O'Connor P, Ghazarian D, Bilbao JM. Paraneoplastic limbic encephalitis in Hodgkin's disease. Can J Neurol Sci 1996; 23:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/23\">",
"      Hughes RA, Britton T, Richards M. Effects of lymphoma on the peripheral nervous system. J R Soc Med 1994; 87:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/24\">",
"      Plante-Bordeneuve V, Baudrimont M, Gorin NC, Gherardi RK. Subacute sensory neuropathy associated with Hodgkin's disease. J Neurol Sci 1994; 121:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/25\">",
"      Ferrari P, Federico M, Grimaldi LM, Silingardi V. Stiff-man syndrome in a patient with Hodgkin's disease. An unusual paraneoplastic syndrome. Haematologica 1990; 75:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/26\">",
"      Briani C, Vitaliani R, Grisold W, et al. Spectrum of paraneoplastic disease associated with lymphoma. Neurology 2011; 76:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/27\">",
"      Dabbs DJ, Striker LM, Mignon F, Striker G. Glomerular lesions in lymphomas and leukemias. Am J Med 1986; 80:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/28\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-1983. A 24-year-old man with cervical lymphadenopathy and the nephrotic syndrome. N Engl J Med 1983; 308:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/29\">",
"      Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993; 82:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/30\">",
"      Rieke JW, Donaldson SS, Horning SJ. Hypercalcemia and vitamin D metabolism in Hodgkin's disease. Is there an underlying immunoregulatory relationship? Cancer 1989; 63:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/31\">",
"      Shah SJ, Warrier RP, Ode DL, et al. Immune thrombocytopenia and hemolytic anemia associated with Hodgkin disease. J Pediatr Hematol Oncol 1996; 18:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/32\">",
"      Sierra RD. Coombs-positive hemolytic anemia in Hodgkin's disease: case presentation and review of the literature. Mil Med 1991; 156:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/33\">",
"      Di Biagio E, S&aacute;nchez-Borges M, Desenne JJ, et al. Eosinophilia in Hodgkin's disease: a role for interleukin 5. Int Arch Allergy Immunol 1996; 110:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/34\">",
"      Teruya-Feldstein J, Jaffe ES, Burd PR, et al. Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood 1999; 93:2463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/35\">",
"      Peters MV, Alison RE, Bush RS. Natural history of Hodgkin's disease as related to staging. Cancer 1966; 19:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/36\">",
"      KAPLAN HS. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology 1962; 78:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/37\">",
"      Rosenberg SA, Kaplan HS. Evidence for an orderly progression in the spread of Hodgkin's disease. Cancer Res 1966; 26:1225.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan HS. On the natural history, treatment and prognosis of Hodgkin's disease. In: Harvey Lectures 1968-69, Academic Press, New York 1970. p.215.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/39\">",
"      Klimm B, Franklin J, Stein H, et al. Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group. J Clin Oncol 2011; 29:3914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/40\">",
"      Leibenhaut MH, Hoppe RT, Efron B, et al. Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. J Clin Oncol 1989; 7:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/41\">",
"      Mauch P, Larson D, Osteen R, et al. Prognostic factors for positive surgical staging in patients with Hodgkin's disease. J Clin Oncol 1990; 8:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/42\">",
"      Sombeck MD, Mendenhall NP, Kaude JV, et al. Correlation of lymphangiography, computed tomography, and laparotomy in the staging of Hodgkin's disease. Int J Radiat Oncol Biol Phys 1993; 25:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/43\">",
"      Cho LC, Levinson BH, Glatstein E. To Lap or Not to Lap. Oncologist 1996; 1:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/568/abstract/44\">",
"      Ng AK, Weeks JC, Mauch PM, Kuntz KM. Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease. J Clin Oncol 1999; 17:3577.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4687 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_568=[""].join("\n");
var outline_f0_35_568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18059316\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Asymptomatic lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mediastinal mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Systemic symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - B symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other nonspecific symptoms and paraneoplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Intraabdominal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cholestatic liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Alcohol-induced pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Skin lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Neurologic syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PATTERNS OF DISEASE PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19852433\">",
"      Variation by histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Risk factors for splenic involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18059316\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4687\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4687|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/63/28668\" title=\"table 1\">",
"      Involved sites in untreated HL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2792?source=related_link\">",
"      Clinical trials of specific regimens in favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=related_link\">",
"      Etiology, clinical features, and diagnosis of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=related_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=related_link\">",
"      Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26983?source=related_link\">",
"      Paraneoplastic cerebellar degeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/41/665?source=related_link\">",
"      Stiff-person syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=related_link\">",
"      The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_35_569="Decompressive hemicraniectomy for malignant middle cerebral artery territory infarction";
var content_f0_35_569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Decompressive hemicraniectomy for malignant middle cerebral artery territory infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/35/569/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/569/contributors\">",
"     Rishi Gupta, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/569/contributors\">",
"     Mitchell SV Elkind, MD, MS, FAAN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/35/569/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/569/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/35/569/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/569/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/35/569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DESCRIPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decompressive hemicraniectomy and durotomy is a surgical technique used to relieve the increased intracranial pressure and brain tissue shifts that occur in the setting of large cerebral hemisphere mass, or space-occupying, lesions. In general, the technique involves removal of bone tissue (skull) and incision of the restrictive dura mater covering the brain, allowing swollen brain tissue to herniate upwards through the surgical defect rather than downwards to compress the brainstem.",
"   </p>",
"   <p>",
"    Hemicraniectomy has been used to treat brain swelling and mass effect secondary to a middle cerebral artery (MCA) territory infarction, hemispheric encephalitis, and large parenchymal intracerebral hemorrhage in subarachnoid hemorrhage. The procedure was first described in 1905 by Harvey Cushing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/1\">",
"     1",
"    </a>",
"    ], and was first utilized specifically for massive cerebral infarction in 1956 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review both the clinical features of malignant (also called massive) MCA territory infarction, and the treatment of this devastating type of stroke with decompressive hemicraniectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF MALIGNANT HEMISPHERIC INFARCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Roughly 10 percent of ischemic strokes are classified as malignant or massive because of the presence of space-occupying cerebral edema that is severe enough to produce elevated intracranial pressure and brain herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The etiology of the majority of these infarcts is cardioembolic or thrombotic occlusion of the internal carotid artery or the proximal segment (stem, or M1) of the middle cerebral artery (MCA).",
"   </p>",
"   <p>",
"    On examination, patients with a malignant MCA territory infarction have forced gaze deviation, visual field deficit, hemiplegia, and aphasia or neglect, depending on the hemisphere involved. This combination of neurologic findings yields a National Institutes of Health Stroke Scale (NIHSS) score &gt;15 for a right hemisphere infarction and &gt;20 for a left hemisphere infarction.",
"   </p>",
"   <p>",
"    Patients with this syndrome have a mortality rate as high as 78 percent due to herniation of the temporal lobe onto the brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/5\">",
"     5",
"    </a>",
"    ]. This reported mortality rate may be higher than the true rate, however, as many patients are removed from ventilatory support because of the expected poor quality of life were they to survive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Radiologic predictors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Head CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large territories of hypodensity (defined as &gt;50 percent of the MCA territory) on early head CT after ischemic stroke may be predictive of fatal brain swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/6\">",
"     6",
"    </a>",
"    ]. The best evidence supporting this comes from two retrospective case-control studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 22 patients with anterior circulation ischemic stroke who had progressive neurologic deterioration leading to coma and death were compared with 104 controls who had anterior circulation ischemic stroke of comparable clinical severity [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/7\">",
"       7",
"      </a>",
"      ]. Head CT was obtained after stroke onset in cases and controls at a median time of 187 and 153 minutes respectively. The only independent radiologic predictor of fatal brain swelling was involvement of &gt;50 percent of the MCA territory on head CT (odds ratio [OR] 6.1; 95% CI 2.3-16.6).",
"     </li>",
"     <li>",
"      In a subsequent multicenter study, 94 patients with large MCA territory ischemic stroke and fatal brain swelling were compared with 107 controls who had correspondingly large strokes and survived hospitalization or died of non-neurologic causes [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/8\">",
"       8",
"      </a>",
"      ]. Hypodensity involving &gt;50 percent of the MCA territory on early head CT (performed at a median of 156 minutes) was an independent predictor of fatal brain edema (OR 6.3; 95% CI 3.5-11.6), as was involvement of additional vascular territories on head CT (OR 3.34; 95% CI 1.19-9.38).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiologic features associated with fatal outcome were also studied in a series of 135 patients with large MCA territory infarction who had follow-up head CT scans performed within 48 hours of stroke onset [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/9\">",
"     9",
"    </a>",
"    ]. Predictors of death within 30 days included midline shift of the septum pellucidum &gt;5 mm (odds ratio 10.9, 95% CI 3.2-37.6) and infarction of vascular territories beyond the MCA (OR 4.9, 95% CI 1.6-15.0).",
"   </p>",
"   <p>",
"    Despite this evidence, it is worth emphasizing that head CT probably has limited utility in predicting outcome. This point is supported by findings from a series of 34 patients with infarction of &gt;50 percent of MCA territory on early (&lt;12 hours) CT scan; only 17 patients (50 percent) developed a malignant course with massive swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because CT findings consistent with infarction may lag behind physiologic tissue infarction, other radiographic methods that are more sensitive to evolving infarction and edema may offer greater utility in predicting patients at risk of herniation who may benefit from surgical decompression. As an example, one study used perfusion CT to calculate infarct volume and routine CT to calculate intracranial cerebrospinal fluid (CSF) volume, a measure of intracranial volume reserve [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/11\">",
"     11",
"    </a>",
"    ]. The ratio of infarct volume to CSF volume was a better predictor of a malignant course than other measures such as ischemic lesion volume or clinical characteristics. Additional methods include positron emission tomography (PET) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/10\">",
"     10",
"    </a>",
"    ], xenon CT [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/12\">",
"     12",
"    </a>",
"    ], single photon emission computed tomography (SPECT) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/13\">",
"     13",
"    </a>",
"    ], diffusion and perfusion magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/14\">",
"     14",
"    </a>",
"    ], and perfusion CT [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/15\">",
"     15",
"    </a>",
"    ] to determine anatomic or physiologic measures predictive of malignant infarction. However, these tests are not widely available in clinical practice, with the possible exceptions of",
"    <span class=\"nowrap\">",
"     diffusion/perfusion",
"    </span>",
"    MRI and perfusion CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to head CT, a large volume of infarction, as measured by diffusion-weighted imaging (DWI) or apparent diffusion coefficient (ADC) mapping, may predict a malignant course in MCA territory stroke that is characterized by cerebral edema.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective observational cohort of 140 patients with occlusion of the MCA diagnosed by magnetic resonance angiography (MRA) within six hours of stroke onset, malignant MCA infarction developed in 27 (19 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/16\">",
"       16",
"      </a>",
"      ]. Independent radiologic predictors for the development of malignant MCA infarction included lesion size on DWI (per 1 mL odds ratio [OR] 1.04, 95% CI 1.02-1.06) and combined occlusion of the internal carotid and middle cerebral arteries (OR 5.38, 95% CI 1.55-18.68). A DWI lesion volume of &gt;82 mL predicted the development of malignant MCA infarction with a high specificity (98 percent). However, the sensitivity of this cutoff was low (52 percent) due to the development of malignant MCA infarction in 14 patients with DWI lesions &lt;82 mL, including 10 patients with DWI lesion volumes &lt;50 mL.",
"     </li>",
"     <li>",
"      In a series of 28 patients with an MCA territory infarction diagnosed by DWI and MCA or carotid T occlusion by MRA performed within 14 hours after onset (mean 6.5 hours), a DWI infarct volume &gt;145 mL was predictive of herniation [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Xenon CT, SPECT, and PET",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantifying cerebral blood flow with Xenon CT may be predictive of cerebral swelling in patients with malignant MCA territory infarction. In a retrospective study, 20 patients with aggressively managed acute MCA territory strokes had measurements of CBF by Xenon CT scanning within six hours of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/12\">",
"     12",
"    </a>",
"    ]. A mean blood flow to the affected hemisphere of &le;15",
"    <span class=\"nowrap\">",
"     mL/100",
"    </span>",
"    g per minute was associated with a statistically significant increase in the risk of severe edema or herniation. Xenon CT may also hold promise for approximating the volume of infarcted tissue, as blood flow values near 8",
"    <span class=\"nowrap\">",
"     mL/100",
"    </span>",
"    g per minute likely represent infarction.",
"   </p>",
"   <p>",
"    Single photon emission computed tomography (SPECT) and positron emission tomography (PET) studies have also been studied as predictors of herniation, although studies have been relatively small. The sensitivity of SPECT for fatal cerebral edema is much higher than CT (82 percent versus 36 percent), while the specificity is similar (98 percent versus 100 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients who develop malignant swelling are also more likely to have reduced cerebral blood flow and irreversible neuronal injury on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    PET imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a prospective study cited earlier of 140 patients with occlusion of the MCA diagnosed by MRA within six hours of stroke onset, malignant MCA infarction developed in 27 (19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/16\">",
"     16",
"    </a>",
"    ]. The severity of neurologic deficit on admission as measured by the NIH stroke scale score was an independent predictor for the development of malignant MCA infarction (per point, odds ratio 1.18, 95% CI 1.01-1.38). However, an NIH stroke scale score &gt;18 predicted the development of malignant MCA infarction with only low to moderate sensitivity and specificity (70 and 63 percent).",
"   </p>",
"   <p>",
"    In retrospective case-control studies, the following clinical parameters were independent predictors of malignant edema after a large MCA territory:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset of",
"      <span class=\"nowrap\">",
"       nausea/vomiting",
"      </span>",
"      within 24 hours of symptom onset [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Systolic blood pressure &ge;180 mmHg after 12 hours from onset [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      History of hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      History of heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elevated white blood cell (WBC) count [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypertension and heart failure may predispose patients to poor cerebral autoregulation and inadequate collateral circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/17\">",
"     17",
"    </a>",
"    ]. This is important as the volume of infarct distal to an occluded artery is related to the collateral supply of that territory. Elevated white blood cell counts may represent a stress response to a large infarct, or they may be associated with fever that has itself been shown to lead to worse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Predictors for malignant MCA territory infarction were also evaluated in an autopsy series of 192 patients with nonlacunar infarction involving the MCA territory that included 45 patients with malignant MCA infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/19\">",
"     19",
"    </a>",
"    ]. The following characteristics were independently and positively associated with malignant MCA infarction:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Younger age",
"     </li>",
"     <li>",
"      No history of stroke",
"     </li>",
"     <li>",
"      Female gender",
"     </li>",
"     <li>",
"      Heart weight",
"     </li>",
"     <li>",
"      Abnormal ipsilateral circle of Willis",
"     </li>",
"     <li>",
"      Carotid occlusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The association of malignant MCA territory infarction with younger age has been suggested by other studies as well [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/7,20,21\">",
"     7,20,21",
"    </a>",
"    ], and may be based upon a protective effect afforded by cerebral atrophy in older patients that accommodates brain swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. Furthermore, extracranial and intracranial carotid occlusion as well as poor collateral circulation (eg, due to an incomplete ipsilateral circle of Willis) are plausible factors contributing to malignant infarction. However, it is unclear why female sex might predispose to malignant MCA territory infarction.",
"   </p>",
"   <p>",
"    The early development of decreased consciousness in patients with malignant hemispheric infarction who are awake at initial presentation is predictive of poor outcome. Supporting evidence comes from an analysis of prospective data from a randomized trial that included 564 placebo-treated patients with major anterior circulation ischemic stroke who did not have impairment in level of consciousness at baseline; the trial enrolled patients up to six hours after symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/22\">",
"     22",
"    </a>",
"    ]. Decreased level of consciousness at three hours after enrollment and maximum score on a level of consciousness scale in the first 24 hours were both significantly associated with increased mortality.",
"   </p>",
"   <p>",
"    Serum biomarkers may also predict poor outcome in MCA infarction. Serum S100B, a protein released after injury to astroglia, reaches the peripheral bloodstream with blood-brain barrier disruption, and it has been shown to correlate with infarct volume [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/23\">",
"     23",
"    </a>",
"    ]. In a study of 51 patients with proximal MCA occlusion, S100B levels measured 12 to 24 hours from symptom onset were significantly higher in those patients who developed clinical herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasma cellular fibronectin (c-FN) is another candidate biomarker of malignant MCA infarction. In a case-control study of 40 patients with malignant MCA territory infarction and 35 control patients matched by admission stroke severity, a plasma c-FN concentration &gt;16.6",
"    <span class=\"nowrap\">",
"     micrograms/mL",
"    </span>",
"    was associated with development of malignant MCA territory stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continuous monitoring of the biochemical profile in the area of infarction, using microdialysis of cerebrospinal fluid, may offer advantages over serial CT scans. Patients with elevations of excitatory neurotransmitters (glutamate and aspartate) and anaerobic metabolites (lactate and pyruvate) are more likely to develop malignant swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These biomarkers, in conjunction with radiographic parameters, may help to define patients at highest risk of malignant swelling and thus most likely to benefit from aggressive surgical procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS OF HEMICRANIECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of hemicraniectomy are to prevent further brain injury by reversing mass effect and brain tissue shifts, decreasing intracranial pressure, and improving cerebral perfusion pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is preliminary evidence from a pooled analysis of three small randomized controlled trials that hemicraniectomy for malignant hemispheric infarction reduces mortality. However, it is unclear whether the ultimate neurologic outcome is acceptable in many cases. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Randomized trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Functional status in many studies is assessed using disability scales such as the Barthel Index that do not account for poor cognitive outcomes, which may be nonetheless extremely disabling.",
"   </p>",
"   <p>",
"    Patient age and timing of surgery may be important variables when considering treatment with hemicraniectomy. In addition, younger patients (50 or less) may have better functional outcome and decreased mortality than older patients. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Selection of patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small randomized, controlled clinical trials evaluated the effectiveness of hemicraniectomy for large MCA territory infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. A preplanned pooled analysis of three trials was reported before final publication of the individual trials (DECIMAL [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/27\">",
"     27",
"    </a>",
"    ], DESTINY [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/28\">",
"     28",
"    </a>",
"    ], and HAMLET [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/29\">",
"     29",
"    </a>",
"    ]) and included 93 patients who were treated within 48 hours after space-occupying MCA territory infarction associated with a decrease in consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/30\">",
"     30",
"    </a>",
"    ]. The following observations were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary outcome measure, favorable outcome at one year defined as a modified Rankin scale [mRS] of 0 to 4 (",
"      <a class=\"graphic graphic_table graphicRef75411 \" href=\"UTD.htm?22/32/23051\">",
"       table 1",
"      </a>",
"      ), was observed in significantly more patients in the decompressive surgery group than in the control group (75 versus 24 percent, pooled absolute risk reduction [ARR] 51 percent, 95% CI 34-69 percent). The probability of surviving with a mRS of 4 (moderately severe disability, unable to walk without assistance) was approximately 10-fold greater in the surgery group, while the probability of surviving with a mRS of 5 (very severe disability) was not increased.",
"     </li>",
"     <li>",
"      More patients in the decompressive surgery group had favorable outcomes, defined as a mRS of 0 to 3 (ie, no worse than moderate disability and able to walk without assistance) (43 versus 21 percent, ARR 23 percent, 95% CI 5-41 percent).",
"     </li>",
"     <li>",
"      Survival at one year was significantly more frequent in the decompressive surgery group (78 versus 29 percent; ARR 50 percent, 95% CI 33-67 percent).",
"     </li>",
"     <li>",
"      Numbers needed to treat with decompressive surgery for mRS &le;4, mRS &le;3, and survival were 2, 4, and 2.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An updated 2009 meta-analysis that included 16 additional patients (total of 109) operated on within 48 hours reported similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/29\">",
"     29",
"    </a>",
"    ]. Another meta-analysis published in 2012 that evaluated the same trials identified a total of 134 patients, including some in the HAMLET trial who had surgery up to 96 hours after stroke onset [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/31\">",
"     31",
"    </a>",
"    ]. Although the results were generally similar, the 2012 meta-analysis found only a nonsignificant trend that surgery reduced poor outcomes when defined as an mRS of &gt;3 (odds ratio 0.56, 95% CI 0.27-1.15).",
"   </p>",
"   <p>",
"    Thus, the main benefit of hemicraniectomy was increased survival, at a cost of an increased number of survivors with moderately severe disability [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/30\">",
"     30",
"    </a>",
"    ]. The trials in the original pooled analysis and subsequent meta-analyses excluded patients older than 55 or 60 years of age, so the results should not be extrapolated to older patients. Additionally, the available data suggest that decompressive hemicraniectomy within 48 hours is more likely to be beneficial than later hemicraniectomy",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Systematic review",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2004 systematic review of case reports and case series analyzed a total of 138 patients treated with hemicraniectomy and durotomy for infarction involving the MCA territory or MCA plus another vascular territory (eg, anterior cerebral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    posterior cerebral arteries) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/32\">",
"     32",
"    </a>",
"    ]. The mean age of the patients was 50 years (range 11 to 76) and the overall mean time to surgery was 59.3 hours (range 8 to 456).",
"   </p>",
"   <p>",
"    The following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall mortality rate was 24 percent. Mortality was significantly higher in patients older than 50 compared with patients age 50 or younger (32 versus 14 percent). However, these mortality rates compared favorably with the historically higher rates among those with large MCA territory infarction who did not undergo decompressive surgery (approaching 78 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Good clinical outcome, defined as functional independence or mild to moderate disability, was found overall in 42 percent.",
"     </li>",
"     <li>",
"      Poor clinical outcome, defined as dead or severely disabled, occurred overall in 58 percent, and was significantly more frequent in patients older than 50 compared with patients age 50 or younger (80 versus 32 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, younger patients had better functional outcomes, while older age appeared to be associated with poor clinical outcomes and death.",
"   </p>",
"   <p>",
"    These data must be interpreted cautiously. All the included studies were retrospective and uncontrolled, the protocols differed among institutions, and the available cases were subject to publication bias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SELECTION OF PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus about which clinical and radiologic features should be used to select patients for decompressive surgery or predict a good response to such surgery. However, the available evidence suggests that large infarct volume, as characterized by early infarction involving &gt;50 percent of the middle cerebral artery (MCA) territory on head computed tomography (CT), is the most important predictor of malignant edema, herniation, and death. Furthermore, the evidence suggests that patients 50 or younger are more likely to benefit from hemicraniectomy than older patients. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Effectiveness of hemicraniectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Timing of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some investigators have advocated early (within 24 hours of onset) surgical decompression for large hemispheric infarction, before the appearance of signs of herniation. This approach has intuitive appeal since it stands to reason that early decompressive surgery (before life-threatening herniation develops) should result in the best clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/26\">",
"     26",
"    </a>",
"    ]. There is also experimental evidence that early surgery is more likely to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Furthermore, there is clinical evidence that aggressive medical reversal of a single episode of transtentorial herniation in the absence of radiographic evidence of midbrain injury may permit good long-term outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/35\">",
"     35",
"    </a>",
"    ]. These findings suggest that herniation alone does not preclude benefit from surgical decompression.",
"   </p>",
"   <p>",
"    However, the data are limited and conflicting regarding the utility of selecting patients for surgical decompression based upon individual clinical features.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In subgroup analyses of pooled data from three randomized controlled trials cited above, there was no difference in outcome between patients assigned to early (&lt;24 hours after stroke onset, n = 45) or later (24 to 48 hours, n = 38) decompressive surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/30\">",
"       30",
"      </a>",
"      ]. In the only trial (HAMLET) that evaluated decompressive hemicraniectomy up to 96 hours after stroke onset, there was no benefit on any outcome measure for patients assigned to surgery after 48 hours (n = 25) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/29\">",
"       29",
"      </a>",
"      ]. Small patient numbers in the meta-analysis and HAMLET trial preclude definitive conclusions.",
"     </li>",
"     <li>",
"      In the 2004 systematic review cited above, time to treatment, clinical signs of herniation, sex, and side of infarction did not predict outcome with decompressive surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Systematic review'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One study compared early aggressive surgical decompression in 63 patients with large hemispheric infarcts presumed to be at high risk of herniation with historical controls who had not been aggressively treated [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/21\">",
"       21",
"      </a>",
"      ]. Mortality rates were lower and functional outcomes better in those who underwent hemicraniectomy within 24 hours compared with hemicraniectomy after 24 hours. Of note, patients in this study had a mean age of 50 years. Other reports have not found time to treatment to be a predictive factor for outcome, although this may be confounded by variables such as age [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Definitive answers to these questions will require further studies in groups of systematically collected patients and, ideally, randomized, controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dominant hemisphere infarctions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Offering potentially life-saving hemicraniectomy for large dominant hemisphere infarcts is controversial. The major concern is that heroic interventions may leave patients alive, but with unacceptably poor quality of life due to severe aphasia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 2004 systematic review cited above (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Systematic review'",
"    </a>",
"    above), there was a bias toward surgery of the nondominant hemisphere [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/32\">",
"     32",
"    </a>",
"    ]. However, among the 27 patients who had decompression of the dominant hemisphere, functional outcome was no worse than among the 111 patients who had non-dominant infarcts. These data must be interpreted cautiously, but it is possible that language deficits may be of less consequence in patients severely disabled by hemiplegia. Additionally, patients may recover significantly from aphasia, especially those who are younger.",
"   </p>",
"   <p>",
"    There is limited observational evidence that decompressive hemicraniectomy for dominant hemisphere infarction may lead to improvement in language function. Support for this notion comes from a study that followed 14 patients with left MCA territory infarction who had surgical decompression; a significant improvement in different aspects of aphasia was observed in 13 patients (93 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to realize that nondominant hemisphere strokes can lead to severe and disabling deficits related to behavioral change, depression, abulia, inattention or neglect. These problems may interfere with rehabilitation efforts as much as or more than aphasia.",
"   </p>",
"   <p>",
"    Finally, our understanding of what patients view as acceptable outcomes may be poor. Assessments of patients at risk of stroke have indicated that severe disabling hemiplegia is sometimes viewed as worse than an aphasia or death [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, the side of infarction should not necessarily be an exclusion criterion for surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment decisions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemicraniectomy is clearly aggressive therapy and may not be appropriate for many patients and families. Alternative treatment options for malignant MCA territory infarction include medical management of increased intracranial pressure for those who desire aggressive treatment, and supportive medical care or withdrawal of medical care for those who do not desire aggressive therapies. It should be noted that hemicraniectomy for malignant MCA territory infarction is not widely practiced, nor does it constitute standard-of-care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malignant MCA territory infarction is not a contraindication to intravenous thrombolysis. Clinical trial data show that intravenous thrombolysis with tPA (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    ) is beneficial for eligible patients with ischemic stroke who can be treated within 4.5 hours of stroke onset. Intravenous or intraarterial thrombolysis does not preclude later hemicraniectomy, although surgery should probably take place no sooner than 24 hours after thrombolytic administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with malignant MCA territory infarction should be enrolled in randomized controlled trials of decompressive hemicraniectomy if this option is available. In the absence of clinical trial availability, and given the dire prognosis associated with medical treatment, we suggest decompressive hemicraniectomy for patients age 50 or younger with an indisputable diagnosis of malignant middle cerebral artery territory infarction (with &gt;50 percent infarction of MCA territory by head CT) who are at high risk of developing malignant edema and who desire aggressive therapy. This surgery may also be offered on a case-by-case basis for otherwise healthy patients older than 50 and beyond 48 hours after stroke onset.",
"   </p>",
"   <p>",
"    Hemicraniectomy should proceed only after a thorough discussion with the patient (if cognizant) and the family regarding the limited evidence of benefit, particularly regarding cognitive outcome among survivors, and the unproven status of the clinical and radiologic markers for developing malignant infarction. The choice of decompressive hemicraniectomy as treatment for malignant MCA territory infarction may be less averse to patients whose highest priority is survival regardless of a substantial likelihood of poor neurologic outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SURGICAL TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical technique of decompressive hemicraniectomy and durotomy varies among the various case reports in the literature. In general, a large question mark-shaped incision is made in the scalp starting from the midline, to include the frontal, parietal, and temporal lobes. A large incision is essential to the success of the procedure in order to avoid both incomplete release of pressure, and further injury to the brain where it is forced against the edges of the bony skull defect.",
"   </p>",
"   <p>",
"    The protocol for one pilot trial defined required margins of the skull defect as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anterior: frontal to mid-pupillary line",
"     </li>",
"     <li>",
"      Posterior: 4 cm posterior to the external auditory canal",
"     </li>",
"     <li>",
"      Superior: superior sagittal sinus",
"     </li>",
"     <li>",
"      Inferior: floor of the middle cranial fossa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bone is removed and either stored in a frozen tissue bank or sewn into the peritoneal cavity of the patient. The dura is opened with a cruciate incision to allow the brain to swell outwards. In some reports, infarcted tissue is resected (\"strokectomy\") [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/41\">",
"     41",
"    </a>",
"    ]. Other surgeons advocate against tissue resection, as the removal of islands of normal functioning tissue not apparent at the time of surgery may worsen outcome. However, removal of large areas of infarcted tissue may be required in certain cases to ensure adequate decompression and reduce the risk of herniation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Complications of craniectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible complications of craniectomy include hydrocephalus, external brain tamponade, infections, seizures, sinking skin flap syndrome, and paradoxical herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The \"sinking skin flap\" syndrome (SSFS), also termed \"syndrome of the trephined\", is a delayed complication of craniectomy that can occur when atmospheric pressure exceeds intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/42\">",
"     42",
"    </a>",
"    ]. The major clinical features are the sunken appearance of the skin over the skull defect and severe orthostatic headache. Associated symptoms may include focal neurologic deficits, seizures, and altered mental status. Unchecked, SSFS may progress to paradoxical brain herniation, coma, and death.",
"   </p>",
"   <p>",
"    In the DECIMAL trial, with follow-up data available from 27 patients, SSFS developed at three to five months after hemicraniectomy in three patients (11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/43\">",
"     43",
"    </a>",
"    ]. Radiologic SSFS developed in another four patients (15 percent) and was generally asymptomatic except for partial seizures affecting one patient.",
"   </p>",
"   <p>",
"    Management of SSFS and paradoxical herniation, which is a neurocritical care emergency, requires measures that increase intracranial pressure, such as Trendelenburg position, intravenous hydration, clamping of CSF drainage, and discontinuation of hyperosmolar measures [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of paradoxical herniation, SSFS may respond to intravenous fluid administration and supine position with head turned down to the side of the craniectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/569/abstract/43\">",
"     43",
"    </a>",
"    ]. Cranioplasty is the definitive treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decompressive hemicraniectomy and durotomy is a surgical technique used to relieve the increased intracranial pressure and brain tissue shifts that occur in the setting of large cerebral hemisphere space-occupying lesions, such as malignant middle cerebral artery (MCA) territory infarction. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and description'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Roughly 10 percent of ischemic strokes are classified as malignant due to cerebral edema. Clinical features of the malignant hemispheric infarction may include forced gaze deviation, visual field deficit, hemiplegia, and aphasia or neglect, depending on the hemisphere involved. The mortality is as high as 78 percent due to herniation of the temporal lobe on to the brainstem. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features of malignant hemispheric infarction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with hypodensity on head CT involving &gt;50 percent of the MCA territory may be more likely to develop signs of herniation. Additional CT findings that may be predictive of malignant edema include midline shift of the septum pellucidum &gt;5 mm and infarction of additional vascular territories. Similarly, a large volume of infarction on MRI as measured by diffusion-weighted imaging may predict development of malignant course in MCA territory stroke. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Radiologic predictors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical parameters that may predict malignant edema after a large MCA territory infarction include severity of neurologic deficit at presentation,",
"      <span class=\"nowrap\">",
"       nausea/vomiting",
"      </span>",
"      within 24 hours of symptom onset, a systolic blood pressure &ge;180 mmHg after 12 hours from onset, a history of hypertension, a history of heart failure, and an elevated white blood cell count. Young age, first-ever stroke, carotid occlusion and poor collateral circulation may also predispose to malignant MCA territory stroke. Early decline in level of consciousness in patients awake at presentation is another clinical feature predictive of poor outcome. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical predictors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A large incision is essential to the success of the surgical procedure. Possible complications of craniectomy include hydrocephalus, infections, seizures, intracranial hemorrhage and fluid collections, sinking skin flap syndrome, and paradoxical herniation. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgical technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pooled data from small randomized trials shows that hemicraniectomy for malignant hemispheric infarction reduces mortality. However, it is unclear whether the ultimate neurologic outcome is acceptable in many cases. Patient age and timing of surgery may be important variables in considering this procedure. Laboratory evidence suggests that early surgery is more likely to be beneficial. Younger patients (50 or less) may have better functional outcome and lower mortality than older patients. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effectiveness of hemicraniectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Selection of patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with malignant infarction involving &gt;50 percent of the MCA territory associated with a decreased level of consciousness, who are thus at high risk of developing malignant edema, we suggest decompressive hemicraniectomy (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ) if all of the following conditions are met:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age 50 or younger",
"     </li>",
"     <li>",
"      Surgery can be initiated within 48 hours of stroke onset",
"     </li>",
"     <li>",
"      Patient has previously expressed (or a surrogate believes that patient would express) a desire for aggressive therapy",
"      <br/>",
"      <br/>",
"      Decompressive hemicraniectomy may also be considered on a case-by-case basis for otherwise healthy patients older than 50 and beyond 48 hours after stroke onset. Eligible patients should be enrolled in randomized trials evaluating hemicraniectomy if available. Hemicraniectomy should proceed only after a thorough discussion with the patient (if cognizant) and the family. The alternative treatment of aggressive medical therapy for malignant edema may be equally reasonable. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effectiveness of hemicraniectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment decisions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/1\">",
"      Cushing H. The establishment of cerebral hernia as a decompressive measure for inaccessible brain tumors; with the description of intermuscular methods of making the bone defect in temporal and occipital regions. Surg Gynecol Obstet 1905; 1:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/2\">",
"      SCARCELLA G. Encephalomalacia simulating the clinical and radiological aspects of brain tumor; a report of 6 cases. J Neurosurg 1956; 13:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/3\">",
"      Moulin DE, Lo R, Chiang J, Barnett HJ. Prognosis in middle cerebral artery occlusion. Stroke 1985; 16:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/4\">",
"      Silver FL, Norris JW, Lewis AJ, Hachinski VC. Early mortality following stroke: a prospective review. Stroke 1984; 15:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/5\">",
"      Hacke W, Schwab S, Horn M, et al. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol 1996; 53:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/6\">",
"      von Kummer R, Meyding-Lamad&eacute; U, Forsting M, et al. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. AJNR Am J Neuroradiol 1994; 15:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/7\">",
"      Krieger DW, Demchuk AM, Kasner SE, et al. Early clinical and radiological predictors of fatal brain swelling in ischemic stroke. Stroke 1999; 30:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/8\">",
"      Kasner SE, Demchuk AM, Berrouschot J, et al. Predictors of fatal brain edema in massive hemispheric ischemic stroke. Stroke 2001; 32:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/9\">",
"      Barber PA, Demchuk AM, Zhang J, et al. Computed tomographic parameters predicting fatal outcome in large middle cerebral artery infarction. Cerebrovasc Dis 2003; 16:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/10\">",
"      Dohmen C, Bosche B, Graf R, et al. Prediction of malignant course in MCA infarction by PET and microdialysis. Stroke 2003; 34:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/11\">",
"      Minnerup J, Wersching H, Ringelstein EB, et al. Prediction of malignant middle cerebral artery infarction using computed tomography-based intracranial volume reserve measurements. Stroke 2011; 42:3403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/12\">",
"      Firlik AD, Yonas H, Kaufmann AM, et al. Relationship between cerebral blood flow and the development of swelling and life-threatening herniation in acute ischemic stroke. J Neurosurg 1998; 89:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/13\">",
"      Berrouschot J, Barthel H, von Kummer R, et al. 99m technetium-ethyl-cysteinate-dimer single-photon emission CT can predict fatal ischemic brain edema. Stroke 1998; 29:2556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/14\">",
"      Oppenheim C, Samson Y, Mana&iuml; R, et al. Prediction of malignant middle cerebral artery infarction by diffusion-weighted imaging. Stroke 2000; 31:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/15\">",
"      Bektas H, Wu TC, Kasam M, et al. Increased blood-brain barrier permeability on perfusion CT might predict malignant middle cerebral artery infarction. Stroke 2010; 41:2539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/16\">",
"      Thomalla G, Hartmann F, Juettler E, et al. Prediction of malignant middle cerebral artery infarction by magnetic resonance imaging within 6 hours of symptom onset: A prospective multicenter observational study. Ann Neurol 2010; 68:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/17\">",
"      Williams JL, Furlan AJ. Cerebral vascular physiology in hypertensive disease. Neurosurg Clin N Am 1992; 3:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/18\">",
"      Reith J, J&oslash;rgensen HS, Pedersen PM, et al. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet 1996; 347:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/19\">",
"      Jaramillo A, G&oacute;ngora-Rivera F, Labreuche J, et al. Predictors for malignant middle cerebral artery infarctions: a postmortem analysis. Neurology 2006; 66:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/20\">",
"      Ng LK, Nimmannitya J. Massive cerebral infarction with severe brain swelling: a clinicopathological study. Stroke 1970; 1:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/21\">",
"      Schwab S, Steiner T, Aschoff A, et al. Early hemicraniectomy in patients with complete middle cerebral artery infarction. Stroke 1998; 29:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/22\">",
"      Cucchiara BL, Kasner SE, Wolk DA, et al. Early impairment in consciousness predicts mortality after hemispheric ischemic stroke. Crit Care Med 2004; 32:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/23\">",
"      B&uuml;ttner T, Weyers S, Postert T, et al. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke 1997; 28:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/24\">",
"      Foerch C, Otto B, Singer OC, et al. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 2004; 35:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/25\">",
"      Serena J, Blanco M, Castellanos M, et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 2005; 36:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/26\">",
"      Wijman CA. Editorial comment--Can we predict massive space-occupying edema in large hemispheric infarctions? Stroke 2003; 34:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/27\">",
"      Vahedi K, Vicaut E, Mateo J, et al. Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial). Stroke 2007; 38:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/28\">",
"      J&uuml;ttler E, Schwab S, Schmiedek P, et al. Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. Stroke 2007; 38:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/29\">",
"      Hofmeijer J, Kappelle LJ, Algra A, et al. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial. Lancet Neurol 2009; 8:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/30\">",
"      Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 2007; 6:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/31\">",
"      Cruz-Flores S, Berge E, Whittle IR. Surgical decompression for cerebral oedema in acute ischaemic stroke. Cochrane Database Syst Rev 2012; 1:CD003435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/32\">",
"      Gupta R, Connolly ES, Mayer S, Elkind MS. Hemicraniectomy for massive middle cerebral artery territory infarction: a systematic review. Stroke 2004; 35:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/33\">",
"      Forsting M, Reith W, Sch&auml;bitz WR, et al. Decompressive craniectomy for cerebral infarction. An experimental study in rats. Stroke 1995; 26:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/34\">",
"      Doerfler A, Engelhorn T, Heiland S, et al. Perfusion- and diffusion-weighted magnetic resonance imaging for monitoring decompressive craniectomy in animals with experimental hemispheric stroke. J Neurosurg 2002; 96:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/35\">",
"      Qureshi AI, Geocadin RG, Suarez JI, Ulatowski JA. Long-term outcome after medical reversal of transtentorial herniation in patients with supratentorial mass lesions. Crit Care Med 2000; 28:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/36\">",
"      Curry WT Jr, Sethi MK, Ogilvy CS, Carter BS. Factors associated with outcome after hemicraniectomy for large middle cerebral artery territory infarction. Neurosurgery 2005; 56:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/37\">",
"      Carter BS, Ogilvy CS, Candia GJ, et al. One-year outcome after decompressive surgery for massive nondominant hemispheric infarction. Neurosurgery 1997; 40:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/38\">",
"      Kastrau F, Wolter M, Huber W, Block F. Recovery from aphasia after hemicraniectomy for infarction of the speech-dominant hemisphere. Stroke 2005; 36:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/39\">",
"      Solomon NA, Glick HA, Russo CJ, et al. Patient preferences for stroke outcomes. Stroke 1994; 25:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/40\">",
"      Frank JI, Krieger D, Chyatte DM, Cancian S. HEADDFIRST: Hemicraniectomy and durotomy upon deterioration from massive hemispheric infarctions: a proposed, multicenter, prospective randomized study. Stroke 1999; :243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/41\">",
"      Kalia KK, Yonas H. An aggressive approach to massive middle cerebral artery infarction. Arch Neurol 1993; 50:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/42\">",
"      Akins PT, Guppy KH. Sinking skin flaps, paradoxical herniation, and external brain tamponade: a review of decompressive craniectomy management. Neurocrit Care 2008; 9:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/569/abstract/43\">",
"      Sarov M, Guichard JP, Chibarro S, et al. Sinking skin flap syndrome and paradoxical herniation after hemicraniectomy for malignant hemispheric infarction. Stroke 2010; 41:560.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1096 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_569=[""].join("\n");
var outline_f0_35_569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DESCRIPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES OF MALIGNANT HEMISPHERIC INFARCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Radiologic predictors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Head CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Xenon CT, SPECT, and PET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical predictors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EFFECTIVENESS OF HEMICRANIECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Randomized trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Systematic review",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SELECTION OF PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Timing of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dominant hemisphere infarctions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment decisions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SURGICAL TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Complications of craniectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1096\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1096|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/32/23051\" title=\"table 1\">",
"      Modified Rankin scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_35_570="Phencyclidine (PCP) intoxication in children and adolescents";
var content_f0_35_570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Phencyclidine (PCP) intoxication in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/35/570/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/570/contributors\">",
"     Michael Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/35/570/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/570/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/35/570/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/35/570/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/35/570/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCP (l-l-phenylcyclohexyl piperidine) is a synthetic hallucinogen, that has a variety of street names, including &ldquo;angel dust,&rdquo; &ldquo;dust,&rdquo; or &ldquo;sherms&rdquo; (",
"    <a class=\"graphic graphic_table graphicRef78468 \" href=\"UTD.htm?36/5/36956\">",
"     table 1",
"    </a>",
"    ). These names, along with others, reflect its unpredictable and volatile effects. It was patented in the 1950s as a dissociative anesthetic agent called Sernyl, but was later withdrawn from the market due to adverse effects, including severe agitation, confusion, hallucinations, and prolonged periods of decreased consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The recreational use of PCP gained popularity during the 1960s due to its hallucinogenic effects and ease of synthesis. In April of 1979, all legal manufacturing of PCP in the United States was terminated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the early 1970s, a laboratory investigation of PCP derivatives led to the discovery of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    . Ketamine is 5 to 10 percent as potent as phencyclidine and is now used clinically to induce dissociative anesthesia. Ketamine is also abused as a recreational drug.",
"   </p>",
"   <p>",
"    Despite a fall in popularity since the 1970s, PCP remains a commonly abused drug that accounts for a significant number of poison center calls and hospitalizations. Early identification and prompt symptomatic treatment are vital to avoid possible sequelae, including self-injury, hyperthermia, rhabdomyolysis, and seizures.",
"   </p>",
"   <p>",
"    An overview of PCP intoxication in children and adolescents will be reviewed here. The clinical manifestations and management of PCP intoxication in adults and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    poisoning are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=see_link\">",
"     \"Phencyclidine (PCP) intoxication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40935?source=see_link\">",
"     \"Ketamine poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the National Institute on Drug Abuse (NIDA) Monitoring the Future study, which tracks reported illicit drug use among high-school students, the recreational use of PCP in the prior year by United States high school seniors decreased from 7 percent in 1979 to 1.1 percent in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, almost 100,000 children between 11 and 21 years of age in the United States report having used PCP at least once in the prior year, and approximately 1500 annual ED visits for PCP intoxication occur in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/6\">",
"     6",
"    </a>",
"    ]. Deaths due to PCP intoxication are uncommon; most fatalities are due to traumatic injury rather than direct drug effects [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCP intoxication in children under six years of age is rare and typically occurs as an inadvertent oral or inhalational exposure due to caregiver drug use [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCP, or 1-(1-phenylcyclohexyl) piperidine hydrochloride, is an arylcyclohexylamine dissociative anesthetic with structural and pharmacologic properties similar to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    . It is synthesized from piperidine and cyclohexanone and is manufactured illegally in underground laboratories and distributed in varying dosage forms, strengths, and purities [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/9\">",
"     9",
"    </a>",
"    ]. Drug users may be exposed inadvertently to PCP because it is used as an additive in LSD, marijuana, and methamphetamine [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    , PCP is longer acting and more likely to cause seizures, confusion, and delirium. Synthetic derivatives of both PCP and ketamine are used as recreational drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40935?source=see_link&amp;anchor=H5#H5\">",
"     \"Ketamine poisoning\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=see_link&amp;anchor=H18#H18\">",
"     \"Designer drugs of abuse\", section on 'Phencyclidine (PCP), ketamine and related drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PCP is available in white powder (\"angel dust\"), tablet (\"Peace Pill\"), crystal, and liquid (\"whack\") forms that can be ingested, inhaled, injected, or smoked. Young children can be exposed to PCP through secondhand smoke inhalation, ingesting PCP-impregnated cigarette butts, or through inadvertent dermal exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/8,11-13\">",
"     8,11-13",
"    </a>",
"    ]. Adolescent use and pharmacologic effects are similar to adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=see_link&amp;anchor=H2#H2\">",
"     \"Phencyclidine (PCP) intoxication in adults\", section on 'Pharmacology and cellular toxicology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=see_link&amp;anchor=H3#H3\">",
"     \"Phencyclidine (PCP) intoxication in adults\", section on 'Kinetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PCP has three primary sites of action in the CNS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The N-methyl-D-aspartate (NMDA) receptor complex &ndash; PCP has great affinity for NMDA receptor complexes in the hippocampus, neocortex, basal ganglia, and limbic system [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/14\">",
"       14",
"      </a>",
"      ]. NMDA antagonism at these sites produces acute psychosis that mimics schizophrenia in humans and leads to excess excitatory neurotransmitters (eg, glutamate, glycine, aspartate) that can cause agitation and seizures. Animal studies also suggest that the developing brain is at greater risk for injury and cell death from excessive levels of these excitatory neurotransmitters [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The neuronal dopamine, norepinephrine, and serotonin reuptake complex &ndash; PCP inhibits reuptake of dopamine, norepinephrine, and serotonin [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/15\">",
"       15",
"      </a>",
"      ]. This action likely explains the adrenergic effects (eg, tachycardia, hypertension) and dopaminergic effects (eg, dystonia, choreoathetosis, anticholinergic findings) seen in children with PCP intoxication.",
"     </li>",
"     <li>",
"      The sigma receptor complex &ndash; PCP binding to the sigma receptor has been demonstrated and may also explain, in part, psychotic, anticholinergic and movement abnormalities seen in human intoxication [",
"      <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kinetics of PCP in young infants and children has not been studied. The kinetics of phencyclidine in adolescents is similar to adults and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=see_link&amp;anchor=H3#H3\">",
"     \"Phencyclidine (PCP) intoxication in adults\", section on 'Kinetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF OVERDOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCP intoxication is a diagnosis that must be suspected clinically. PCP intoxication should be suspected in children with nystagmus, blank staring, strange behavior, altered mental status, agitation, choreoathetosis, seizures, acute psychosis, or a combination of these symptoms. Duration of action is generally brief (four to eight hours).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2410268\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history of unexpected exposure or overdose in young children under six years of age is rarely available [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/12\">",
"     12",
"    </a>",
"    ]. Caregivers typically note an abrupt onset of altered behavior consistent with neurobehavioral effects of PCP [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/8,11,12\">",
"     8,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older children and adolescents usually are exposed to PCP through recreational use, although passive or inadvertent exposure (eg, being unaware of PCP in a marijuana cigarette) may also occur. In many instances, the patient is unable to provide a history. Sometimes friends or emergency medical services personnel may provide useful details. It can be helpful to know the street names for PCP, which include angel dust, embalming fluid, fry, wets, killer weed, peace pill, horse tranquilizer, and hog (",
"    <a class=\"graphic graphic_table graphicRef78468 \" href=\"UTD.htm?36/5/36956\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2411938\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCP intoxication produces a wide range of vital sign and neuropsychiatric findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2412093\">",
"    <span class=\"h3\">",
"     General findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination should begin with an assessment of the patient's airway, breathing, circulation, and mental status. Respiratory depression occurs more commonly in children with PCP intoxication than in adults. Apnea may immediately precede or follow generalized seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. These episodes usually are brief and self-limited, but some patients require mechanical ventilation. Patients may also exhibit irregular breathing, with alternating episodes of apnea and tachypnea [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/8,11\">",
"     8,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2412100\">",
"    <span class=\"h3\">",
"     Vital signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardia and hypertension (both systolic and diastolic) are frequently seen. Hypertension is present in 30 percent of infants with PCP intoxication, but is usually transient and asymptomatic. However, subarachnoid hemorrhage has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/8\">",
"     8",
"    </a>",
"    ]. Severe neuromuscular excitability can result in hyperthermia while environmental exposure may cause hypothermia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2412164\">",
"    <span class=\"h3\">",
"     Eye findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Horizontal, vertical, or rotatory nystagmus is found in the majority of children and adolescents with PCP intoxication (",
"    <a class=\"graphic graphic_table graphicRef74834 \" href=\"UTD.htm?0/31/507\">",
"     table 2",
"    </a>",
"    ). A stuporous blank stare is also often seen [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/8,11,12\">",
"     8,11,12",
"    </a>",
"    ]. Classically, PCP has been listed as a cause of miosis. However, dilated pupils may also be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2412295\">",
"    <span class=\"h3\">",
"     Neuropsychiatric findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and young children who are exposed to PCP may present with seizures, irritability, lethargy, coma, fluctuations in level of consciousness, choreoathetosis, dystonia, and ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/8,11,12\">",
"     8,11,12",
"    </a>",
"    ]. In one review of PCP intoxication in 28 children younger than five years of age, choreoathetosis was present in more than 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/11\">",
"     11",
"    </a>",
"    ]. Opisthotonos and hyperreflexia are less commonly seen [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/8,11,17\">",
"     8,11,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older children and adolescents may also present with lethargy, coma, agitation, seizures, and ataxia. However, a significant number may be alert with bizarre behavior.",
"   </p>",
"   <p>",
"    Psychomotor agitation is commonly seen in older children and adolescents with PCP intoxication. Similar to adults, these patients may demonstrate violent and unpredictable behavior that is exacerbated by decreased pain perception, hallucinations, paranoid delusions, and delusions of super-human strength. Patients require a cautious approach during initial treatment to ensure staff safety while addressing the child&rsquo;s medical needs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=see_link&amp;anchor=H9#H9\">",
"     \"Phencyclidine (PCP) intoxication in adults\", section on 'Neuropsychiatric findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional categorization of psychiatric symptoms is derived from studies in adults (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=see_link&amp;anchor=H9#H9\">",
"     \"Phencyclidine (PCP) intoxication in adults\", section on 'Neuropsychiatric findings'",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minor symptoms &ndash; Intermittent lethargy or stupor in combination with bizarre behavior, violence, agitation, or euphoria in patients who were otherwise alert and oriented",
"     </li>",
"     <li>",
"      Major symptoms &ndash; Psychosis with hallucinations, catatonia, coma, or acute brain syndrome (disorientation, confusion, lack of judgement, inappropriate affect, or memory loss)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2412500\">",
"    <span class=\"h3\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diaphoresis may accompany other findings of adrenergic excess (eg, tachycardia, hypertension, agitation). Hypersalivation is also frequently seen.",
"   </p>",
"   <p>",
"    Injuries occur commonly in patients with PCP intoxication because the drug produces a dissociative state with violent and unpredictable behavior. The evaluation of patients with suspected trauma is complicated by the anesthetic effects of PCP, which can mask serious injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2412543\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatalities in the setting of PCP intoxication are uncommon and most are secondary to trauma. Other causes include hyperthermia, respiratory arrest, rhabdomyolysis with hyperkalemia, and intracranial hemorrhage.",
"   </p>",
"   <p>",
"    Treating clinicians should be aware of the potential for multiple serious complications in children with PCP intoxication. These occur most often with large ingestions and may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rhabdomyolysis",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Hypoglycemia",
"     </li>",
"     <li>",
"      Prolonged comatose state",
"     </li>",
"     <li>",
"      Prolonged psychosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Perinatal exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCP crosses the placenta and can be detected in umbilical cord blood [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/19\">",
"     19",
"    </a>",
"    ], amniotic fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/20\">",
"     20",
"    </a>",
"    ], breast milk [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/20\">",
"     20",
"    </a>",
"    ], and neonatal urine [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Although microcephaly [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/22\">",
"     22",
"    </a>",
"    ] and dysmorphic facial features have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/23\">",
"     23",
"    </a>",
"    ], teratologic effects of PCP on the developing fetus are not well described. Newborns of mothers, who have used PCP during pregnancy, present with jitteriness, sleep problems during the first year, and other neurobehavioral abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/22,24,25\">",
"     22,24,25",
"    </a>",
"    ]. Similar to adults, neonates may have sudden changes in the level of consciousness, with alternating periods of lethargy and irritability [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical picture of PCP intoxication shares features common to many other intoxications and medical conditions, especially those that cause acute psychosis. The differential diagnosis and approach to acute psychosis in the emergency department is provided in the tables and algorithm (",
"    <a class=\"graphic graphic_table graphicRef52785 \" href=\"UTD.htm?24/61/25564\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50275 \" href=\"UTD.htm?25/40/26251\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef56663 \" href=\"UTD.htm?27/2/27680\">",
"     algorithm 1",
"    </a>",
"    ) and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4666?source=see_link&amp;anchor=H2#H2\">",
"     \"Emergency department evaluation of acute onset psychosis in children\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4666?source=see_link&amp;anchor=H19#H19\">",
"     \"Emergency department evaluation of acute onset psychosis in children\", section on 'Approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nystagmus is also a prominent physical finding in children with PCP intoxication. Other toxins that cause nystagmus are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef74834 \" href=\"UTD.htm?0/31/507\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Children without an apparent underlying medical or toxicologic etiology warrant evaluation for psychiatric causes of psychosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of psychosis\", section on 'Psychotic disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ANCILLARY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PCP intoxication must be suspected clinically. Exposure to PCP is suggested by fluctuating levels of consciousness, psychotic features, nystagmus, and autonomic stimulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6403425\">",
"    <span class=\"h2\">",
"     General studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ancillary studies are obtained to support the clinical diagnosis, to evaluate for coingestants, and to assess for the presence of rhabdomyolysis and its complications. We recommend the following studies in children and adolescents with altered mental status and suspected PCP intoxication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rapid fingerstick blood glucose",
"      </strong>",
"      &ndash; Rapid assessment of blood glucose is essential in all patients with altered mental status. PCP intoxication is associated with hypoglycemia in adults due to excess energy demands. Infants and young children may be predisposed to hypoglycemia after PCP exposure to an even greater degree because of higher turnover of glucose per kilogram of body weight relative to adults.",
"     </li>",
"     <li>",
"      <strong>",
"       Serum",
"      </strong>",
"      <strong>",
"       creatine",
"      </strong>",
"      <strong>",
"       kinase (CK)",
"      </strong>",
"      &ndash; CK elevation is commonly seen in patients with PCP intoxication and is an important indicator of rhabdomyolysis.",
"     </li>",
"     <li>",
"      <strong>",
"       Urine for myoglobin",
"      </strong>",
"      &ndash; Myoglobinuria supports the diagnosis of rhabdomyolysis.",
"     </li>",
"     <li>",
"      <strong>",
"       Liver enzymes",
"      </strong>",
"      &ndash; Elevations of aspartate transaminase (AST) and alanine transaminase (ALT) is seen in approximately half of PCP intoxicated patients.",
"     </li>",
"     <li>",
"      <strong>",
"       Electrocardiogram",
"      </strong>",
"      &ndash; Conduction abnormalities or arrhythmias may accompany hyperkalemia caused by rhabdomyolysis or may indicate the presence of other cardiotoxic agents.",
"     </li>",
"     <li>",
"      <strong>",
"       Serum",
"      </strong>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      <strong>",
"       (older children and adolescents with risk for intentional overdose)",
"      </strong>",
"      &ndash; Acetaminophen is a common coingestant in the adolescent age group.",
"     </li>",
"     <li>",
"      <strong>",
"       Serum salicylate level",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Salicylate toxicity has some features (eg, hyperthermia, altered mental status) that are similar to PCP intoxication.",
"     </li>",
"     <li>",
"      <strong>",
"       Urine pregnancy test (postmenarchal females)",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further testing is performed based upon clinical assessment. As examples, BUN and serum creatinine are obtained if rhabdomyolysis or other potential causes of renal failure are suspected, while computed tomography of the head and evaluation of cerebrospinal fluid may be needed in the setting of a persistently altered mental status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6403279\">",
"    <span class=\"h2\">",
"     Testing for PCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug testing for PCP is not necessary in patients who admit to recreational use but may be helpful in patients with an undifferentiated psychosis and to identify inappropriate PCP exposure and initiate necessary social work assessment in victims of child abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4666?source=see_link&amp;anchor=H18#H18\">",
"     \"Emergency department evaluation of acute onset psychosis in children\", section on 'Ancillary studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link&amp;anchor=H10#H10\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\", section on 'Toxicology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Qualitative testing of urine is more helpful than quantitative concentrations since serum levels do not correlate well with brain concentrations or clinical toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Confirmatory testing using gas chromatography with mass spectroscopy is performed on rare occasions when definitive drug identification is needed (eg, in cases of suspected child abuse).",
"   </p>",
"   <p>",
"    The US National Institute on Drug Abuse (NIDA) guidelines for federal workplace drug testing use a cutoff urine PCP concentration of 25",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Urine toxicology screens may remain positive for several weeks. In one series of chronic users, urine screens remained positive for an average of 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/28\">",
"     28",
"    </a>",
"    ]. CSF testing has been reported in two cases with concentrations one to four times the serum levels [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple causes of false positive urine tests have been reported and the potential adverse medicolegal consequences of such results are profound. Drugs capable of causing a false positive urine test include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/30\">",
"     30",
"    </a>",
"    ],",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/21/34132?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/31,32\">",
"     31,32",
"    </a>",
"    ],",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/33\">",
"     33",
"    </a>",
"    ],",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/18/19752?source=see_link\">",
"     venlafaxine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/34\">",
"     34",
"    </a>",
"    ], and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/7/26743?source=see_link\">",
"     tramadol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/35\">",
"     35",
"    </a>",
"    ]. When evaluating a positive qualitative test for PCP, the clinician should consider the clinical presentation and obtain confirmation with gas chromatography and mass spectrophotometry if clinical findings are inconsistent with PCP toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for care of children and adolescents with PCP intoxication poisoning are derived from case series and reports, including observations in adults, and are driven by physical findings. The treatment of PCP toxicity is primarily supportive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6404400\">",
"    <span class=\"h2\">",
"     Airway, breathing, and circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of PCP intoxication begins with stabilization of airway, breathing, and circulation. Capillary glucose and pulse oximetry should be determined in patients presenting with altered mental status. A rectal temperature is imperative in agitated or seizing patients to assess for the presence of hyperthermia (rectal temperature &gt;38.5&deg;C [101&deg;F]). Respiratory depression and apnea may occur abruptly in infants and young children necessitating rapid sequence intubation (RSI). We suggest avoiding",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    when performing RSI in patients with known or suspected PCP intoxication who exhibit significant psychomotor agitation or hyperthermia because of the risk of exacerbating rhabdomyolysis-related hyperkalemia. Further acute interventions are based upon clinical findings, as quantitative testing for PCP is generally unavailable and unhelpful. (See",
"    <a class=\"local\" href=\"#H6404407\">",
"     'Treatment of complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Tachycardia is common, but rarely requires specific treatment in children and adolescents.",
"   </p>",
"   <p>",
"    Agitated patients warrant careful evaluation for traumatic injuries once adequate sedation is achieved. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6404377\">",
"    <span class=\"h2\">",
"     Sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid control of psychomotor agitation is the cornerstone of successful management. Physical restraints may be necessary initially and several staff members are often needed to control patients agitated from PCP. Thereafter, chemical sedation is essential to control agitation, prevent or treat hyperthermia, perform a thorough physical examination, and obtain necessary studies.",
"   </p>",
"   <p>",
"    Little evidence exists to guide the use of sedatives in the management of PCP intoxication. Based upon observational reports and broad clinical experience, we believe benzodiazepines (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, typical maximum single dose: 4 mg or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, typical maximum single dose: 10 mg) are the preferred agents for the initial treatment of PCP-induced agitation. Benzodiazepine dosing may be repeated every 8 to 10 minutes depending upon individual patient response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6404384\">",
"    <span class=\"h3\">",
"     Severe agitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early management of agitation or violent behavior is essential to prevent patient and staff injury. The emergency provider should exclude life-threatening hypoglycemia and hypoxia as contributing factors to agitation as soon as is safely possible. We treat severely agitated patients immediately with intravenous (IV) benzodiazepines (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, typical maximum single dose: 4 mg or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, typical maximum single dose 10 mg). These doses can be repeated every eight to ten minutes based upon patient response. Although IV administration is preferred, intramuscular administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    (0.5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum single dose: 10 mg) may be given in patients in whom intravenous access cannot be rapidly achieved.",
"   </p>",
"   <p>",
"    Butyrophenones (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/3/11318?source=see_link\">",
"     droperidol",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/51/38711?source=see_link\">",
"     haloperidol",
"    </a>",
"    ) are used as adjunctive therapy in adults with PCP intoxication when benzodiazepines do not adequately control symptoms and in adults with violent behavior due to other causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=see_link&amp;anchor=H17#H17\">",
"     \"Phencyclidine (PCP) intoxication in adults\", section on 'Sedation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link&amp;anchor=H17#H17\">",
"     \"Assessment and management of the acutely agitated or violent adult\", section on 'Chemical sedation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, young children may be more susceptible to adverse effects of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/51/38711?source=see_link\">",
"     haloperidol",
"    </a>",
"    (eg, dystonic reaction, seizures). In the United States,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/3/11318?source=see_link\">",
"     droperidol",
"    </a>",
"    is also subject to a black box warning from the Food and Drug Administration that recommends it only be used after a 12-lead EKG is obtained and only if other treatments have failed. Furthermore, the warning states that droperidol should be used with EXTREME CAUTION in patients who have risk factors for prolonged QT syndrome, are on medications that may prolong the QT interval, or have received intravenous benzodiazepines. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     \"Droperidol: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, we suggest the following approach in children and adolescents with PCP-induced agitation not responsive to benzodiazepines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Butyrophenones should be avoided in infants and children under 12 years of age with PCP intoxication. If agitation is severe and risks life-threatening complications (eg, hyperthermia, rhabdomyolysis), then these patients should undergo rapid sequence intubation (RSI) and muscle relaxation (",
"      <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/51/38711?source=see_link\">",
"       Haloperidol",
"      </a>",
"      (initial dose 5 mg",
"      <span class=\"nowrap\">",
"       IM/IV)",
"      </span>",
"      may be given to adolescents whose agitation is not controlled with intravenous benzodiazepines. Some clinicians prefer to avoid butyrophenones because they are purported to lower the seizure threshold and impair heat dissipation in hyperthermic patients. However, there are no high quality studies in adolescents to support such claims. Furthermore, haloperidol may treat underlying psychotic symptoms that may, in part, be the source of agitation. Patients who receive haloperidol warrant a 12-lead EKG and cardiac monitoring. Adolescents whose agitation persists despite treatment with appropriate doses of benzodiazepines and haloperidol and whose agitation risks life-threatening complications (eg, hyperthermia, rhabdomyolysis) should undergo RSI and muscle relaxation (",
"      <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      When RSI is performed for agitation,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      should be",
"      <strong>",
"       AVOIDED",
"      </strong>",
"      if rhabdomyolysis-induced hyperkalemia is present or highly suspected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"       \"Rapid sequence intubation in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link&amp;anchor=H11#H11\">",
"       \"Rapid sequence intubation in adults\", section on 'Neuromuscular blocking agents'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H25#H25\">",
"       \"Rapid sequence intubation (RSI) in children\", section on 'Succinylcholine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/3/11318?source=see_link\">",
"       droperidol",
"      </a>",
"      <strong>",
"       NOT",
"      </strong>",
"      be used in children and adolescents with PCP intoxication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6404392\">",
"    <span class=\"h3\">",
"     Mild to moderate agitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild to moderate agitation should be placed in a quiet environment (darkened, quiet room). We suggest that these patients be given benzodiazepines (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"     Lorazepam",
"    </a>",
"    0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, typical maximum single dose 2 mg or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, typical maximum single dose; 5 mg). Oral benzodiazepines (eg, lorazepam 0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    typical maximum single dose 2 mg) can be given instead of parenteral benzodiazepines to mildly agitated but cooperative patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6404407\">",
"    <span class=\"h2\">",
"     Treatment of complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should anticipate seizures, hyperthermia, rhabdomyolysis, hypertension, and dystonia in children and adolescents with phencyclidine intoxication. Cardiac monitoring and frequent reexamination are essential in patients with any of these complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6404487\">",
"    <span class=\"h3\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"     Lorazepam",
"    </a>",
"    , initial dose 0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum single dose 4 mg, repeat in one to two minutes if seizures continue) are the first-line treatment for phencyclidine-induced seizures. If seizures persist despite benzodiazepine administration, administer",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum initial dose: 1 gram) or initiate an intravenous infusion of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    . Respiratory depression requiring endotracheal intubation and ventilation is typical and should be anticipated (",
"    <a class=\"graphic graphic_table graphicRef55368 \" href=\"UTD.htm?29/20/30029\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     \"Propofol: Pediatric drug information\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link\">",
"     \"Management of status epilepticus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     Phenytoin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23258?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    is not effective for toxin-induced seizures and should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6404583\">",
"    <span class=\"h3\">",
"     Hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthermia (rectal temperature &gt;38.5&deg;C [101&deg;F]) may result from PCP-induced myotonic activity, seizures, rhabdomyolysis, or a combination of the three and should be managed aggressively with mechanical cooling measures.",
"   </p>",
"   <p>",
"    Augmentation of evaporative cooling is considered the treatment modality of choice because it is effective, noninvasive, and easily performed. The naked patient is sprayed with a mist of lukewarm water while air is circulated with large fans. Shivering may be suppressed with intravenous benzodiazepines, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum single dose 5 mg IV) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    (0.05 to 0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum single dose 1 to 2 mg IV). Cold inspired oxygen, cold gastric lavage, cooling blankets, and cold intravenous fluids may be helpful adjuncts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link&amp;anchor=H18#H18\">",
"     \"Heat stroke in children\", section on 'Rapid cooling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some experts advocate that patients with marked hyperthermia (temperature &gt;40&ordm;C) might benefit from rapid sequence intubation (RSI) followed by prolonged paralysis to stop heat generation from muscle activity (",
"    <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"     table 5",
"    </a>",
"    ). The clinician should",
"    <strong>",
"     AVOID",
"    </strong>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    when performing rapid sequence intubation if hyperkalemia due to rhabdomyolysis is present or highly suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H25#H25\">",
"     \"Rapid sequence intubation (RSI) in children\", section on 'Succinylcholine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is",
"    <strong>",
"     NO ROLE",
"    </strong>",
"    for antipyretic agents, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    , in the management of drug-induced hyperthermia since the underlying mechanism does not involve a change in the hypothalamic temperature set-point. Alcohol sponge baths should also be avoided because large amounts of the drug may be absorbed through dilated cutaneous vessels and produce toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6404788\">",
"    <span class=\"h3\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthermia, agitation, seizures, and muscle rigidity may lead to muscle cell breakdown (rhabdomyolysis) with significant risk for renal failure. Patients with rhabdomyolysis can present with the classic triad of pigmented granular casts in the urine, a red to brown color of the urine supernatant, and a marked elevation in the plasma level of creatine kinase (CK) although rhabdomyolysis is not uncommon in patients whose urine is without visually discernable color change. Primary treatment goals consist of (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid repletion with normal saline infusion (20 to 40",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour up to 1 to 2 L per hour); the emergency provider should closely monitor urine output with the goal of maintaining a minimum urine flow of 4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour; 200 mL per hour in adults. Once diuresis is established with normal saline, alkalinization of the urine is commonly employed but efficacy is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link&amp;anchor=H25398992#H25398992\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Bicarbonate'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Evaluation for significant electrolyte abnormalities (hyperkalemia, hyperphosphatemia, and hypocalcemia); management of hyperkalemia is of particular importance. Hypocalcemia is usually transient and calcium administration should be avoided unless severe symptoms (eg, tetany) are present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6404679\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is frequently transient and many patients need no specific treatment. Benzodiazepine administration for agitation is often effective for elevated blood pressure. Because hypertension may primarily reflect alpha adrenergic effects due to decreased reuptake of norepinephrine, persistent, severe elevations of blood pressure may be treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/52/40773?source=see_link\">",
"     nitroprusside",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/36/14917?source=see_link\">",
"     phentolamine",
"    </a>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum single dose 5 mg). Pure beta adrenergic blockers are contraindicated because they may cause unopposed accentuation of alpha adrenergic effects with exacerbation of hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of specific hypertensive emergencies\", section on 'Acute increase in sympathetic activity'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Rarely, persistent hypertension in patients with depressed mental status or severe headache may indicate the presence of a subarachnoid hemorrhage with increased intracranial pressure. Such patients should undergo computed tomography of the head and treatment to reduce increased intracranial pressure while maintaining adequate cerebral perfusion pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'General management'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6404840\">",
"    <span class=\"h3\">",
"     Dystonic reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"     Diphenhydramine",
"    </a>",
"    (0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, maximum dose: 50 mg) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/45/36563?source=see_link\">",
"     benztropine",
"    </a>",
"    (0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, maximum single dose: 2 mg in children over three years of age) typically provides rapid treatment of a dystonic reaction within minutes of administration. If possible, diphenhydramine should be administered after the urine sample is obtained for toxicologic screening if documentation of PCP intoxication is important, because diphenhydramine may cause the specimen to test positive for PCP by immunoassay method [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4600?source=see_link&amp;anchor=H13#H13\">",
"     \"First generation (Typical) antipsychotic medication poisoning\", section on 'Acute extrapyramidal syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients survive PCP intoxication uneventfully with supportive care; decontamination is generally unnecessary in isolated ingestions. However, decontamination with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) may be useful if a massive ingestion of PCP or a potentially dangerous coingestant is present and treatment is started within one hour of ingestion. Patients who ingest large amounts of PCP to avoid police detection (body stuffers) or to transport drug for distribution (body packers) may sustain massive ingestions. Any potential benefit from AC must be weighed against the risk of aspiration, especially given the potential for altered mental status and seizures with severe PCP intoxication. AC is given in a dose of 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    (maximum 50 g). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=see_link&amp;anchor=H19#H19\">",
"     \"Phencyclidine (PCP) intoxication in adults\", section on 'Decontamination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The greatest benefit occurs if AC is given within one hour. The efficacy of AC as a function of time from ingestion is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H10032558#H10032558\">",
"     \"Decontamination of poisoned children\", section on 'Efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H26755739#H26755739\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Evidence of efficacy and adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend not performing gastric emptying by gastric lavage or by syrup of ipecac-induced emesis in patients who are exposed to PCP. This recommendation is based on randomized controlled trials showing minimal benefit and possible risk to patients who undergo gastric emptying after poisoning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H18993963#H18993963\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Syrup of Ipecac'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H18993923#H18993923\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Gastric lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest",
"    <strong>",
"     not",
"    </strong>",
"    performing nasogastric suction in patients with PCP intoxication. Nasogastric suction is theoretically beneficial when performed soon after ingestion due to the high concentration of PCP in the stomach's acidic environment. However, it has no proven benefit and may cause electrolyte abnormalities, aspiration, and unwanted difficulty in agitated patients.",
"   </p>",
"   <p>",
"    Whole bowel irrigation is",
"    <strong>",
"     not",
"    </strong>",
"    routinely recommended. It should only be used in patients who have ingested potentially lethal amounts of PCP, as may occur with body stuffers or body packers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"     \"Internal concealment of drugs of abuse (body packing)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6404866\">",
"    <span class=\"h2\">",
"     Elimination enhancement",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do",
"    <strong>",
"     not",
"    </strong>",
"    typically use multi-dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (MDAC) in patients with PCP intoxication. Although PCP undergoes enterohepatic circulation, its typical duration of action is short. Also, there is no evidence of clinical benefit in humans, and the potential for aspiration exists whenever AC is given.",
"   </p>",
"   <p>",
"    Neither urine acidification nor charcoal hemoperfusion should be used in the treatment of PCP intoxication. Urinary acidification, in particular, is dangerous as it may worsen renal injury in patients with rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemodialysis, which eliminates PCP only from the serum, is ineffective because of the large volume of distribution of drug (6.2",
"    <span class=\"nowrap\">",
"     L/kg).",
"    </span>",
"   </p>",
"   <p>",
"    Elimination enhancement following phencyclidine intoxication is covered in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=see_link&amp;anchor=H20#H20\">",
"     \"Phencyclidine (PCP) intoxication in adults\", section on 'Enhanced elimination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1397570\">",
"    <span class=\"h2\">",
"     Antidote",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of PCP intoxication is supportive; an effective antidote has not been developed. Anti-PCP Fab fragments have been studied in animals but are not available for use in humans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=see_link&amp;anchor=H23#H23\">",
"     \"Phencyclidine (PCP) intoxication in adults\", section on 'Future considerations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1397986\">",
"    <span class=\"h2\">",
"     Child protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of nonrecreational phencyclidine exposure in an infant or young child should prompt involvement of an experienced child protection team (eg, social worker, nurse, subspecialist physician), if available. In many parts of the world (including the United States, United Kingdom, and Australia), a mandatory report to appropriate government authorities is also required for cases of suspected abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link&amp;anchor=H4#H4\">",
"     \"Child abuse: Social and medicolegal issues\", section on 'Mandatory reporting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with mild recreational PCP intoxication typically improve rapidly to normal functioning within four to eight hours after exposure. Such patients may be discharged provided the effects of intoxication have resolved and the patient remains symptom-free during a brief (one to two hours) period of observation. Prior to discharge, these patients warrant assessment for drug abuse and possible referral to drug rehabilitation. In some adolescents, psychiatric evaluation or referral for concurrent mental illness may also be appropriate.",
"   </p>",
"   <p>",
"    Infants and young children with mild PCP intoxication need a full assessment of the social circumstances that led to the exposure. Such an investigation often requires admission.",
"   </p>",
"   <p>",
"    Any patient with significant complications (eg, rhabdomyolysis, coma, status epilepticus) or severe symptoms (eg, uncontrolled hypertension, hyperthermia) should be admitted to an intensive care setting. Patients with less severe but persistent symptoms should be admitted to an appropriate inpatient setting for further monitoring and treatment. Return to normal function may take weeks in patients with large ingestions. Severely intoxicated infants have been reported to need 48 hours to 4 days to recover [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the PCP is eliminated and the intoxication level improves, some adolescent patients may develop psychosis, bizarre behavior, or depression (the so-called \"emergence phenomenon\") that may last from days to weeks and may require admission for psychiatric treatment, possibly including psychotropic medication [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/37\">",
"     37",
"    </a>",
"    ]. Recovery from psychosis can take weeks to months [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/38\">",
"     38",
"    </a>",
"    ]. Prolonged psychosis occurs more commonly in chronic abusers and is a poor prognostic sign. Withdrawal symptoms, such as depression, anxiety, irritability, restlessness, anergia, and disturbances of thought and sleep, have been described in chronic users after as little as one day of abstinence [",
"    <a class=\"abstract\" href=\"UTD.htm?0/35/570/abstract/37\">",
"     37",
"    </a>",
"    ]. Chronic abusers may benefit from behavioral treatment for substance abuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106227300\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6404873\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PCP is a dissociative anesthetic that is abused by a significant number of adolescents. PCP exposure is rare in young infants and children and typically represents an inadvertent oral or inhalational exposure due to caregiver drug use. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23852189\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PCP intoxication produces a wide range of vital sign and neuropsychiatric findings. In infants and young children altered mental status (eg, lethargy, irritability), nystagmus, choreoathetosis, seizures, ataxia, and blank staring are common features. Abrupt respiratory depression with apnea may occur. In adolescents, nystagmus, psychomotor agitation, hallucinations, and violent behavior are prevalent. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features of overdose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical picture of PCP intoxication shares features common to many other intoxications and medical conditions, especially those that cause acute psychosis. The differential diagnosis and approach to acute psychosis in the emergency department is provided in the tables and algorithm (",
"      <a class=\"graphic graphic_table graphicRef52785 \" href=\"UTD.htm?24/61/25564\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef50275 \" href=\"UTD.htm?25/40/26251\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef56663 \" href=\"UTD.htm?27/2/27680\">",
"       algorithm 1",
"      </a>",
"      ) and is discussed in detail separately. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4666?source=see_link&amp;anchor=H2#H2\">",
"       \"Emergency department evaluation of acute onset psychosis in children\", section on 'Differential diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4666?source=see_link&amp;anchor=H19#H19\">",
"       \"Emergency department evaluation of acute onset psychosis in children\", section on 'Approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Quantitative drug levels have little role in the management of acute toxicity of known recreational drug users. Qualitative urine testing is appropriate when distinguishing acute psychosis due to drug toxicity from other types of psychosis and in situations where child abuse is suspected. Results may remain positive for weeks. Thus, a positive urine test may not indicate acute intoxication. (See",
"      <a class=\"local\" href=\"#H6403279\">",
"       'Testing for PCP'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=see_link&amp;anchor=H14#H14\">",
"       \"Phencyclidine (PCP) intoxication in adults\", section on 'Testing for PCP'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23852197\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of PCP intoxication is primarily supportive. In addition to careful assessment and support of airway, breathing, and circulation, as needed, the clinician should anticipate and aggressively manage agitation, seizures, hyperthermia, rhabdomyolysis, hypertension, and dystonic reactions. (See",
"      <a class=\"local\" href=\"#H6403425\">",
"       'General studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6404377\">",
"       'Sedation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6404407\">",
"       'Treatment of complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early management of agitation or violent behavior is essential to prevent patient and staff injury. Chemical sedation should be administered as rapidly as possible. The emergency provider should exclude life-threatening hypoglycemia and hypoxia as contributing factors to agitation as soon as is safely possible. &nbsp;",
"     </li>",
"     <li>",
"      We suggest treating severely agitated children and adolescents immediately with intravenous (IV) benzodiazepines (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"       lorazepam",
"      </a>",
"      0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV, typical maximum single dose: 4 mg or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"       diazepam",
"      </a>",
"      0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV, typical maximum single dose 10 mg) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These doses can be repeated every eight to ten minutes based upon patient response. Although IV administration is preferred, intramuscular administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      (0.5",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      typical maximum single dose: 10 mg) may be given in patients in whom intravenous access cannot be rapidly achieved. (See",
"      <a class=\"local\" href=\"#H6404384\">",
"       'Severe agitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that adolescent patients, with severe agitation that threatens harm to themselves or others and is not controlled with parenteral benzodiazepines, receive parenteral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/51/38711?source=see_link\">",
"       haloperidol",
"      </a>",
"      (initial dose 5 mg, IV or IM) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Adolescents whose agitation persists despite treatment with appropriate doses of benzodiazepines and haloperidol and whose agitation risks life-threatening complications (eg, hyperthermia, rhabdomyolysis) should undergo rapid sequence intubation and muscle relaxation (",
"      <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6404384\">",
"       'Severe agitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that infants and children under 12 years of age with severe PCP intoxication, that risks life-threatening complications (eg, hyperthermia, rhabdomyolysis), undergo rapid sequence intubation and muscle relaxation (",
"      <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"       table 5",
"      </a>",
"      )",
"      <strong>",
"      </strong>",
"      rather than receiving",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/51/38711?source=see_link\">",
"       haloperidol",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6404384\">",
"       'Severe agitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that mildly or moderately PCP intoxicated patients receive benzodiazepines (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"       lorazepam",
"      </a>",
"      0.05",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV, typical maximum single dose 2 mg or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"       diazepam",
"      </a>",
"      0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV, typical maximum single dose: 5 mg) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Benzodiazepines may be repeated as needed (See",
"      <a class=\"local\" href=\"#H6404392\">",
"       'Mild to moderate agitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children and adolescents with PCP intoxication",
"      <strong>",
"       NOT",
"      </strong>",
"      undergo gastric emptying (induced vomiting or gastric lavage) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that pediatric patients with PCP intoxication",
"      <strong>",
"       NOT",
"      </strong>",
"      receive continuous nasogastric suctioning (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children and adolescents with isolated PCP intoxication",
"      <strong>",
"       NOT",
"      </strong>",
"      be given",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/47/33525?source=see_link\">",
"       activated charcoal",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients with co-ingestants that bind to activated charcoal may benefit from its administration. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Decontamination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of phencyclidine exposure in an infant or young child should prompt involvement of an experienced child protection team (eg, social worker, nurse, subspecialist physician), if available, and mandatory reporting, depending on the local legal requirements. Infants and young children with mild PCP intoxication need a full assessment of the social circumstances that allowed the exposure. Such an investigation often requires admission. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link&amp;anchor=H4#H4\">",
"       \"Child abuse: Social and medicolegal issues\", section on 'Mandatory reporting'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H33\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients of any age with persistent symptoms should be admitted to a monitored setting. Due to the relatively short duration of action, older children and adolescents with mild symptoms are candidates for a period of observation and discharge. Patients whose medical symptoms resolve but have persistent behavioral issues should receive psychiatric evaluation. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Pali MJ, Tharratt RS, Albertson TE. Phencyclidine and its congeners. In: Critical Care Toxicology, 1st, Brent J, Wallace KL, Burkhart KK, et al (Eds), Mosby, Philadelphia 2005. p.777.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/2\">",
"      CHEN G, ENSOR CR, RUSSELL D, BOHNER B. The pharmacology of 1-(1-phenylcyclohexyl) piperidine-HCl. J Pharmacol Exp Ther 1959; 127:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/3\">",
"      Wright HH, Cole EA, Batey SR, Hanna K. Phencyclidine-induced psychosis: eight-year follow-up of ten cases. South Med J 1988; 81:565.",
"     </a>",
"    </li>",
"    <li>",
"     PCP/Phencyclidine. National Institute of Drug Abuse, National Institutes of Health. National Institutes of Health. file://drugabuse.gov/DrugPages/PCP.html (Accessed on October 20, 2010).",
"    </li>",
"    <li>",
"     Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national survey results on drug use, 1975-2009. Volume I: Secondary school students (NIH Publication No. 10-7584). National Institute on Drug Abuse. Bethesda, MD, 2010.",
"    </li>",
"    <li>",
"     Drug Abuse Warning Network, 2008: Selected Tables of National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Office of Applied Studies, SAMHSA, 2009. https://dawninfo.samhsa.gov/data/ (Accessed on October 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/7\">",
"      Poklis A, Graham M, Maginn D, et al. Phencyclidine and violent deaths in St. Louis, Missouri: a survey of medical examiners' cases from 1977 through 1986. Am J Drug Alcohol Abuse 1990; 16:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/8\">",
"      Welch MJ, Correa GA. PCP intoxication in young children and infants. Clin Pediatr (Phila) 1980; 19:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/9\">",
"      Shesser R, Jotte R, Olshaker J. The contribution of impurities to the acute morbidity of illegal drug use. Am J Emerg Med 1991; 9:336.",
"     </a>",
"    </li>",
"    <li>",
"     Liang IV, Boyer EW. Dissociative agents: Phencyclidine, ketamine, and dextromethorphan. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th, Shannon MW, Borron SW, Burns MJ (Eds), Saunders Elsevier, Philadelphia 2007. p.773.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/11\">",
"      Karp HN, Kaufman ND, Anand SK. Phencyclidine poisoning in young children. J Pediatr 1980; 97:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/12\">",
"      Schwartz RH, Einhorn A. PCP intoxication in seven young children. Pediatr Emerg Care 1986; 2:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/13\">",
"      McDonald JW, Johnston MV. Excitatory amino acid neurotoxicity in the developing brain. NIDA Res Monogr 1993; 133:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/14\">",
"      Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/15\">",
"      Akunne HC, Reid AA, Thurkauf A, et al. [3H]1-[2-(2-thienyl)cyclohexyl]piperidine labels two high-affinity binding sites in human cortex: further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex. Synapse 1991; 8:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/16\">",
"      Wolfe SA Jr, De Souza EB. Sigma and phencyclidine receptors in the brain-endocrine-immune axis. NIDA Res Monogr 1993; 133:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/17\">",
"      Seiden JA, Mittal MK. An infant with obtundation and tongue thrusting. Phencyclidine poisoning. Pediatr Emerg Care 2008; 24:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/18\">",
"      McCarron MM, Schulze BW, Thompson GA, et al. Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. Ann Emerg Med 1981; 10:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/19\">",
"      Kaufman KR, Petrucha RA, Pitts FN Jr, Kaufman ER. Phencyclidine in umbilical cord blood: preliminary data. Am J Psychiatry 1983; 140:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/20\">",
"      Kaufman KR, Petrucha RA, Pitts FN Jr, Weekes ME. PCP in amniotic fluid and breast milk: case report. J Clin Psychiatry 1983; 44:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/21\">",
"      Chasnoff IJ, Burns WJ, Hatcher RP, Burns KA. Phencyclidine: effects on the fetus and neonate. Dev Pharmacol Ther 1983; 6:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/22\">",
"      Strauss AA, Modaniou HD, Bosu SK. Neonatal manifestations of maternal phencyclidine (PCP) abuse. Pediatrics 1981; 68:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/23\">",
"      Golden NL, Sokol RJ, Rubin IL. Angel dust: possible effects on the fetus. Pediatrics 1980; 65:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/24\">",
"      Rahbar F, Fomufod A, White D, Westney LS. Impact of intrauterine exposure to phencyclidine (PCP) and cocaine on neonates. J Natl Med Assoc 1993; 85:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/25\">",
"      Ali SF, Ahmad G, Slikker W Jr, Bondy SC. Effects of gestational exposure to phencyclidine: distribution and neurochemical alterations in maternal and fetal brain. Neurotoxicology 1989; 10:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/26\">",
"      Bailey DN. Phencyclidine abuse. Clinical findings and concentrations in biological fluids after nonfatal intoxication. Am J Clin Pathol 1979; 72:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/27\">",
"      Barton CH, Sterling ML, Vaziri ND. Phencyclidine intoxication: clinical experience in 27 cases confirmed by urine assay. Ann Emerg Med 1981; 10:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/28\">",
"      Simpson GM, Khajawall AM, Alatorre E, Staples FR. Urinary phencyclidine excretion in chronic abusers. J Toxicol Clin Toxicol 1982; 19:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/29\">",
"      Donaldson JO, Baselt RC. CSF phencyclidine. Am J Psychiatry 1979; 136:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/30\">",
"      Hoffman, RJ, Saddock, V, Nelson, L. Effect of ketamine on phencyclidine immunoassays (abstract). J Toxicol Clin Toxicol 2001; 39:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/31\">",
"      Budai B, Iskandar H. Dextromethorphan can produce false positive phencyclidine testing with HPLC. Am J Emerg Med 2002; 20:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/32\">",
"      Schier J. Avoid unfavorable consequences: dextromethorpan can bring about a false-positive phencyclidine urine drug screen. J Emerg Med 2000; 18:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/33\">",
"      Levine BS, Smith ML. Effects of diphenhydramine on immunoassays of phencyclidine in urine. Clin Chem 1990; 36:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/34\">",
"      Santos PM, L&oacute;pez-Garc&iacute;a P, Navarro JS, et al. False positive phencyclidine results caused by venlafaxine. Am J Psychiatry 2007; 164:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/35\">",
"      Hull MJ, Griggs D, Knoepp SM, et al. Postmortem urine immunoassay showing false-positive phencyclidine reactivity in a case of fatal tramadol overdose. Am J Forensic Med Pathol 2006; 27:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/36\">",
"      Patel R, Connor G. A review of thirty cases of rhabdomyolysis-associated acute renal failure among phencyclidine users. J Toxicol Clin Toxicol 1985; 23:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/37\">",
"      Rappolt RT Sr, Gay GR, Farris RD. Phencyclidine (PCP) intoxication: diagnosis in stages and algorithms of treatment. Clin Toxicol 1980; 16:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/35/570/abstract/38\">",
"      Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry 1978; 135:1081.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6506 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_570=[""].join("\n");
var outline_f0_35_570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6404873\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES OF OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2410268\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2411938\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2412093\">",
"      - General findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2412100\">",
"      - Vital signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2412164\">",
"      - Eye findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2412295\">",
"      - Neuropsychiatric findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2412500\">",
"      - Other findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2412543\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Perinatal exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ANCILLARY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6403425\">",
"      General studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6403279\">",
"      Testing for PCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6404400\">",
"      Airway, breathing, and circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6404377\">",
"      Sedation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6404384\">",
"      - Severe agitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6404392\">",
"      - Mild to moderate agitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6404407\">",
"      Treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6404487\">",
"      - Seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6404583\">",
"      - Hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6404788\">",
"      - Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6404679\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6404840\">",
"      - Dystonic reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6404866\">",
"      Elimination enhancement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1397570\">",
"      Antidote",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1397986\">",
"      Child protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H106227300\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6404873\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23852189\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23852197\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6506\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6506|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?27/2/27680\" title=\"algorithm 1\">",
"      Approach psychosis child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6506|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/5/36956\" title=\"table 1\">",
"      Street names phencyclidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/31/507\" title=\"table 2\">",
"      Poisons causing nystagmus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/61/25564\" title=\"table 3\">",
"      Organic psychosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/40/26251\" title=\"table 4\">",
"      Drug psychosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/26/17837\" title=\"table 5\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/20/30029\" title=\"table 6\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=related_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/47/1784?source=related_link\">",
"      Designer drugs of abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=related_link\">",
"      Droperidol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4666?source=related_link\">",
"      Emergency department evaluation of acute onset psychosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4600?source=related_link\">",
"      First generation (Typical) antipsychotic medication poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=related_link\">",
"      Heat stroke in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=related_link\">",
"      Internal concealment of drugs of abuse (body packing)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40935?source=related_link\">",
"      Ketamine poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=related_link\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=related_link\">",
"      Phencyclidine (PCP) intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=related_link\">",
"      Propofol: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18614?source=related_link\">",
"      Treatment of specific hypertensive emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_35_571="Causes of nonspecific pl effus";
var content_f0_35_571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential causes of nonspecific pleural effusions after cardiac surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Atelectasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postpericardiotomy syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgical tissue trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topical cardiac cooling with ice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleurotomy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_571=[""].join("\n");
var outline_f0_35_571=null;
var title_f0_35_572="Risk of preterm delivery as a function of cervical length";
var content_f0_35_572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative risk of preterm delivery as a function of cervical length",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cervical length (mm)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Centile",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative risk of PTD",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confidence interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        &le;35",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        2.35",
"       </td>",
"       <td class=\"centered\">",
"        1.42 to 3.89",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        &le;30",
"       </td>",
"       <td class=\"centered\">",
"        25",
"       </td>",
"       <td class=\"centered\">",
"        3.79",
"       </td>",
"       <td class=\"centered\">",
"        2.32 to 6.19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        &le;26",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"       <td class=\"centered\">",
"        6.19",
"       </td>",
"       <td class=\"centered\">",
"        3.84 to 9.97",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        &le;22",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        9.49",
"       </td>",
"       <td class=\"centered\">",
"        5.95 to 15.15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        &le;13",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        13.99",
"       </td>",
"       <td class=\"centered\">",
"        7.89 to 24.78",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Relative risk is in comparison to women whose cervical lengths were above the 75th percentile.",
"    <br/>",
"    Data from an asymptomatic general obstetrical population evaluated between 22 and 30 weeks of gestation with exclusion of women with multiple gestations, fetal anomalies, cerclage, or placental previa.",
"    <div class=\"footnotes\">",
"     PTD: preterm delivery.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Iams JD, Goldenberg RL, Meis PJ, et al, N Engl J Med 1996; 334:567.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_572=[""].join("\n");
var outline_f0_35_572=null;
var title_f0_35_573="High resolution manometry diagnostic criteria";
var content_f0_35_573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=46\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=46\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    High resolution manometry diagnostic criteria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Achalasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type I achalasia",
"       </td>",
"       <td>",
"        Mean IRP &gt;upper limit of normal, 100 percent failed peristalsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type II achalasia",
"       </td>",
"       <td>",
"        Mean IRP &gt;upper limit of normal, no normal peristalsis, panesophageal pressurization with &ge;20 percent of swallows",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Type III achalasia",
"       </td>",
"       <td>",
"        Mean IRP &gt;upper limit of normal, no normal peristalsis, preserved fragments of distal peristalsis or premature contractions with &ge;20 percent of swallows",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         EGJ outflow obstruction",
"        </strong>",
"       </td>",
"       <td>",
"        Mean IRP &gt;upper limit of normal, some instances of intact peristalsis or weak peristalsis with small breaks such that it does not meet criteria for achalasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <strong>",
"         Abnormal motor function",
"        </strong>",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Patterns not observed in normal individuals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distal esophageal spasm",
"       </td>",
"       <td>",
"        Normal mean IRP, &ge;20 percent premature contractions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypercontractile (jackhammer) esophagus",
"       </td>",
"       <td>",
"        Normal mean IRP, at least one swallow with contraction of DCI &gt;8000 mmHg-s-cm",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Absent peristalsis",
"       </td>",
"       <td>",
"        Normal mean IRP, 100 percent of swallows with failed peristalsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <strong>",
"         Borderline motor function",
"        </strong>",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Defined by exceeding the statistical normal range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frequent failed peristalsis",
"       </td>",
"       <td>",
"        Normal mean IRP, &gt;30 percent, but &lt;100 percent of swallows with failed peristalsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weak peristalsis with large peristaltic defects",
"       </td>",
"       <td>",
"        Normal mean IRP and &gt;20 percent swallows with large (&gt;5 cm in length) breaks in the 20 mmHg isobaric contour",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weak peristalsis with small peristaltic defects",
"       </td>",
"       <td>",
"        Normal mean IRP and &gt;30 percent swallows with small (2 to 5 cm in length) breaks in the 20 mmHg isobaric contour",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rapid contractions with normal latency",
"       </td>",
"       <td>",
"        Normal mean IRP, rapid contraction with &ge;20 percent of swallows, DL &lt;4.5 seconds",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Hypertensive (nutcracker) esophagus",
"       </td>",
"       <td>",
"        Normal mean IRP, mean DCI &gt;5000 mmHg-s-cm but not meeting criteria for hypercontractile esophagus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Normal",
"        </strong>",
"       </td>",
"       <td>",
"        Not achieving any of the above diagnostic criteria",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IRP: integrated relaxation pressure; EGJ: esophagogastric junction; DCI: distal contractile integral; DL: distal latency.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_573=[""].join("\n");
var outline_f0_35_573=null;
var title_f0_35_574="Risk assignment childhood ALL";
var content_f0_35_574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical risk assignment and suggested therapies in childhood acute lymphoblastic leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"15%\">",
"     </colgroup>",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"15%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended therapy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Projected five-year event-free survival",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          ALL",
"         </strong>",
"         of the following:",
"        </p>",
"        <ol>",
"         <li>",
"          <p>",
"           NCI standard risk group*",
"          </p>",
"         </li>",
"         <li>",
"          <p>",
"           Lesser risk cytogenetics:",
"           <br/>",
"           Trisomies 4 and 10",
"           <br/>",
"           <strong>",
"            or",
"            <br/>",
"           </strong>",
"           ETV-RUNX1 (United States)",
"           <br/>",
"           <strong>",
"            or",
"           </strong>",
"           <br/>",
"           Hyperdiploid (Europe)",
"          </p>",
"         </li>",
"         <li>",
"          <p>",
"           Rapid response to therapy",
"           <sup>",
"            &bull;",
"           </sup>",
"          </p>",
"         </li>",
"        </ol>",
"       </td>",
"       <td>",
"        15 percent",
"       </td>",
"       <td>",
"        Conventional antimetabolite-based therapy",
"       </td>",
"       <td>",
"        &gt;95 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Average",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          EITHER",
"         </strong>",
"         of the following:",
"        </p>",
"        <ol>",
"         <li>",
"          <p>",
"           NCI standard risk group*",
"           <br/>",
"           <strong>",
"            and",
"            <br/>",
"           </strong>",
"           Rapid response to therapy",
"           <sup>",
"            &bull;",
"           </sup>",
"          </p>",
"         </li>",
"         <li>",
"          <p>",
"           NCI standard risk group*",
"           <br/>",
"           <strong>",
"            and",
"            <br/>",
"           </strong>",
"           Lesser risk cytogenetics",
"           <br/>",
"           <strong>",
"            and",
"            <br/>",
"           </strong>",
"           Slow response to therapy",
"           <sup>",
"            &Delta;",
"           </sup>",
"          </p>",
"         </li>",
"        </ol>",
"       </td>",
"       <td>",
"        36 percent",
"       </td>",
"       <td>",
"        Intensified antimetabolite therapy",
"       </td>",
"       <td>",
"        90 to 95 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          ANY",
"         </strong>",
"         of the following:",
"        </p>",
"        <ol>",
"         <li>",
"          <p>",
"           NCI high risk group",
"           <sup>",
"            &loz;",
"            <br/>",
"           </sup>",
"           <strong>",
"            and",
"            <br/>",
"           </strong>",
"           Rapid response to therapy",
"           <sup>",
"            &bull;",
"           </sup>",
"          </p>",
"         </li>",
"         <li>",
"          <p>",
"           NCI standard risk group*",
"           <br/>",
"           <strong>",
"            and",
"            <br/>",
"           </strong>",
"           Slow response to therapy",
"           <sup>",
"            &Delta;&sect;",
"           </sup>",
"          </p>",
"         </li>",
"         <li>",
"          <p>",
"           CNS positive leukemia",
"          </p>",
"         </li>",
"         <li>",
"          <p>",
"           Testicular leukemia",
"          </p>",
"         </li>",
"        </ol>",
"       </td>",
"       <td>",
"        25 percent",
"       </td>",
"       <td>",
"        Intensive multi-agent chemotherapy",
"       </td>",
"       <td>",
"        88 to 90 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Very high",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          ANY",
"         </strong>",
"         of the following:",
"        </p>",
"        <ol>",
"         <li>",
"          <p>",
"           MRD+ at day 29",
"           <sup>",
"            &sect;",
"           </sup>",
"          </p>",
"         </li>",
"         <li>",
"          <p>",
"           Induction failures",
"          </p>",
"         </li>",
"         <li>",
"          <p>",
"           MLL rearrangements",
"           <br/>",
"           <strong>",
"            or",
"            <br/>",
"           </strong>",
"           iAMP21 amplification",
"          </p>",
"         </li>",
"         <li>",
"          <p>",
"           Age &lt;1 year (or &gt;13 years if treated on a COG protocol)",
"          </p>",
"         </li>",
"        </ol>",
"       </td>",
"       <td>",
"        24 percent",
"       </td>",
"       <td>",
"        <p>",
"         Consider allogeneic hematopoietic cell transplantation in first remission",
"        </p>",
"        <p>",
"         Allogeneic transplant",
"         <strong>",
"          not",
"         </strong>",
"         recommended for infants",
"        </p>",
"       </td>",
"       <td>",
"        &lt;80 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Special groups",
"       </td>",
"       <td>",
"        <p>",
"         T cell ALL",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Intensive multi-agent chemotherapy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         78 to 80 percent",
"         <sup>",
"          &yen;",
"         </sup>",
"        </p>",
"        <p>",
"         <sup>",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"        <p>",
"         Philadelphia chromosome",
"         <br/>",
"         [t (9; 22)]",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"        <p>",
"         Intensive multi-agent chemotherapy containing a BCR-ABL tyrosine kinase inhibitor",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"        <p>",
"         80 to 88 percent",
"         <sup>",
"          ������",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WBC: white blood cell count; NCI: National Cancer Institute; MRD: minimal residual disease; CNS: central nervous system; MLL: mixed lineage leukemia gene; iAMP21: intrachromosomal amplification of chromosome 21; COG: Children's Oncology Group; ALL: acute lymphoblastic leukemia.",
"     <br>",
"      * NCI standard risk group: WBC &lt;50,000/microL",
"      <strong>",
"       AND",
"      </strong>",
"      age&nbsp;one to &lt;10 years.",
"      <br>",
"       &bull;&nbsp;MRD negative at days 8 and 29 (rapid response to therapy).",
"       <br>",
"        &Delta;&nbsp;MRD positive at day 8 and negative at day 29 (slow response to therapy).",
"        <br>",
"         &loz; NCI high risk group: WBC &ge;50,000 microL",
"         <strong>",
"          OR",
"         </strong>",
"         age &ge;10 years (up to 13 years if treated on a COG protocol).",
"         <br>",
"          &sect;&nbsp;With some exceptions.",
"          <br>",
"           &yen;&nbsp;The number of responders in patients with T cell ALL is difficult to define.",
"           <br>",
"            &Dagger;&nbsp;Three-year event-free survival.",
"            <sup>",
"             [1]",
"            </sup>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br/>",
"     <ol>",
"      <li>",
"       Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009; 27:5175.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_574=[""].join("\n");
var outline_f0_35_574=null;
var title_f0_35_575="Erythema migrans uniform";
var content_f0_35_575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema migrans lesion with uniform erythema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema migrans lesion with uniform erythema. Note that the lesion is not a perfect circle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eugene D Shapiro, MD, FAAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_35_575=[""].join("\n");
var outline_f0_35_575=null;
